
<html lang="en"     class="pb-page"  data-request-id="1467fa4d-883f-4f21-856b-aedd471f50d3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm201743s;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2012.55.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells" /></meta><meta name="dc.Creator" content="Si  Wang" /></meta><meta name="dc.Creator" content="William J.  Placzek" /></meta><meta name="dc.Creator" content="John L.  Stebbins" /></meta><meta name="dc.Creator" content="Sayantan  Mitra" /></meta><meta name="dc.Creator" content="Roberta  Noberini" /></meta><meta name="dc.Creator" content="Mitchell  Koolpe" /></meta><meta name="dc.Creator" content="Ziming  Zhang" /></meta><meta name="dc.Creator" content="Russell  Dahl" /></meta><meta name="dc.Creator" content="Elena B.  Pasquale" /></meta><meta name="dc.Creator" content="Maurizio  Pellecchia" /></meta><meta name="dc.Description" content="The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects. We report that the EphA2 receptor is overexpressed preferentially in several human cancer ce..." /></meta><meta name="Description" content="The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects. We report that the EphA2 receptor is overexpressed preferentially in several human cancer ce..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 27, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201743s" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201743s" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201743s" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201743s" /></link>
        
    
    

<title>Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201743s" /></meta><meta property="og:title" content="Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0004.jpeg" /></meta><meta property="og:description" content="The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects. We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors. Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel. We found that the peptide–drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site. We believe these studies open the way to the development of a new class of therapeutic compounds that exploit the EphA2 receptor for drug delivery to cancer cells." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201743s"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201743s">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201743s&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201743s&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201743s&amp;href=/doi/10.1021/jm201743s" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2427-2436</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201713h" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2005942" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Si++Wang">Si Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+J.++Placzek">William J. Placzek</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+L.++Stebbins">John L. Stebbins</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sayantan++Mitra">Sayantan Mitra</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roberta++Noberini">Roberta Noberini</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mitchell++Koolpe">Mitchell Koolpe</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziming++Zhang">Ziming Zhang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Russell++Dahl">Russell Dahl</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elena+B.++Pasquale">Elena B. Pasquale</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maurizio++Pellecchia">Maurizio Pellecchia</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Cancer Research Center, Sanford-Burnham Medical Research Institute, 10901 N. Torrey Pines Road, La Jolla, California 92037, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-646-3159. E-mail: <a href="/cdn-cgi/l/email-protection#b9d4c9dcd5d5dcdadad1d0d8f9cad8d7dfd6cbdddbcccbd7d1d8d497d6cbde"><span class="__cf_email__" data-cfemail="e38e93868f8f8680808b8a82a390828d858c91878196918d8b828ecd8c9184">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201743s&amp;href=/doi/10.1021%2Fjm201743s" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2427–2436</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 13, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 December 2011</li><li><span class="item_label"><b>Published</b> online</span>27 February 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 March 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201743s" title="DOI URL">https://doi.org/10.1021/jm201743s</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2427%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSi%2BWang%252C%2BWilliam%2BJ.%2BPlaczek%252C%2BJohn%2BL.%2BStebbins%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D5%26contentID%3Djm201743s%26title%3DNovel%2BTargeted%2BSystem%2BTo%2BDeliver%2BChemotherapeutic%2BDrugs%2Bto%2BEphA2-Expressing%2BCancer%2BCells%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2436%26publicationDate%3DMarch%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201743s"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2133</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">64</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201743s" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Si&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;J. Placzek&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;L. Stebbins&quot;},{&quot;first_name&quot;:&quot;Sayantan&quot;,&quot;last_name&quot;:&quot;Mitra&quot;},{&quot;first_name&quot;:&quot;Roberta&quot;,&quot;last_name&quot;:&quot;Noberini&quot;},{&quot;first_name&quot;:&quot;Mitchell&quot;,&quot;last_name&quot;:&quot;Koolpe&quot;},{&quot;first_name&quot;:&quot;Ziming&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Russell&quot;,&quot;last_name&quot;:&quot;Dahl&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;B. Pasquale&quot;},{&quot;first_name&quot;:&quot;Maurizio&quot;,&quot;last_name&quot;:&quot;Pellecchia&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;2427-2436&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201743s&quot;},&quot;abstract&quot;:&quot;The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects. We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors. Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel. We found that the peptide–drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site. We believe these studies open the way to the development of a new class of therapeutic compounds that exploit the EphA2 receptor for drug delivery to cancer cells.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201743s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201743s" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201743s&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201743s" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201743s&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201743s" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201743s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201743s&amp;href=/doi/10.1021/jm201743s" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201743s" /></input><a href="/doi/pdf/10.1021/jm201743s" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201743s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201743s%26sid%3Dliteratum%253Aachs%26pmid%3D22329578%26genre%3Darticle%26aulast%3DWang%26date%3D2012%26atitle%3DNovel%2BTargeted%2BSystem%2BTo%2BDeliver%2BChemotherapeutic%2BDrugs%2Bto%2BEphA2-Expressing%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D5%26spage%3D2427%26epage%3D2436%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jmcmar.2012.55.issue-5/production/jmcmar.2012.55.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_trg1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0004.gif" alt="" id="trg1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=f_trg1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects. We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors. Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel. We found that the peptide–drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site. We believe these studies open the way to the development of a new class of therapeutic compounds that exploit the EphA2 receptor for drug delivery to cancer cells.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span></span> Author Contributions</h4><p class="last">S.W., W.J.P., and J.L.S. contributed equally to this work. M.P. designed the research strategy for the peptide conjugates. S.W. synthesized the peptide−PTX conjugates. W.J.P. performed the qPCR experiments, EphA2 protein quantification, and characterization of peptide−PTX conjugates in cultured PC3 cells. J.L.S. performed the tumor xenograft experiments. S.M. and R.N. performed the ELISA and cell culture experiments, in Figures <a class="ref internalNav" href="#fig3" aria-label=""></a> and <a class="ref internalNav" href="#fig4" aria-label=""></a>. M.K. performed the YSA cell labeling and internalization experiments in Figure <a class="ref internalNav" href="#fig2" aria-label=""></a>. R.D. performed the plasma and microsomal stability experiments. E.P.B. and M.P. helped the other authors design and interpret experiments, and M.P. wrote the manuscript with help from the other authors.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11478" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11478" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Current cancer therapy relies heavily on indiscriminate, highly toxic, chemotherapeutic agents resulting in systemic toxicity and adverse side effects. For instance, the mitotic inhibitor, paclitaxel, is widely utilized in cancer treatment even though it is highly toxic and only a small portion of the delivered dose reaches the tumor.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> An ideal solution to such chemotherapeutic limitations would be the selective delivery of anticancer drugs to tumor tissues. To this end, recent advances in our understanding of the cell surface proteome of cancer cells as well as cells of the tumor microenvironment have led to the identification of a number of tumor specific cell surface biomarkers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Attempts to exploit these targets have thus far focused on developing a variety of agents including antibodies, polymers, polyunsaturated fatty acids, vitamins, hormones, and peptides as selective tumor-homing reagents coupled to a variety of anticancer or imaging agents.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a></div><div class="NLM_p">The most advanced tumor-homing molecules among these make use of humanized monoclonal antibodies. Such compounds rely on the selective nature of antibodies to specifically bind to targets that have been identified on the surface of cancer cells. These antibodies function as drug delivery agents, serving to increase the local concentration of payload drugs at or near the tumor site. Monoclonal antibody-based cancer therapeutics are currently being evaluated in a number of clinical trials (<a href="http://www.cancer.gov" class="extLink">www.cancer.gov</a>). However, while antibodies can display high affinity and tumor specificity, they suffer from clinical limitations. For example, the formulation and preparation of homogeneous antibody–drug conjugates present challenges due to the many factors that can affect protein stability.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Moreover, humanization of antibodies may reduce the risk of induced immune responses, but it cannot eliminate immunogenicity completely.</div><div class="NLM_p">In this regard, short peptides that bind to tumor-specific targets show a great deal of promise for selective tumor targeting. Phage display technology and combinatorial chemistry methods have identified highly tumor specific peptide sequences capable of selectively binding cancer cell-specific targets.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Conjugation of known chemotherapeutic agents to these peptides at specific sites results in a homogeneous drug/peptide ratio. Furthermore, some tumor targeting peptides have the ability to not only selectively bind to cancer cells but also mediate cell-permeabilization of both the peptide and conjugate molecule.<a onclick="showRef(event, 'cit5a'); return false;" href="javascript:void(0);" class="ref cit5a">(5a)</a> By possessing the ability to identify tumor cells and mediate drug internalization, such peptides increase drug activity and reduce drug toxicity by overcoming the inherent poor selectivity and limited cellular penetration of many anticancer drugs. For example, the synthetic peptides RC-160 and iRGD have been used to target the somatostatin receptor<a onclick="showRef(event, 'cit3a'); return false;" href="javascript:void(0);" class="ref cit3a">(3a)</a> and neuropilin-1 receptor,<a onclick="showRef(event, 'cit2a'); return false;" href="javascript:void(0);" class="ref cit2a">(2a)</a> respectively. However, many tumor specific peptides that have been characterized are unable to facilitate cell penetration.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In this regard, peptides that are capable of both directly targeting tumor cells and mediating cell permeabilization represent the most attractive molecular entities for use as drug delivery agents.</div><div class="NLM_p">The Eph family of receptor tyrosine kinases represents a possible target for tumor-specific peptide development.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The Eph receptors play a central role in cellular proliferation and survival processes and act on the actin cytoskeleton influencing cell shape and migration. Several studies have demonstrated that the disruption of binding of one family member, the EphA2 receptor, to ephrin ligands in preclinical mouse tumor models results in decreased tumor growth, likely due to inhibition of tumor angiogenesis.<a onclick="showRef(event, 'cit7a ref8'); return false;" href="javascript:void(0);" class="ref cit7a ref8">(7a, 8)</a> Furthermore, EphA2 is highly expressed in a high proportion of cancer types, and in some cancers the level of EphA2 expression has been correlated with the degree of malignancy.<a onclick="showRef(event, 'cit7a cit8b ref9'); return false;" href="javascript:void(0);" class="ref cit7a cit8b ref9">(7a, 8b, 9)</a> Therefore, EphA2 is being actively studied as a target for tumor diagnosis and treatment.<a onclick="showRef(event, 'cit9b ref10'); return false;" href="javascript:void(0);" class="ref cit9b ref10">(9b, 10)</a></div><div class="NLM_p">Recently, a chimeric protein consisting of a protein toxin (PE38QQR exotoxin) fused to the natural EphA2 ligand, ephrin-A1, has been shown to cause potent and dose-dependent killing of glioblastoma and breast and prostate cancer cells that express high levels of the EphA2 receptor.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Alternatively, a human EphA2 monoclonal antibody has been developed and conjugated with the tubulin binding agent monomethylauristatin.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This antibody–drug conjugate targets tumors expressing high levels of EphA2 and shows impressive efficacy in mouse xenograft models. However, both the natural ligand and the EphA2 antibody conjugate strategies still have the traditional drawbacks of protein-based therapeutics, such as immunogenic or allergic responses as well as difficulties in ensuring homogeneous conjugation between drug and protein. It is therefore desirable to develop peptide or small molecule ligands that selectively bind to EphA2 and take advantage of its ability to mediate internalization.<a onclick="showRef(event, 'cit7b'); return false;" href="javascript:void(0);" class="ref cit7b">(7b)</a></div><div class="NLM_p last">By using phage display, we have previously identified two short peptides, YSA (amino acid sequence YSAYPDSVPMMS) and SWL (amino acid sequence SWLAYPGAVSYR), which selectively target EphA2 in preference to other Eph receptors.<a onclick="showRef(event, 'cit5b'); return false;" href="javascript:void(0);" class="ref cit5b">(5b)</a> Of the two biotinylated peptides, YSA showed higher affinity for EphA2 (<i>K</i><sub>D</sub> ≈ 200 nM) and was able to inhibit binding of ephrin-A ligands to immobilized EphA2 receptor with IC<sub>50</sub> values in the low micromolar range. Consistent with these previous findings, Scarberry et al. recently reported that magnetic cobalt ferrite nanoparticles coated with the YSA peptide can selectively target EphA2 expressing ovarian carcinoma cells.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Similar to the ephrin ligands, the YSA peptide can also induce EphA2 activation and downstream signaling as well as decrease receptor levels on the cell surface.<a onclick="showRef(event, 'cit5b ref14'); return false;" href="javascript:void(0);" class="ref cit5b ref14">(5b, 14)</a> In order to exploit the diagnostic and therapeutic cancer-targeting potential of the YSA peptide toward EphA2 overexpressing cells, we have developed an effective YSA-based targeting agent using a synthetic strategy that allows the conjugation of a variety of anticancer and/or imaging reagents to the peptide. In particular, here we report the characterization of the YSA peptide conjugated to paclitaxel and demonstrate its successful delivery to tumors in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> EphA2 Receptor Is Overexpressed in Most Solid Tumors</h3><div class="NLM_p">We employed a qPCR (quantitative real-time polymerase chain reaction) screen of total cDNA libraries collected from 68 human cancer cell lines across nine separate cancer types as well as samples extracted from 17 normal tissue types to quantify the expression of the EphA2 receptor (NM_004431.2). The data were compared to the expression of the EphA4 receptor (NM_004438.3) and normalized to the expression levels observed in a cultured human dermal fibroblast (HDF) cell line (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information Figure 1">Supporting Information Figure 1</a>). In the 17 normal human tissues total RNA samples we observed an average of 2.83 ± 0.45 (mean ± SEM) fold expression of EphA2 compared to the levels observed in the HDF cell line. As a comparison, the EphA4 expression levels were uniformly higher in 16 of the normal tissue samples, while the normal brain total RNA sample showed 45.74 ± 11.87 fold the expression seen in the reference HDF cell line.The trend is reversed when observing cancer cell lines, with the expression of the EphA4 receptor substantially unchanged with respect to the HDF reference cell line (0.96 ± 0.16 fold across the 68 cell lines studied; <i>p</i> < 0.0001, Mann–Whitney test) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A and <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information Figure 1">Supporting Information Figure 1</a>), while the expression of the EphA2 was markedly higher (>7× compared to HDF) in more than half of the cell lines studied. When the cell lines were grouped according to their tissue of origin, overexpression of EphA2 was broadly observed in the colon (13.50 ± 2.95 fold the HDF expression levels; <i>P</i> = 0.0003), ovarian (13.72 ± 3.46 fold the HDF expression levels; <i>P</i> = 0.0004), and renal (7.59 ± 1.39 fold the HDF expression levels; <i>P</i> = 0.0043) derived cancer cell lines (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>C). For each of these three groups more than 50% of the cell lines showed significant overexpression. The leukemia cell lines showed significant underexpression of EphA2 (0.26 ± 0.13; <i>P</i> = 0.0012) compared to the normal tissue samples (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information Figure 1">Supporting Information Figure 1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. EphA2 and EphA4 expression in 68 human cancer cell lines and 17 normal tissue RNA samples. (A) EphA2 and EphA4 receptor expression in normal and cancer cell lines. Bar graph shows the fold expression of both EphA2 and EphA4 receptors in MDA-MD-231, PC-3, and LNCaP cancer cell lines compared to cultured human dermal fibroblast (HDF) and to a total human prostate RNA sample (prostate). (B) Correlation between EphA2 mRNA expression and EphA2 protein levels in 30 selected human cancer cell lines. (C) Box and Whisker plots of the 10th to 90th percentile of EphA2 expression for the RNA samples grouped according to their tissue of origin. Dotted lines depict cutoffs for 7-fold and 14-fold expression levels observed in the reference HDF cell line, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further verify that the mRNA expression data collected reflect protein levels in cell, we performed ELISA-based assays for 30 of the cell lines that are designed to quantify the amount of total EphA2 protein present in the cells. The ELISA analysis identified a significant correlation between the mRNA and levels for EphA2 in these 30 cell lines (R2 = 0.6679, <i>P</i> < 0.0001) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B, <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>), corroborating our analysis based on mRNA levels.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> The YSA Peptide Targets the EphA2 Receptor and Induces Its Internalization</h3><div class="NLM_p">In order to investigate the EphA2 targeting ability of our previously described YSA peptide, we transfected COS cells with a plasmid encoding either the extracellular and transmembrane domains of the EphA2 receptor fused to EGFP (EphA2-EGFP) or membrane-targeted EGFP (EGFP-F). Incubation of COS cells with biotinylated YSA peptide (a YSA peptide conjugated at the C-terminal with biotin) bound to streptavidin conjugated red fluorescent quantum dots (YSA-Qdots) revealed the presence of quantum dots bound to cells transfected with EphA2-EGFP but not control cells transfected with EGFP-F or untransfected cells (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A). Although COS cells express endogenous EphA2, overexpressing the receptor provides increased sensitivity. We also observed that the YSA peptide targets quantum dots to endogenous EphA2 located on the surface of human umbilical vein endothelial (HUVE) cells while a control peptide that does not bind to EphA2 or quantum dots without any bound peptide does not bind to the HUVE cell surface (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). In addition, we used the lysosomal marker Lamp1 to show that the YSA peptide successfully mediates cellular uptake of quantum dots into lysosomes in the MDA-MB-231 breast cancer cell line, which expresses high levels of EphA2<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C). Thus, the YSA peptide not only binds to EphA2 but also is able to initiate the active internalization of the receptor into cancer cells, resulting in the concomitant internalization of its cargo.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. YSA peptide targets cells expressing EphA2. (A) The YSA peptide targets quantum dots to EphA2 on the cell surface. COS cells transfected with either the extracellular and transmembrane portions of EphA2 fused to enhanced green fluorescent protein (EphA2-EGFP) or membrane targeted EGFP-F were incubated with YSA bound to red fluorescent quantum dots (YSA–Qdots). YSA–Qdots only bind to cells transfected with EphA2-EGFP. EGFP fluorescence is green. Nuclei are stained in blue with DAPI. (B) YSA targets quantum dots to endogenous EphA2 on the cell surface. HUVE cells were incubated at 4 °C with YSA conjugated Qdots (YSA–Qdots), an unrelated 12-mer control peptide that does not bind to EphA2 also conjugated to Qdots (Ctrl-Qdots), or unconjugated Qdots (Qdots). Only quantum dots conjugated to the YSA peptide bind to the HUVE cells. (C) YSA targets Qdots to lysosomes. MDA-MB-231 cells, which express high levels of endogenous EphA2, were incubated at 4 °C with YSA–Qdots followed by incubation at 37 °C for 0, 15, and 60 min. YSA–Qdots are seen on the cell surface at 0 min but become concentrated in structures near the nucleus at 15 and 60 min (arrow). Double labeling with the lysosomal marker Lamp1 (green) shows colocalization of the quantum dots in lysosomes at 60 min (arrows).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design, Synthesis, and Characterization of a YSA–Paclitaxel Conjugate (YSA–PTX)</h3><div class="NLM_p">We developed a novel antitriazole linker for the synthesis of YSA peptide–drug conjugates to avoid the compatibility problems of disulfide and hydrazone linkers. Conjugation at the C-terminus of the peptide was preferred because modifications at the N-terminus of the YSA peptide decrease EphA2 binding activity (data not shown). Hence, the C-terminus of YSA was derivatized with <i>N</i>ε-(5-hexynoyl)lysine, resulting in the amino acid sequence YSAYPDSVPMMS[<i>N</i>ε-(5-hexynoyl)-K], hereafter referred to as “YSA motif”. This motif provides the alkyne moiety for subsequent coupling of modified paclitaxel using click chemistry.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> To provide the azide counterpart of click chemistry, we attached a diglycolic acid 6-azidohexanyl monoester to the 2′-hydroxyl of paclitaxel by employing a selective protection/deprotection strategy (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>). Coupling of the YSA motif with the azide-linker-derived paclitaxel (PTX) was accomplished under mild click-chemistry reaction conditions, generating the desired YSA–PTX conjugate (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). A similar synthetic approach was used to conjugate a YSA scrambled peptide control (DYP–PTX; amino acid sequence DYPSMAMYSPSV[<i>N</i>ε-(5-hexynoyl)-K])<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to PTX (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A) as well as for biotinylated peptides, YSA–PTX–biotin and DYP–PTX–biotin (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. YSA–PTX retains high potency for inhibition of EphA2-ephrin-A5 binding and high EphA2 binding affinity. (A) General chemical structures of YSA and DYP peptide–drug conjugates. (B) YSA, YSA–PTX, and control DYP–PTX were incubated at the indicated concentrations together with a constant concentration of ephrin-A5 AP in ELISA wells precoated with EphA2 Fc. The ratio of ephrin-A5 AP bound in the presence and in the absence of peptide is shown. (C) Biotinylated YSA–PTX and control DYP–PTX were incubated at the indicated concentrations in EphA2 Fc-coated ELISA wells and were then detected with streptavidin–HRP. The graphs show averages ± SE from quadruplicate measurements in representative experiments, while the <i>K</i><sub>D</sub> and IC<sub>50</sub> values are calculated from three to five experiments. (D) ATP-Lite analysis of viability of PC-3 cells 72 h after the addition of DYP, DYP–PTX, YSA, YSA–PTX, or PTX at 10 nM (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After preparation of the YSA–PTX conjugate, we confirmed that the conjugation does not interfere with the ability of YSA to bind EphA2 and cause its internalization. The ability of YSA–PTX to efficiently compete, in a dose dependent manner, with ephrin-A5 fused to alkaline phosphatase (ephrin-A5 AP) for binding to the EphA2 extracellular domain fused to Fc (EphA2 Fc) in ELISA assays demonstrates that the conjugate retains its EphA2 binding ability (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B). In contrast, neither of the control compounds, the DYP motif nor DYP–PTX conjugate, show any detectable displacement of ephrin-A5. We measured a <i>K</i><sub>D</sub> of ∼0.8 μM for the binding of biotinylated YSA–PTX to EphA2 Fc immobilized in ELISA wells, whereas binding of the biotinylated control DYP–PTX was undetectable (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. EphA2 Inhibition<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">sequence</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>n</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YSA</td><td class="colsep0 rowsep0" align="left">YSAYPDSVPMMS</td><td class="colsep0 rowsep0" align="left">12.6 ± 1.03</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YSA motif</td><td class="colsep0 rowsep0" align="left">YSAYPDSVPMMS-K*</td><td class="colsep0 rowsep0" align="left">1.68 ± 0.26</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YSA–PTX</td><td class="colsep0 rowsep0" align="left">YSAYPDSVPMMS-K*-PTX</td><td class="colsep0 rowsep0" align="left">6.82 ± 0.81</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYP motif</td><td class="colsep0 rowsep0" align="left">DYPSMAMYSPSV-K*</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYP–PTX</td><td class="colsep0 rowsep0" align="left">DYPSMAMYSPSV-K*-PTX</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">K* is a modified lysine with an alkyne linker.</p></div></div></div><div class="NLM_p">In vitro cell viability assays confirmed that the YSA–PTX conjugate retained the ability of paclitaxel to induce cell death at low nanomolar concentrations in the EphA2 overexpressing prostate cancer cell line PC3 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>D), while paclitaxel conjugated to the scrambled peptide, DYP–PTX, showed no significant cell killing in the same assay (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>D). These data suggest that the peptide has sufficient affinity for the receptor to deliver an effective dose of drug.</div><div class="NLM_p">Further analysis of YSA–PTX–Qdots revealed that the peptide conjugate facilitates Qdot uptake into the lysosomes of the highly EphA2 expressing prostate cancer cell line, PC3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In contrast, YSA–PTX–Qdots does not target the LNCaP prostate cancer cell line (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A), which, according to both our qPCR data (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A) and previous literature data,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> does not express detectable levels of EphA2. As a further control, the DYP–PTX control scrambled peptide does not target PC3 cells and does not trigger EphA2 internalization (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). Moreover, we confirmed that even when not coupled to quantum dots, YSA–PTX causes EphA2 internalization into the lysosomes of PC3 cells, similar to the ephrin-A1 Fc ligand (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). YSA–PTX, but not DYP–PTX, also causes EphA2 tyrosine phosphorylation (which is indicative of activation) and loss of the receptor from the surface of not only PC3 cancer cells but also HUVE endothelial cells (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C). These data indicate that the YSA–PTX conjugate retains the ability of YSA to bind EphA2 and allows effective internalization of PTX into cells. Furthermore, they suggest that YSA–PTX may be useful to target not only cancer cells but also the tumor vasculature.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. YSA–PTX is internalized in cancer and endothelial cells expressing EphA2. (A) YSA–PTX coupled to fluorescent quantum dots, but not DYP–PTX, is internalized with EphA2 into lysosomes of prostate cancer cells expressing EphA2. PC3 prostate cancer cells, which express high levels of EphA2, or LNCaP prostate cancer cells, which do not detectably express EphA2 protein, were treated for 20 min with 100 μM YSA–PTX or control DYP–PTX, followed by a 20 min of incubation with streptavidin-conjugated quantum dots (Qdots). After removal of the solution containing the peptides and the quantum dots, the cells were incubated for 2 h at 37 °C to allow EphA2 internalization induced by YSA–PTX binding. The cells were stained for EphA2 (left) or the lysosomal marker Lamp1 (right). Qdots were also imaged, and nuclei were labeled with DAPI in blue. Representative fluorescence micrographs are shown. Scale bar = 25 μM. (B) Ephrin-A1 Fc and YSA–PTX, but not DYP–PTX, cause EphA2 internalization into lysosomes. PC3 cells were treated for 2 h with 0.2 μg/mL ephrin-A1 Fc, 100 μM YSA–PTX, or 100 μM control DYP–PTX. The cells were stained for Lamp1 (red) and EphA2 (green). Nuclei were labeled with DAPI (blue). Representative confocal micrographs are shown. Scale bar = 25 μm. (C) Ephrin-A1 Fc and YSA–PTX, but not DYP–PTX, cause EphA2 internalization into cells. PC3 prostate cancer and HUVE endothelial cells were treated for 1 h with 0.2 μg/mL ephrin-A1 Fc, 100 μM YSA–PTX, or 100 μM control DYP–PTX. Proteins present on the cell surface were then labeled with biotin. EphA2 immunoprecipitates were probed with antiphosphotyrosine antibody (PTyr), streptavidin–HRP (biotin), and EphA2 antibody. The amount of GAPDH in the cell lysates used for the immune precipitations is also shown as a control for equal amounts of protein in the lysates used for immunoprecipitation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> YSA–PTX Targets Tumors in Vivo</h3><div class="NLM_p">In preparation for in vivo studies of the YSA–PTX conjugate, we found that YSA–PTX shows favorable plasma and microsomal half-lives (43 and 23 min, respectively) and is able to release native paclitaxel in the presence of PC3 cells with nearly complete release in about 60 min (data not shown). Therefore, we examined the effects of YSA–PTX in preliminary in vivo studies using PC3 tumor xenografts. Tumor-bearing mice were treated twice weekly with an intravenous injection of PTX or YSA–PTX for a total of 3 weeks. Remarkable tumor growth inhibition (<i>p</i> < 0.05) was observed with YSA–PTX (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A) while unconjugated PTX administered at an equimolar dose did not significantly affect tumor growth compared to vehicle control. Moreover, mouse body weights were not affected by YSA–PTX administration in comparison to administration of vehicle control, and no adverse signs of toxicity in the YSA–PTX-treated mice were observed. To confirm preferential delivery of paclitaxel to tumor xenografts, we analyzed tumors dissected from mice treated with PTX or YSA–PTX to determine PTX tumor delivery using mass spectrometry. Tumor-bearing mice were treated with a single dose of PTX or YSA–PTX at equimolar doses, and PTX levels were measured in tumor tissue and plasma 30 min after administration. This revealed that the tumor tissue from the YSA–PTX group shows significantly higher PTX levels compared to the group where unconjugated PTX was administered, while plasma PTX concentrations were equivalent (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Expression of EphA2 and cellular and in vivo activity of drug conjugates. (A) Groups of five to seven SCID beige mice bearing pre-established subcutaneous PC3 tumors were treated with twice weekly with intravenous doses of vehicle (CT), paclitaxel (5 mg/kg), YSA–paclitaxel (equimolar doses of the paclitaxel dose), starting at day 0. Tumor sizes were measured, and averages ± SEM are shown. <i>p</i> < 0.05 for the comparison of YSA–paclitaxel with control, by repeated-measures two-way ANOVA using all the measurements as well as by one-way ANOVA and Dunnett’s post hoc test using the measurements at day 18. (B) Biodistribution analysis. PC3 tumors (<i>n</i> = 3, average volume of 200 mm<sup>3</sup>) were excised 30 min after equimolar amounts of YSA–PTX or PTX (25 mg/kg) were injected intravenously. LC–MS analysis was performed to quantify PTX levels from tumor extracts. The histogram shows averages ± SEM. <i>p < </i>0.05 for the comparison of PTX levels, by <i>t</i> test analysis. Plasma levels of PTX were not significantly different (YSA–PTX = 998 ± 742 ng/mL; PTX = 771 ± 585 ng/mL).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of tumor specific, cell penetrating molecules remains a primary focus in cancer research. Our data demonstrate that the YSA peptide is capable of specifically targeting the EphA2 receptor and of causing receptor activation and internalization, which also results in the internalization of the YSA peptide and any conjugated biomolecule. As expected, YSA–PTX can induce activation of EphA2, thus mediating its internalization into cancer and endothelial cells. In addition, conjugation of PTX to the YSA peptide does not interfere with the chemotherapeutic function of PTX.</div><div class="NLM_p">Our qPCR studies show that overexpression of EphA2 is a common (occurring in one-third of the solid tumor-derived cell lines studies) but not universal characteristic of solid tumor types. Recent studies have reported that EphA2 expression levels may be up-regulated in response to hypoxic stress.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As a result, the overexpression of EphA2 in tumor tissues in vivo may be much higher than the levels observed in tissue culture environment, where oxygen levels are abnormally high compared to not only the hypoxic regions of tumors but also the levels in normal tissues. In addition, EphA2 is widely up-regulated in the tumor vasculature but is not expressed in normal quiescent vasculature.<a onclick="showRef(event, 'cit7a cit8a'); return false;" href="javascript:void(0);" class="ref cit7a cit8a">(7a, 8a)</a> Our results suggest that the YSA peptide could be used as a vehicle for the delivery of diagnostic and chemotherapeutic agents to EphA2 expressing tumors.</div><div class="NLM_p">Our preliminary paclitaxel biodistribution studies demonstrate that the YSA–PTX conjugate affords a significant increase in the amount of drug delivered to the tumor compared with administration of free paclitaxel. Consistent with this, our results show that YSA–PTX is much more effective in inhibiting PC3 tumor xenograft growth than free paclitaxel, with no overt signs of toxicity. We speculate that the enhanced antitumor activity of YSA–PTX can be attributed to its two sought-after traits: tumor selectivity and tumor tissue penetration. Conjugation of the YSA peptide to paclitaxel endows YSA–PTX with the ability to selectively bind to and activate EphA2, leading to internalization of the EphA2–YSA–PTX complex. As a result, paclitaxel is actively transported into cells rather than relying on passive transport as is the case when a tumor selective molecule lacks the ability to mediate internalization. Our data demonstrate that for equivalent molar dosing, YSA–PTX delivers a higher proportion of active drug molecules into the tumors, leading to a dramatic decrease in tumor growth.</div><div class="NLM_p">Along with increasing tumor selectivity and tumor tissue penetration, conjugation to YSA may increase the water solubility of paclitaxel, thus making it more bioavailable,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> as well as allow an increase in the therapeutic window of the drug. In fact, EphA2 expression is limited in normal tissues,<a onclick="showRef(event, 'cit7a cit8b ref9'); return false;" href="javascript:void(0);" class="ref cit7a cit8b ref9">(7a, 8b, 9)</a> and in normal epithelial cells EphA2 is likely found in complex with ephrin ligands and therefore cannot be efficiently targeted by YSA, an ephrin antagonist, in contrast to tumor tissue where EphA2 is not frequently coexpressed with ephrin ligands.<a onclick="showRef(event, 'ref15 ref22'); return false;" href="javascript:void(0);" class="ref ref15 ref22">(15, 22)</a> The low EphA2 expression observed in normal tissues and its engagement with ephrin ligands, as well as our biodistribution data, highlight the fact that the use of the YSA peptide for drug delivery may reduce exposure of normal tissues to cytotoxic drugs, thus presumably reducing toxic side effects. As a result, YSA–PTX may broaden the therapeutic window of paclitaxel to an extent that elevated doses could still be safely used. Administering larger doses of YSA–PTX to patients may increase the chances of eradicating tumors while decreasing the cancer cells’ ability to evade either the YSA targeting molecule or the cell stress caused by the chemotherapeutic.</div><div class="NLM_p">The use of a targeting peptide, as opposed to a protein or antibody drug conjugate, for delivery of anticancer drugs has also a number of significant advantages over the use of full length ephrins or antibodies. The short peptide sequence is a single, relatively small molecule that lacks the size necessary to mount an immune response during therapy. Also not to be overlooked is the significant lower cost for the synthesis of a homogeneous short peptide when compared to the preparation of proteins and humanized antibodies.</div><div class="NLM_p last">In summary, YSA–PTX has been demonstrated to have a powerful antitumor activity in vitro and in vivo and could serve as a valuable candidate for further preclinical and eventually clinical evaluation in humans. The use of small peptide ligands targeting EphA2-expressing tumors for drug delivery could provide a new arsenal of diagnostic and therapeutic options for cancer patients. With this report we intend to share our compelling preliminary findings, which we believe open the way to future studies to optimize the peptide sequence for binding affinity and in vivo stability, investigate additional YSA–drug conjugates, conjugate YSA and optimized derivatives with MRI or PET imaging agents such as DTPA or DOTA, and perform detailed studies on the pharmacokinetics of the conjugates.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Chemical Synthesis and Purification</h3><div class="NLM_p last">Unless otherwise noted, all reagents and anhydrous solvents were obtained from commercial sources and used without purification, and the fully protected peptides on resin were purchased from Biopeptide Co. The YSA and DYP peptides were purchased from either Medical College of Wisconsin or Abgent, Inc. (San Diego, CA). All reactions were performed in oven-dried glassware. All reactions involving air or moisture sensitive reagents were performed under a nitrogen atmosphere. Silica gel chromatography was performed using prepacked silica gel or C-18 cartridges (RediSep). All final compounds were purified to >95% purity, as determined by a HPLC Breeze from Waters Co. using an Atlantis T3 5.0 μm, 4.6 mm ×150 mm reverse phase column. 1D and 2D NMR spectra were recorded on a Bruker 600 MHz instrument. Chemical shifts are reported in ppm (δ) relative to <sup>1</sup>H (Me<sub>4</sub>Si at 0.00 ppm). Coupling constant (<i>J</i>) are reported in Hz throughout, and NMR signal assignments were based on DEPT, 2D [<sup>13</sup>C,<sup>1</sup>H]HSQC, 2D [<sup>1</sup>H,<sup>1</sup>H]COSY, 2D [<sup>1</sup>H,<sup>1</sup>H]-TOCSY, and 2D [<sup>1</sup>H,<sup>1</sup>H]HMBC experiments. Low resolution and high resolution mass spectral data were acquired on an Esquire LC00066 mass spectrometer, an Agilent ESI-TOF mass spectrometer, or a Bruker Daltonic Autoflex MALDI-TOF/TOF mass spectrometer. Detailed synthetic procedures and analytical data for compound intermediates and final compounds are reported in the <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a> section.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> ELISA-Based Displacement and Binding Assays</h3><div class="NLM_p last">EphA2 Fc (R&D Systems, Minneapolis, MN) diluted to 1 μg/mL in TBST buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, with 0.01% Tween 20) was immobilized in protein A coated wells. The wells were then incubated for 3 h with 0.01 nM ephrin-A5 fused to alkaline phosphatase (ephrin-A5 AP)<a onclick="showRef(event, 'cit5b'); return false;" href="javascript:void(0);" class="ref cit5b">(5b)</a> in culture medium diluted in TBST in the presence of different concentrations of YSA, YSA–PTX, or DYP–PTX. The concentration of ephrin-A5 AP was calculated based on AP activity measurements.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Bound ephrin-A5 AP was quantified by adding pNPP as the substrate and measuring the absorbance at 405 nm. Absorbance from wells where human Fc (R&D Systems, Minneapolis, MN) was added instead of EphA2 Fc was subtracted as the background. Curves for the binding of biotinylated YSA–PTX and DYP–PTX to EphA2 Fc were measured by adding different concentrations of the peptides to ELISA wells precoated with protein A and EphA2 Fc. Bound biotinylated peptides were detected with horseradish peroxidase (HRP) conjugated streptavidin (Thermo Scientific/Pierce, Rockford, IL; 1:2000 dilution in TBST). Absorbance at 405 nm was measured following incubation with 0.2 mg/mL 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) (Sigma-Aldrich, Steinheim, Germany) in citric acid as a substrate, and the absorbance in wells without peptide was subtracted as background. The inhibition and binding curves were analyzed using nonlinear regression and the program Prism (GraphPad Software Inc.).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Fluorescence Cell Imaging</h3><div class="NLM_p">COS cells and MDA-MB-231 breast cancer cells (ATCC) were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech, Inc., Herndon, VA) with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and Pen/Strep (Omega Scientific, Tarzana, CA). PC3-3M-luc-C6 Bioware (Caliper) and LNCaP prostate cancer cells (ATCC) were grown in RPMI 1640 medium (Mediatech, Inc., Herndon, VA) with 10% FBS and Pen/Strep. Human umbilical vein endothelial cells (HUVECs, Cascade Biologics, Portland, OR) were grown in medium 200 supplemented with low serum growth supplements (Cascade Biologics), 10% FBS, Pen/Strep, and fungizone (Omega Scientific, Tarzana, CA).</div><div class="NLM_p">To label cells expressing transfected EphA2 with fluorescent quantum dots, COS cells grown in 6 cm plates were transfected with 3 μg of a plasmid encoding EphA2 extracellular and transmembrane domains fused to enhanced green fluorescent protein (EGFP) or 3 μg of a vector encoding farnesylated EGFP (F-EGFP) (BD Biosciences Clontech) as control, using SuperFect transfection reagent (Qiagen, Inc., Valencia, CA). The cells were plated on glass coverslips and labeled 2 days after transfection. For the labeling experiments, 20 nM streptavidin-conjugated Qdot 655 quantum dots (Invitrogen/Molecular Probes, Eugene, OR) were preincubated for 20 min at 4 °C with 500 nM biotinylated YSA peptide (YSAYPDSVPMMS-GSGSK-biotin), or a biotinylated control 12-mer peptide that does not bind to EphA2, in quantum dots binding buffer (1 mM CaCl<sub>2</sub>, 2% BSA in PBS). The cells were then incubated for 20 min at 4 °C with quantum dots containing the YSA peptide or the control peptide, or quantum dots without peptide as a further control, and then washed with ice cold 1 mM CaCl<sub>2</sub> in PBS. To label human umbilical endothelial (HUVE) cells expressing endogenous EphA2, the cells were plated on glass coverslips coated with fibronectin (10 μg/mL) and incubated with 100 μM biotinylated YSA peptide in quantum dots binding buffer for 20 min at 4 °C. The cells were then washed with ice cold 1 mM CaCl<sub>2</sub> in PBS, followed by incubation with 20 nM streptavidin quantum dots for 20 min at 4 °C in quantum dots binding buffer.</div><div class="NLM_p">For quantum dot internalization experiments, MDA-MB-231, PC3, and LNCaP cells were grown on glass coverslips. For MDA-MB-231 cells, 20 nM streptavidin-conjugated QDot 655 quantum dots were preincubated for 20 min on ice with 500 nM biotinylated YSA peptide in conditioned medium supplemented with 10 mM HEPES. The cells were then incubated for 20 min on ice with the quantum dot/YSA peptide mixture, or quantum dots without peptide (negative control), and then in a 37 °C CO<sub>2</sub> incubator for various periods of time. For PC3 and LNCaP cells, the conditioned medium was removed from the cells, supplemented with 10 mM HEPES and stored at 4 °C, and the cells were serum starved for 3 h in serum-free medium. The cells were then treated with 100 μM biotinylated YSA–PTX or DYP–PTX in quantum dots binding buffer for 20 min on ice, followed by 20 nM streptavidin-conjugated Qdot 655 in binding buffer for 20 min on ice. After removal of the quantum dot solution, the cells were washed with the binding buffer and incubated with the stored conditioned medium in a 37 °C CO<sub>2</sub> incubator for 2 h to allow internalization of the EphA2–YSA–PTX–quantum dots complexes. The cells were then washed with ice cold PBS, fixed in 4% formaldehyde with 4% sucrose for 10 min, permeabilized for 5 min with 0.05% Triton-X100 in PBS, and incubated for 1 h with PBS containing 10% goat serum and 2% BSA. For EphA2 staining, the coverslips were incubated with a rabbit anti-EphA2 antibody (Life Technologies/Invitrogen) followed by a secondary anti-rabbit antibody conjugated with Alexa Fluor 488 (Life Technologies/Molecular Probes). For staining of lysosomes, the coverslips were incubated with polyclonal rabbit anti-human Lamp1 antibody<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> followed by a secondary anti-rabbit antibody conjugated with Alexa Fluor 568. The nuclei were counterstained with DAPI. Images were obtained with an inverted TE300 Nikon fluorescence microscope and processed using Adobe Photoshop.</div><div class="NLM_p last">To image EphA2 internalization and colocalization with lysosomes after stimulation PC3 cells plated on glass coverslips were serum starved for 1 h in serum-free medium and then stimulated with 0.2 μg/mL Fc (as a negative control), 0.2 μg/mL ephrin-A1 Fc (as a positive control), 100 μM YSA–PTX–biotin or 100 μM DYP–PTX–biotin for 2 h. The cells were then fixed, permeabilized, and labeled as described above. Images were acquired using a Radiance 2100 MP confocal microscope.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Immunoprecipitation and Immunoblotting</h3><div class="NLM_p last">PC3 cells were serum-starved for 1 h in serum-free medium and treated for 1 h with 0.2 μg/mL human Fc (as a negative control), 0.2 μg/mL ephrin-A1 Fc (as a positive control), 100 μM YSA–PTX, or 100 μM DYP–PTX. The cells were then placed on ice, rinsed once with cold PBS, and incubated for 20 min at 4 °C with a 0.5 mg/mL EZ-link sulfo-NHS-biotin (Thermo Scientific/Pierce, Rockford, IL) in PBS. The cells were then washed 3 times with a 100 mM glycine in PBS to quench the biotinylation reaction, followed by PBS. The cells were lysed in modified RIPA lysis buffer (150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 20 mM Tris, pH 8.0) containing protease inhibitors and 1 mM sodium orthovanadate. For immunoprecipitations, cell lysates were incubated with 2 μg of anti-EphA2 antibody (Millipore-Upstate, Inc. Temecula, CA) immobilized on GammaBind Sepharose beads (GE Healthcare Life Sciences). Immunoprecipitates and lysates were probed by immunoblotting with anti-phosphotyrosine antibody (Millipore, Inc., Temecula, CA), streptavidin coupled to HRP (Thermo Scientific/Pierce, Rockford, IL), anti-EphA2 antibody (Life Technologies/Invitrogen), and anti-GAPDH antibody (Sigma-Aldrich, Steinheim, Germany).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> RNA Expression of Tumor Cells</h3><div class="NLM_p">Cancer cell lines and human dermal fibroblast cells were cultured, and total RNA was isolated from each as previously described.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The Firstchoice Human Total RNA Survey Panel (Agilent Technologies) was purchased to serve as control for normal tissue RNA expression levels. Total RNA was extracted from 3 × 10<sup>6</sup> cells from each line harvested at 70–80% confluence and prepared using the Illustra RNAspin mini total RNA extraction kit (GE Healthcare) according to the manufacturer’s recommendations for cultured cells. DNA contamination and sample concentration for each sample were determined using a NanoDrop ND-1000 spectrophotometer. The RNA integrity of each sample was further confirmed using a BioRad Experion bioanalyzer to assess the ratio of 28s and 18s RNA. All samples exhibited 28s/18s ratios of 1.8–2.2 and RIN values of 9 or greater, which indicates the presence of high quality total RNA. cDNA was produced using qScript cDNA Supermix (Quanta Biosciences) according to manufacturer’s recommendations in 20 μL reaction mixtures using 400 ng of total RNA as the template. The resultant cDNA was stored at −40 °C and diluted 1:7 prior to use in qPCR.</div><div class="NLM_p">Primers for use in qPCR were identified using the Universal Probe Library design tools (Roche Applied Sciences) for both EphA2 receptor (NM_004431.2; sense, ggcaggagttggcttctttat; antisense, tgttctgacttggagaagtaaacg) and EphA4 receptor (NM_004438.3; sense, gatagcaagccctctggaag; antisense, ggtaggttcggattggtgtatt) in combination with the universal probe no. 69 (Roche Applied Sciences). Each qPCR reaction also contained the primers and probe necessary to run a simultaneous internal G6PH multiplexed control (Roche Applied Sciences). Primers were purchased from Invitrogen. All qPCR reactions were performed in 17 μL reaction mixtures containing 2 μL of the diluted cDNA, 0.5 μL of G6PH primer mix, 0.5 μL G6PH probe, 1.0 μL of EphA2 or EphA4 primer mix, 0.5 μL probe no. 69, 10 μL of Mastermix (Roche Applied Sciences), and 2.5 μL of molecular grade water. Each sample was run in triplicate in a 96-well polypropylene plate (Stratagene) with the Mx3000P qPCR system (Stratagene). Thermocycling conditions consisted of an initial polymerase inactivation step at 95 °C for 10 min, followed by 40 cycles at 95 °C for 30 s, 55 °C for 1 min, and 72 °C for 1 min. Baselines and thresholds were automatically set by the software. Serial dilution showed that the <i>C</i><sub>q</sub> value for all data was linear over 5 orders of magnitude (<i>R</i><sup>2</sup> of 0.996). Control experiments without primers, template, or probe exhibited no detectable signal.</div><div class="NLM_p last">Calculated <i>C</i><sub>q</sub> values were exported to Excel 2007 (Microsoft) and Prism 5.04 (Graphpad Softward Inc.) for further analysis. Each cell type’s data were normalized to the average level of mRNA expression (<i>C</i><sub>q</sub> value) of G6PH across all cell lines. SEM values for the three replicates for each gene in all 68 cell lines and 17 normal tissue cDNA pools were then calculated from these normalized <i>C</i><sub>q</sub> values. The <i>C</i><sub>q</sub> value for each cell line was compared to that observed in the cultured human dermal fibroblast cell line. The average ± the SEM values were calculated and transformed into fold expression values for the purpose of displaying the error bars in graphical representations of the data.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> EphA2 Protein Quantification</h3><div class="NLM_p last">The amount of EphA2 protein in each cell line was assayed using the human total EphA2 DuoSet Elisa kit (R&D Systems, Minneapolis, MN). Lysates were collected from a selection of the cell lines studied using a concentration of 1 million cells/mL of lysis buffer no. 9. Total protein samples were flash frozen and stored at −80 °C until tested. The protein concentration from each sample was determined by BCA protein analysis (Pierce Biotechnology Inc., Rockford, IL), and 100 and/or 30 μg of total protein was analyzed as outlined by the manufacturer’s directions. Each protein sample dilution was tested in duplicate. A standard curve of recombinant EphA2 protein (<i>R</i><sup>2</sup> = 0.996) was used to quantify the resulting absorbance values.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> ATP-Lite Based Analysis of Cell Viability</h3><div class="NLM_p last">PC3 cells were cultured and tested using the ATP-Lite Onestep kit (Perkin-Elmer) as outlined previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> A fixed concentration of 0.5% DMSO was present in each 100 μL culture volume upon addition of the compounds, and ATP concentration was recorded 72 h after addition of the compounds.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Microsomal and Plasma Stability Assays</h3><div class="NLM_p">To assess microsomal stability of YSA–PTX, the conjugate was incubated with rat liver microsomes (RLM) for 60 min at 37 °C. The final incubation solutions contained 4 μM YSA–PTX, 2 mM NADPH, 1 mg/mL (total protein) microsomes, and 50 mM phosphate (pH 7.2). Compound solutions, protein, and phosphate were preincubated at 37 °C for 5 min, and the reactions were initiated by the addition of NADPH and incubated for 1 h at 37 °C. Aliquots were taken at 30 min time-points and quenched with the addition of methanol containing an internal standard. Following protein precipitation and centrifugation, the samples were analyzed by LC–MS. YSA–PTX was run in duplicate with a control compound of known half-life. HLM <i>t</i><sub>1/2</sub> ≥ 30 min is generally classified as good microsomal stability.</div><div class="NLM_p last">For measurements of plasma stability, 1 μM YSA–PTX was incubated at 37 °C with fresh rat plasma, 2.5% final DMSO concentration. The reactions were terminated at 0, 30, and 60 min by the addition of two volumes of methanol containing an internal standard. Following protein precipitation and centrifugation, the samples were analyzed by LC–MS. The percentage of YSA–PTX remaining at each time point relative to the 0 min sample is calculated from peak area ratios in relation to the internal standard. YSA–PTX was run in duplicate with a positive control known to be degraded in plasma.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> In Vivo Xenograft Studies</h3><div class="NLM_p last">PC3-3M-luc-C6 cells (1 × 10<sup>6</sup>) were injected subcutaneously in SCID-beige mice, and tumor sizes were monitored twice per week using calipers. Once the tumors reached sizes of ∼100 mm<sup>3</sup>, the mice were treated twice a week with intravenous doses of vehicle, PTX (5 mg/kg), and YSA–PTX (at a dose that is equimolar to the taxol dose, i.e., 15 mg/kg). Both YSA–PTX and PTX were dissolved in a mixture of 84% PBS, 8% DMSO, and 8% water and injected in a 100 μL final volume.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Tissue Drug Level Determination</h3><div class="NLM_p">Tumor samples were weighted, homogenized, and extracted with 4 equal volumes (5-fold dilution) of quenching solution: water/acetonitrile (20:80) with 0.05% formic acid. The plasma samples were extracted with 1 equal volume (2-fold dilution) of quenching solution. The samples were centrifuged at approximately 14000<i>g</i> for 15 min, and the supernatants were mixed 1:1 with quenching solution containing an internal standard (2.5 μM indomethacin). After a second centrifugation, the supernatants were transferred to an autosampler vial and the relative concentrations were assessed by LC–MS/MS in multiple reaction monitoring (MRM) mode. LC–MS/MS was performed using a Prominence liquid chromatography system (Shimadzu) directly coupled to an API3000 triple quadrupole mass spectrometer. (Applied Biosystems) using MRM. Chromatography was carried out using gradient elution (water/acetonitrile) on a C18 reversed-phase column (Kromasil 100-5 μm, C18 50 mm × 2.1 mm i.d., Peeke Scientific) at a flow rate of 0.4 mL/min.</div><div class="NLM_p last">PTX concentrations were determined using an eight-point calibration curve derived from peak areas obtained from serially diluted solutions of the compound. The standard solutions were prepared using the same procedure outlined above. PTX concentrations in tissue extracts were determined using Analyst 1.4.2 software (Applied Biosystems). This gives a very accurate quantification of drug levels in tissues.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21"><a href="/doi/suppl/10.1021/jm201743s">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Detailed experimental procedures and spectral and purity analysis of all compounds; data relative to EphA2 and EphA4 RNA expression from 68 cancer cell lines. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201743s/suppl_file/jm201743s_si_001.pdf">jm201743s_si_001.pdf (691.92 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm201743s" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86440" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86440" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maurizio Pellecchia</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ea879a8f86868f898982838baa998b848c85988e889f9884828b87c485988d"><span class="__cf_email__" data-cfemail="1875687d74747d7b7b707179586b79767e776a7c7a6d6a7670797536776a7f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Si Wang</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William J. Placzek</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John L. Stebbins</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sayantan Mitra</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberta Noberini</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitchell Koolpe</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziming Zhang</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Russell Dahl</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena B. Pasquale</span> - <span class="hlFld-Affiliation affiliation">Cancer Research Center, Sanford-Burnham
Medical Research Institute, 10901 N. Torrey Pines Road,
La Jolla, California 92037, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d686e765-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support was obtained in part by NIH Grant CA138390 to M.P. and E.B.P.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i23" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i23"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i24" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i24"> Abbreviations Used</h2><tr><td class="NLM_term">YSA</td><td class="NLM_def"><p class="first last">linear peptide of sequence YSAYPDSVPMMS</p></td></tr><tr><td class="NLM_term">DYP</td><td class="NLM_def"><p class="first last">linear peptide of sequence DYPSMAMYSPSV</p></td></tr><tr><td class="NLM_term">PTX</td><td class="NLM_def"><p class="first last">paclitaxel</p></td></tr><tr><td class="NLM_term">qPCR</td><td class="NLM_def"><p class="first last">quantitative real-time polymerase chain reaction</p></td></tr><tr><td class="NLM_term">DTPA</td><td class="NLM_def"><p class="first last">diethylenetriaminepentaacetic acid</p></td></tr><tr><td class="NLM_term">DOTA</td><td class="NLM_def"><p class="first last">1,4,7,10-tetraazacyclododecane-<i>N</i>,<i>N</i>′,<i>N</i>″,<i>N</i>‴-tetraacetic acid</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">HDF</td><td class="NLM_def"><p class="first last">human dermal fibroblast</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Gangloff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesner, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiesewetter, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pio, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czernin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, D. H.</span><span> </span><span class="NLM_article-title">Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1866</span><span class="NLM_x">–</span> <span class="NLM_lpage">1871</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=1866-1871&issue=11&author=A.+Gangloffauthor=W.+A.+Hsuehauthor=A.+L.+Kesnerauthor=D.+O.+Kiesewetterauthor=B.+S.+Pioauthor=M.+D.+Pegramauthor=M.+Berytauthor=A.+Townsendauthor=J.+Czerninauthor=M.+E.+Phelpsauthor=D.+H.+Silverman&title=Estimation+of+paclitaxel+biodistribution+and+uptake+in+human-derived+xenografts+in+vivo+with+%2818%29F-fluoropaclitaxel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangloff%26aufirst%3DA.%26aulast%3DHsueh%26aufirst%3DW.%2BA.%26aulast%3DKesner%26aufirst%3DA.%2BL.%26aulast%3DKiesewetter%26aufirst%3DD.%2BO.%26aulast%3DPio%26aufirst%3DB.%2BS.%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DBeryt%26aufirst%3DM.%26aulast%3DTownsend%26aufirst%3DA.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DPhelps%26aufirst%3DM.%2BE.%26aulast%3DSilverman%26aufirst%3DD.%2BH.%26atitle%3DEstimation%2520of%2520paclitaxel%2520biodistribution%2520and%2520uptake%2520in%2520human-derived%2520xenografts%2520in%2520vivo%2520with%2520%252818%2529F-fluoropaclitaxel%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2005%26volume%3D46%26issue%3D11%26spage%3D1866%26epage%3D1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sugahara, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teesalu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karmali, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotamraju, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agemy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwald, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x"> (</span><span class="NLM_issue">5981</span><span class="NLM_x">) </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1126%2Fscience.1183057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20378772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2010&pages=1031-1035&issue=5981&author=K.+N.+Sugaharaauthor=T.+Teesaluauthor=P.+P.+Karmaliauthor=V.+R.+Kotamrajuauthor=L.+Agemyauthor=D.+R.+Greenwaldauthor=E.+Ruoslahti&title=Coadministration+of+a+tumor-penetrating+peptide+enhances+the+efficacy+of+cancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs</span></div><div class="casAuthors">Sugahara, Kazuki N.; Teesalu, Tambet; Karmali, Priya Prakash; Kotamraju, Venkata Ramana; Agemy, Lilach; Greenwald, Daniel R.; Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">5981</span>),
    <span class="NLM_cas:pages">1031-1035</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy.  We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue.  Importantly, this effect did not require the drugs to be chem. conjugated to the peptide.  Systemic injection with iRGD improved the therapeutic index of drugs of various compns., including a small mol. (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab).  Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnpbZBSXSmfrVg90H21EOLACvtfcHk0ljpXGk0aEH4OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D&md5=c8103ff227adc4061b92a62157b7a36f</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1183057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1183057%26sid%3Dliteratum%253Aachs%26aulast%3DSugahara%26aufirst%3DK.%2BN.%26aulast%3DTeesalu%26aufirst%3DT.%26aulast%3DKarmali%26aufirst%3DP.%2BP.%26aulast%3DKotamraju%26aufirst%3DV.%2BR.%26aulast%3DAgemy%26aufirst%3DL.%26aulast%3DGreenwald%26aufirst%3DD.%2BR.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DCoadministration%2520of%2520a%2520tumor-penetrating%2520peptide%2520enhances%2520the%2520efficacy%2520of%2520cancer%2520drugs%26jtitle%3DScience%26date%3D2010%26volume%3D328%26issue%3D5981%26spage%3D1031%26epage%3D1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&issue=9&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0ljpXGk0aEH4OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26issue%3D9%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jaracz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuznetsova, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Recent advances in tumor-targeting anticancer drug conjugates</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5043</span><span class="NLM_x">–</span> <span class="NLM_lpage">5054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5043-5054&issue=17&author=S.+Jaraczauthor=J.+Chenauthor=L.+V.+Kuznetsovaauthor=I.+Ojima&title=Recent+advances+in+tumor-targeting+anticancer+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJaracz%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKuznetsova%26aufirst%3DL.%2BV.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DRecent%2520advances%2520in%2520tumor-targeting%2520anticancer%2520drug%2520conjugates%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26issue%3D17%26spage%3D5043%26epage%3D5054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">New methods of drug delivery</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">249</span><span class="NLM_x"> (</span><span class="NLM_issue">4976</span><span class="NLM_x">) </span> <span class="NLM_fpage">1527</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=1990&pages=1527-1533&issue=4976&author=R.+Langer&title=New+methods+of+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DNew%2520methods%2520of%2520drug%2520delivery%26jtitle%3DScience%26date%3D1990%26volume%3D249%26issue%3D4976%26spage%3D1527%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schrama, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisfeld, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span> </span><span class="NLM_article-title">Antibody targeted drugs as cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=147-159&issue=2&author=D.+Schramaauthor=R.+A.+Reisfeldauthor=J.+C.+Becker&title=Antibody+targeted+drugs+as+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchrama%26aufirst%3DD.%26aulast%3DReisfeld%26aufirst%3DR.%2BA.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26atitle%3DAntibody%2520targeted%2520drugs%2520as%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D2%26spage%3D147%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">van Vlerken, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiji, M. M.</span><span> </span><span class="NLM_article-title">Multi-functional polymeric nanoparticles for tumour-targeted drug delivery</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=205-216&issue=2&author=L.+E.+van+Vlerkenauthor=M.+M.+Amiji&title=Multi-functional+polymeric+nanoparticles+for+tumour-targeted+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVlerken%26aufirst%3DL.%2BE.%26aulast%3DAmiji%26aufirst%3DM.%2BM.%26atitle%3DMulti-functional%2520polymeric%2520nanoparticles%2520for%2520tumour-targeted%2520drug%2520delivery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2006%26volume%3D3%26issue%3D2%26spage%3D205%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leader, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baca, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golan, D. E.</span><span> </span><span class="NLM_article-title">Protein therapeutics: a summary and pharmacological classification</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fnrd2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=18097458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=21-39&issue=1&author=B.+Leaderauthor=Q.+J.+Bacaauthor=D.+E.+Golan&title=Protein+therapeutics%3A+a+summary+and+pharmacological+classification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Protein therapeutics: a summary and pharmacological classification</span></div><div class="casAuthors">Leader, Benjamin; Baca, Quentin J.; Golan, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-39</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in no. and frequency of use since the introduction of the first recombinant protein therapeutic - human insulin - 25 years ago.  Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy.  This article overviews some of the key characteristics of protein therapeutics, summarizes the more than 130 protein therapeutics used currently and suggests a new classification of these proteins according to their pharmacol. action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDJwirgv5WN7Vg90H21EOLACvtfcHk0licLdAPQ_QeCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ygtQ%253D%253D&md5=761a9860e38c98295385641dda94b31f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2399%26sid%3Dliteratum%253Aachs%26aulast%3DLeader%26aufirst%3DB.%26aulast%3DBaca%26aufirst%3DQ.%2BJ.%26aulast%3DGolan%26aufirst%3DD.%2BE.%26atitle%3DProtein%2520therapeutics%253A%2520a%2520summary%2520and%2520pharmacological%2520classification%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26issue%3D1%26spage%3D21%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Marx, J. L.</span><span> </span><span class="NLM_article-title">Monoclonal antibodies in cancer</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">216</span><span class="NLM_x"> (</span><span class="NLM_issue">4543</span><span class="NLM_x">) </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=1982&pages=283-285&issue=4543&author=J.+L.+Marx&title=Monoclonal+antibodies+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarx%26aufirst%3DJ.%2BL.%26atitle%3DMonoclonal%2520antibodies%2520in%2520cancer%26jtitle%3DScience%26date%3D1982%26volume%3D216%26issue%3D4543%26spage%3D283%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aina, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutcliffe, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. S.</span><span> </span><span class="NLM_article-title">From combinatorial chemistry to cancer-targeting peptides</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp700073y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=631-651&issue=5&author=O.+H.+Ainaauthor=R.+Liuauthor=J.+L.+Sutcliffeauthor=J.+Marikauthor=C.+X.+Panauthor=K.+S.+Lam&title=From+combinatorial+chemistry+to+cancer-targeting+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">From Combinatorial Chemistry to Cancer-Targeting Peptides</span></div><div class="casAuthors">Aina, Olulanu H.; Liu, Ruiwu; Sutcliffe, Julie L.; Marik, Jan; Pan, Chong-Xian; Lam, Kit S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">631-651</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S.  Food and Drug Administration and are widely used in the treatment of some cancers.  These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy.  The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kDa) and its relatively nonspecific binding to the reticuloendothelial system.  This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site.  Peptides, peptidomimetic, or small mols. are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy.  Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets.  Phage-display peptide library and one-bead one-compd. (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells.  The phage-display peptide library method, because of its biol. nature, can only display L-amino acid peptides.  In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain L-amino acids, D-amino acids, unnatural amino acids, or other org. moieties.  We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity.  Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot7yoDgcS21LVg90H21EOLACvtfcHk0licLdAPQ_QeCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtbfI&md5=3e65fab3d9f5b9d2cf20773d65482b87</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fmp700073y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp700073y%26sid%3Dliteratum%253Aachs%26aulast%3DAina%26aufirst%3DO.%2BH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BL.%26aulast%3DMarik%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DC.%2BX.%26aulast%3DLam%26aufirst%3DK.%2BS.%26atitle%3DFrom%2520combinatorial%2520chemistry%2520to%2520cancer-targeting%2520peptides%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2007%26volume%3D4%26issue%3D5%26spage%3D631%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koolpe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dail, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquale, E. B.</span><span> </span><span class="NLM_article-title">An ephrin mimetic peptide that selectively targets the EphA2 receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">46974</span><span class="NLM_x">–</span> <span class="NLM_lpage">46979</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46974-46979&issue=49&author=M.+Koolpeauthor=M.+Dailauthor=E.+B.+Pasquale&title=An+ephrin+mimetic+peptide+that+selectively+targets+the+EphA2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DDail%26aufirst%3DM.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DAn%2520ephrin%2520mimetic%2520peptide%2520that%2520selectively%2520targets%2520the%2520EphA2%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D49%26spage%3D46974%26epage%3D46979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hatakeyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akama, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobkov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohyama, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M. N.</span><span> </span><span class="NLM_article-title">Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">19587</span><span class="NLM_x">–</span> <span class="NLM_lpage">19592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=19587-19592&issue=49&author=S.+Hatakeyamaauthor=K.+Sugiharaauthor=T.+K.+Shibataauthor=J.+Nakayamaauthor=T.+O.+Akamaauthor=N.+Tamuraauthor=S.+M.+Wongauthor=A.+A.+Bobkovauthor=Y.+Takanoauthor=C.+Ohyamaauthor=M.+Fukudaauthor=M.+N.+Fukuda&title=Targeted+drug+delivery+to+tumor+vasculature+by+a+carbohydrate+mimetic+peptide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DT.%2BK.%26aulast%3DNakayama%26aufirst%3DJ.%26aulast%3DAkama%26aufirst%3DT.%2BO.%26aulast%3DTamura%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DS.%2BM.%26aulast%3DBobkov%26aufirst%3DA.%2BA.%26aulast%3DTakano%26aufirst%3DY.%26aulast%3DOhyama%26aufirst%3DC.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DM.%2BN.%26atitle%3DTargeted%2520drug%2520delivery%2520to%2520tumor%2520vasculature%2520by%2520a%2520carbohydrate%2520mimetic%2520peptide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26issue%3D49%26spage%3D19587%26epage%3D19592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cutrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dibra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fmt.2011.38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21386825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVGgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1468-1477&issue=8&author=J.+Cutreraauthor=D.+Dibraauthor=X.+Xiaauthor=A.+Hasanauthor=S.+Reedauthor=S.+Li&title=Discovery+of+a+linear+peptide+for+improving+tumor+targeting+of+gene+products+and+treatment+of+distal+tumors+by+IL-12+gene+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and Treatment of Distal Tumors by IL-12 Gene Therapy</span></div><div class="casAuthors">Cutrera, Jeffry; Dibra, Denada; Xia, Xueqing; Hasan, Azeem; Reed, Scott; Li, Shulin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1468-1477</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Like many effective therapeutics, interleukin-12 (IL-12) therapy often causes side effects.  Tumor targeted delivery may improve the efficacy and decrease the toxicity of systemic IL-12 treatments.  In this study, a novel targeting approach was investigated.  A secreted alk. phosphatase (SEAP) reporter gene-based screening process was used to identify a mini-peptide which can be produced in vivo to target gene products to tumors.  The coding region for the best peptide was inserted into an IL-12 gene to det. the antitumor efficacy.  Affinity chromatog., mass spectrometry anal., and binding studies were used to identify a receptor for this peptide.  The authors discovered that the linear peptide VNTANST increased the tumor accumulation of the reporter gene products in five independent tumor models including one human xenogeneic model.  The product from VNTANST-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment, and in three tumor models, VNTANST-IL-12 gene therapy inhibited distal tumor growth.  In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced.  The receptor for VNTANST was identified as vimentin.  These results show the promise of using VNTANST to improve IL-12 treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5-GLHuvlz1LVg90H21EOLACvtfcHk0linn_B__KSVfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVGgtLo%253D&md5=f5ffc6569bcc18cd7708490e23c4607a</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1038%2Fmt.2011.38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2011.38%26sid%3Dliteratum%253Aachs%26aulast%3DCutrera%26aufirst%3DJ.%26aulast%3DDibra%26aufirst%3DD.%26aulast%3DXia%26aufirst%3DX.%26aulast%3DHasan%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520linear%2520peptide%2520for%2520improving%2520tumor%2520targeting%2520of%2520gene%2520products%2520and%2520treatment%2520of%2520distal%2520tumors%2520by%2520IL-12%2520gene%2520therapy%26jtitle%3DMol.%2520Ther.%26date%3D2011%26volume%3D19%26issue%3D8%26spage%3D1468%26epage%3D1477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Corti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curnis, F.</span><span> </span><span class="NLM_article-title">Tumor vasculature targeting through NGR peptide-based drug delivery systems</span> <span class="citation_source-journal">Curr. Pharm. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1128</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F138920111796117373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21470145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1128-1134&issue=8&author=A.+Cortiauthor=F.+Curnis&title=Tumor+vasculature+targeting+through+NGR+peptide-based+drug+delivery+systems"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor vasculature targeting through NGR peptide-based drug delivery systems</span></div><div class="casAuthors">Corti, Angelo; Curnis, Flavio</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1128-1134</span>CODEN:
                <span class="NLM_cas:coden">CPBUBP</span>;
        ISSN:<span class="NLM_cas:issn">1389-2010</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Various peptide sequences were discovered by selecting peptide-phage display libraries in vitro against specific receptors or in vivo in tumor-bearing animals.  One class of these peptides is characterized by the presence of Asn-Gly-Asp (NGR), a structural motif that can recognize the endothelium and other cells of neoangiogenic vessels.  Because of this property these peptides were used by several investigators to deliver a variety of drugs, cytokines, nanoparticles, viruses and imaging agents to tumor blood vessels.  Here the authors review the reports on these conjugates and discuss the structural, functional and stability properties of NGR embedded into different mol. scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCmXOz-qEG5bVg90H21EOLACvtfcHk0linn_B__KSVfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqsrjE&md5=a854755bfdbc74ec368792e279aa681e</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.2174%2F138920111796117373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920111796117373%26sid%3Dliteratum%253Aachs%26aulast%3DCorti%26aufirst%3DA.%26aulast%3DCurnis%26aufirst%3DF.%26atitle%3DTumor%2520vasculature%2520targeting%2520through%2520NGR%2520peptide-based%2520drug%2520delivery%2520systems%26jtitle%3DCurr.%2520Pharm.%2520Biotechnol.%26date%3D2011%26volume%3D12%26issue%3D8%26spage%3D1128%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wu, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, D. K.</span><span> </span><span class="NLM_article-title">Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy</span> <span class="citation_source-journal">J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">723798</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1155%2F2010%2F723798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20454584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A280%3ADC%252BC3czit12ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=723798&author=H.+C.+Wuauthor=D.+K.+Chang&title=Peptide-mediated+liposomal+drug+delivery+system+targeting+tumor+blood+vessels+in+anticancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5fR"><div class="casContent"><span class="casTitleNuber">5f</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy</span></div><div class="casAuthors">Wu Han-Chung; Chang De-Kuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2010</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">723798</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Solid tumors are known to recruit new blood vessels to support their growth.  Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer.  Current efforts are focusing on developing therapeutic agents capable of specifically targeting cancer cells and tumor-associated microenvironments including tumor blood vessels.  These therapies hold the promise of high efficacy and low toxicity.  One recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics is to encapsulate anticancer drugs into targeting liposomes that bind to the cell surface receptors expressed on tumor-associated endothelial cells.  These anti-angiogenic drug delivery systems could be used to target both tumor blood vessels as well as the tumor cells, themselves.  This article reviews the mechanisms and advantages of various present and potential methods using peptide-conjugated liposomes to specifically destroy tumor blood vessels in anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOi_tOgfpAYlvAgqb2vdc5fW6udTcc2eay_mrtbWpmt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czit12ktg%253D%253D&md5=ea59379c165dc202f6cd828b7e06cf1c</span></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.1155%2F2010%2F723798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2010%252F723798%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BC.%26aulast%3DChang%26aufirst%3DD.%2BK.%26atitle%3DPeptide-mediated%2520liposomal%2520drug%2520delivery%2520system%2520targeting%2520tumor%2520blood%2520vessels%2520in%2520anticancer%2520therapy%26jtitle%3DJ.%2520Oncol.%26date%3D2010%26volume%3D2010%26spage%3D723798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Brown, K. C.</span><span> </span><span class="NLM_article-title">Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1040</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F138161210790963788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20030617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFymu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1040-1054&issue=9&author=K.+C.+Brown&title=Peptidic+tumor+targeting+agents%3A+the+road+from+phage+display+peptide+selections+to+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5gR"><div class="casContent"><span class="casTitleNuber">5g</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications</span></div><div class="casAuthors">Brown, Kathlynn C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1054</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer has become the no. one cause of death amongst Americans, killing approx. 1,600 people per day.  Novel methods for early detection and the development of effective treatments are an eminent priority in medicine.  For this reason, isolation of tumor-specific ligands is a growing area of research.  Tumor-specific binding agents can be used to probe the tumor cell surface phenotype and customize treatment accordingly by conjugating the appropriate cell-targeting ligand to an anticancer drug.  This refines the mol. diagnosis of the tumor and creates guided drugs that can target the tumor while sparing healthy tissues.  Addnl., these targeting agents can be used as in vivo imaging agents that allow for earlier detection of tumors and micrometastasis.  Phage display is a powerful technique for the isolation of peptides that bind to a particular target with high affinity and specificity.  The biopanning of intact cancer cells or tumors in animals can be used to isolate peptides that bind to cancer-specific cell surface biomarkers.  Over the past 10 years, unbiased biopanning of phage-displayed peptide libraries has generated a suite of cancer targeting peptidic ligands.  This review discusses the recent advances in the isolation of cancer-targeting peptides by unbiased biopanning methods and highlights the use of the isolated peptides in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAdZc950F8i7Vg90H21EOLACvtfcHk0ljoAKrOJEvpZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFymu74%253D&md5=2e9f83012dab637a7b50943d576733e4</span></div><a href="/servlet/linkout?suffix=cit5g&amp;dbid=16384&amp;doi=10.2174%2F138161210790963788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210790963788%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DK.%2BC.%26atitle%3DPeptidic%2520tumor%2520targeting%2520agents%253A%2520the%2520road%2520from%2520phage%2520display%2520peptide%2520selections%2520to%2520clinical%2520applications%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26issue%3D9%26spage%3D1040%26epage%3D1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Newton, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutscher, S. L.</span><span> </span><span class="NLM_article-title">In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">504</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1007%2F978-1-60327-569-9_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=19159103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslWhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2009&pages=275-290&author=J.+R.+Newtonauthor=S.+L.+Deutscher&title=In+vivo+bacteriophage+display+for+the+discovery+of+novel+peptide-based+tumor-targeting+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5hR"><div class="casContent"><span class="casTitleNuber">5h</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents</span></div><div class="casAuthors">Newton, Jessica R.; Deutscher, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">Biosensors and Biodetection, Volume 2</span>),
    <span class="NLM_cas:pages">275-290</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A powerful strategy for targeted drug discovery is the use of bacteriophage (phage) display technol. for identification of peptide-based tumor targeting agents.  Peptide pharmaceuticals may possess clin. desirable properties because of their rapid blood clearance, non-immunogenic nature, and ease of synthesis.  Phage display has identified hundreds of different peptide sequences that bind a desired target in vitro.  Regrettably, few of these peptides offer good targeting efficacy in vivo.  One reason for this is the synthesized peptide may not retain its optimal activity outside the microenvironment of the phage.  Another possible explanation is that traditionally, phage selections are performed in vitro outside the complicated milieu of a living animal.  Given these shortcomings, we have developed methods to select phage peptide display libraries in living mice, to identify, a priori, phage (and corresponding synthesized peptides) with ideal tumor-targeting propensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLhfOLuJWIqrVg90H21EOLACvtfcHk0ljoAKrOJEvpZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslWhtr8%253D&md5=b863514a9b31546c78a81659cd6bea52</span></div><a href="/servlet/linkout?suffix=cit5h&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-569-9_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60327-569-9_17%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DJ.%2BR.%26aulast%3DDeutscher%26aufirst%3DS.%2BL.%26atitle%3DIn%2520vivo%2520bacteriophage%2520display%2520for%2520the%2520discovery%2520of%2520novel%2520peptide-based%2520tumor-targeting%2520agents%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D504%26spage%3D275%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span> </span><span class="NLM_article-title">TMTP1, a novel tumor-homing peptide specifically targeting metastasis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5494</span><span class="NLM_x">–</span> <span class="NLM_lpage">5502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5i&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1158%2F1078-0432.CCR-08-0233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5i&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=18765541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5i&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5494-5502&issue=17&author=W.+Yangauthor=D.+Luoauthor=S.+Wangauthor=R.+Wangauthor=R.+Chenauthor=Y.+Liuauthor=T.+Zhuauthor=X.+Maauthor=R.+Liuauthor=G.+Xuauthor=L.+Mengauthor=Y.+Luauthor=J.+Zhouauthor=D.+Ma&title=TMTP1%2C+a+novel+tumor-homing+peptide+specifically+targeting+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5iR"><div class="casContent"><span class="casTitleNuber">5i</span><div class="casTitle"><span class="NLM_cas:atitle">TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis</span></div><div class="casAuthors">Yang, Wanhua; Luo, Danfeng; Wang, Shixuan; Wang, Rui; Chen, Rui; Liu, Yan; Zhu, Tao; Ma, Xiangyi; Liu, Ronghua; Xu, Gang; Meng, Li; Lu, Yunping; Zhou, Jianfeng; Ma, Ding</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5494-5502</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor metastasis continues to be the major obstacle to cancer therapy and the leading cause of cancer-related death.  Methods used to detect metastasis, esp. occult metastases, have received a great deal attention.  In this study, a novel selective peptide was assessed for its specific binding to metastasis.  The FliTrx bacterial peptide display system, an alternative to phage peptide display, was used to identify a 5-amino acid peptide termed TMTP1 (NVVRQ), which binds to the highly metastatic prostate cancer cell line PC-3M-1E8.  The synthetic TMTP1 was tested in vitro for its binding specificity and affinity to highly metastatic cancer cells.  The tumor targeting assays were done in vivo by i.v. injection of FITC-conjugated TMTP1 into tumor-bearing mice.  TMTP1 specifically bound to a series of highly metastatic tumor cells, including prostate cancer PC-3M-1E8, breast cancer MDA-MB-435S, lung cancer PG-BE1, and gastric cancer MKN-45sci, in vitro and in vivo but not to the poorly metastatic or nonmetastatic cell line, including prostate cancer PC-3M-2B4, breast cancer MCF-7, lung cancer PG-LH7, or murine fibroblast cell NIH/3T3.  FITC-TMTP1 strongly and specifically targeted the metastasis foci in tumor-bearing mice 24 h after i.v. peptide injection.  Moreover, the occult metastases were specifically detected by FITC-TMTP1.  Our results suggest that TMTP1 is a potential strategy for the development of new diagnostic tracers or alternative anticancer agents for tumor metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OGApMAXOSLVg90H21EOLACvtfcHk0ljoAKrOJEvpZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbnN&md5=ee52c659e51a92f971b96b19033e187a</span></div><a href="/servlet/linkout?suffix=cit5i&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0233%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DTMTP1%252C%2520a%2520novel%2520tumor-homing%2520peptide%2520specifically%2520targeting%2520metastasis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D17%26spage%3D5494%26epage%3D5502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Laakkonen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porkka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">A tumor-homing peptide with a targeting specificity related to lymphatic vessels</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">751</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5j&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=12053175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5j&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFehsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=751-755&issue=7&author=P.+Laakkonenauthor=K.+Porkkaauthor=J.+A.+Hoffmanauthor=E.+Ruoslahti&title=A+tumor-homing+peptide+with+a+targeting+specificity+related+to+lymphatic+vessels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5jR"><div class="casContent"><span class="casTitleNuber">5j</span><div class="casTitle"><span class="NLM_cas:atitle">A tumor-homing peptide with a targeting specificity related to lymphatic vessels</span></div><div class="casAuthors">Laakkonen, Pirjo; Porkka, Kimmo; Hoffman, Jason A.; Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">751-755</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Blood vessels of tumors carry specific markers that are usually angiogenesis-related.  We previously used phage-displayed peptide libraries in vivo to identify peptides that home to tumors through the circulation and that specifically bind to the endothelia of tumor blood vessels.  Here we devised a phage screening procedure that would favor tumor-homing to targets that are accessible to circulating phage, but are not blood vessels.  Screening on MDA-MB-435 breast carcinoma xenografts yielded multiple copies of a phage that displays a cyclic 9-amino-acid peptide, LyP-1.  Homing and binding to tumor-derived cell suspensions indicated that LyP-1 also recognizes an osteosarcoma xenograft, and spontaneous prostate and breast cancers in transgenic mice, but not two other tumor xenografts.  Fluorescein-labeled LyP-1 peptide was detected in tumor structures that were pos. for three lymphatic endothelial markers and neg. for three blood vessel markers.  LyP-1 accumulated in the nuclei of the putative lymphatic cells, and in the nuclei of tumor cells.  These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8uLZe86w8sLVg90H21EOLACvtfcHk0ljRw7FE51g9dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFehsb8%253D&md5=4cec9c4b05a860bc45bd9499728c906c</span></div><a href="/servlet/linkout?suffix=cit5j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaakkonen%26aufirst%3DP.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DHoffman%26aufirst%3DJ.%2BA.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DA%2520tumor-homing%2520peptide%2520with%2520a%2520targeting%2520specificity%2520related%2520to%2520lymphatic%2520vessels%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26issue%3D7%26spage%3D751%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">Targeting tumor vasculature with homing peptides from phage display</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5k&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1006%2Fscbi.2000.0334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5k&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=11170865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5k&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVGhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=435-442&issue=6&author=E.+Ruoslahti&title=Targeting+tumor+vasculature+with+homing+peptides+from+phage+display"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5kR"><div class="casContent"><span class="casTitleNuber">5k</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumor vasculature with homing peptides from phage display</span></div><div class="casAuthors">Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-442</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with refs.  Tumor vasculature expresses a no. of mol. markers at much lower levels than those seen in the blood vessels of normal tissues, and in some cases, such markers are undetectable.  The presence of these markers relates to angiogenesis; the same markers are shared by all blood vessels undergoing angiogenesis.  The endothelial cells, pericytes and smooth muscle cells, and the vascular extracellular matrix in angiogenic vessels can each express such markers.  Molecularly, they represent vascular growth factor receptors, cell adhesion proteins and their receptors.  Screening of phage display libraries for peptides that home to tumor vasculature when injected into mice has recently provided a new tool for analyzing the distinguishing features of tumor vasculature.  Tumor-homing peptides isolated in this manner, as well as an antibody against a form of fibronectin expressed in tumor blood vessels, have been found to serve as targeting devices to conc. drugs and other therapeutic materials to tumors in in vivo models.  Such a targeting strategy can therefore potentially improve the efficacy of drugs and reduce their side effects.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6KxHiU1n6y7Vg90H21EOLACvtfcHk0ljRw7FE51g9dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVGhtbY%253D&md5=9b0907617a9fcf8e8a69f6a25364e2f4</span></div><a href="/servlet/linkout?suffix=cit5k&amp;dbid=16384&amp;doi=10.1006%2Fscbi.2000.0334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fscbi.2000.0334%26sid%3Dliteratum%253Aachs%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DTargeting%2520tumor%2520vasculature%2520with%2520homing%2520peptides%2520from%2520phage%2520display%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2000%26volume%3D10%26issue%3D6%26spage%3D435%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Koivunen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arap, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtanen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainisalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikkila, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gahmberg, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorsa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualini, R.</span><span> </span><span class="NLM_article-title">Tumor targeting with a selective gelatinase inhibitor</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">768</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=768-774&issue=8&author=E.+Koivunenauthor=W.+Arapauthor=H.+Valtanenauthor=A.+Rainisaloauthor=O.+P.+Medinaauthor=P.+Heikkilaauthor=C.+Kantorauthor=C.+G.+Gahmbergauthor=T.+Saloauthor=Y.+T.+Konttinenauthor=T.+Sorsaauthor=E.+Ruoslahtiauthor=R.+Pasqualini&title=Tumor+targeting+with+a+selective+gelatinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5l&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoivunen%26aufirst%3DE.%26aulast%3DArap%26aufirst%3DW.%26aulast%3DValtanen%26aufirst%3DH.%26aulast%3DRainisalo%26aufirst%3DA.%26aulast%3DMedina%26aufirst%3DO.%2BP.%26aulast%3DHeikkila%26aufirst%3DP.%26aulast%3DKantor%26aufirst%3DC.%26aulast%3DGahmberg%26aufirst%3DC.%2BG.%26aulast%3DSalo%26aufirst%3DT.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26aulast%3DSorsa%26aufirst%3DT.%26aulast%3DRuoslahti%26aufirst%3DE.%26aulast%3DPasqualini%26aufirst%3DR.%26atitle%3DTumor%2520targeting%2520with%2520a%2520selective%2520gelatinase%2520inhibitor%26jtitle%3DNat.%2520Biotechnol.%26date%3D1999%26volume%3D17%26issue%3D8%26spage%3D768%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gersuk, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vessella, R. L.</span><span> </span><span class="NLM_article-title">High-affinity peptide ligands to prostate-specific antigen identified by polysome selection</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">578</span><span class="NLM_x">–</span> <span class="NLM_lpage">582</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=1997&pages=578-582&issue=2&author=G.+M.+Gersukauthor=M.+J.+Coreyauthor=E.+Coreyauthor=J.+E.+Strayauthor=G.+H.+Kawasakiauthor=R.+L.+Vessella&title=High-affinity+peptide+ligands+to+prostate-specific+antigen+identified+by+polysome+selection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGersuk%26aufirst%3DG.%2BM.%26aulast%3DCorey%26aufirst%3DM.%2BJ.%26aulast%3DCorey%26aufirst%3DE.%26aulast%3DStray%26aufirst%3DJ.%2BE.%26aulast%3DKawasaki%26aufirst%3DG.%2BH.%26aulast%3DVessella%26aufirst%3DR.%2BL.%26atitle%3DHigh-affinity%2520peptide%2520ligands%2520to%2520prostate-specific%2520antigen%2520identified%2520by%2520polysome%2520selection%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1997%26volume%3D232%26issue%3D2%26spage%3D578%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pasquale, E. B.</span><span> </span><span class="NLM_article-title">Eph receptors and ephrins in cancer: bidirectional signalling and beyond</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fnrc2806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20179713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=165-180&issue=3&author=E.+B.+Pasquale&title=Eph+receptors+and+ephrins+in+cancer%3A+bidirectional+signalling+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Eph receptors and ephrins in cancer: bidirectional signaling and beyond</span></div><div class="casAuthors">Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-180</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumor blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression.  Eph gene mutations probably also contribute to cancer pathogenesis.  Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumor growth, invasiveness, angiogenesis and metastasis in vivo.  However, Eph signaling activities in cancer seem to be complex, and are characterized by puzzling dichotomies.  Nevertheless, the Eph receptors are promising new therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryHNhAMFltdbVg90H21EOLACvtfcHk0ljq1FKTzlWdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D&md5=bbbb8188202649354faa3c50d204d0c5</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2806%26sid%3Dliteratum%253Aachs%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DEph%2520receptors%2520and%2520ephrins%2520in%2520cancer%253A%2520bidirectional%2520signalling%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D3%26spage%3D165%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Noberini, R.; Lamberto, I.; Pasquale, E. B.</span><span> </span><span class="NLM_article-title">Targeting Eph receptors with peptides and small molecules: progress and challenges</span>.  <span class="citation_source-journal">Semin. Cell Dev. Biol.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1016/j.semcdb.2011.10.023</span> . Published Online: Oct 25,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1016%2Fj.semcdb.2011.10.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Noberini&author=I.+Lamberto&author=E.+B.+Pasquale&title=Targeting+Eph+receptors+with+peptides+and+small+molecules%3A+progress+and+challenges&doi=10.1016%2Fj.semcdb.2011.10.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2011.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2011.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DNoberini%26aufirst%3DR.%26atitle%3DTargeting%2520Eph%2520receptors%2520with%2520peptides%2520and%2520small%2520molecules%253A%2520progress%2520and%2520challenges%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26doi%3D10.1016%2Fj.semcdb.2011.10.023%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ireton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span> </span><span class="NLM_article-title">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&issue=3&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+receptor+tyrosine+kinase+as+a+promising+target+for+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0ljq1FKTzlWdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520target%2520for%2520cancer%2520therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wykosky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debinski, W.</span><span> </span><span class="NLM_article-title">The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1795</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1158%2F1541-7786.MCR-08-0244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=19074825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1795-1806&issue=12&author=J.+Wykoskyauthor=W.+Debinski&title=The+EphA2+receptor+and+ephrinA1+ligand+in+solid+tumors%3A+function+and+therapeutic+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting</span></div><div class="casAuthors">Wykosky, Jill; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1795-1806</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and ephrin ligands have been studied extensively for their roles in developmental processes.  In recent years, Eph receptors and ephrins have been found to be integral players in cancer formation and progression.  Among these are EphA2 and ephrinA1, which are involved in the development and maintenance of many different types of solid tumors.  The function of EphA2 and ephrinA1 in tumorigenesis and tumor progression is complex and seems to be dependent on cell type and microenvironment.  These variables affect the expression of the EphA2 and ephrinA1 proteins, the pathways through which they induce signaling, and the functional consequences of that signaling on the behavior of tumor cells and tumor-assocd. cells.  This review will specifically focus on the roles that EphA2 and ephrinA1 play in the different cell types that contribute to the malignancy of solid tumors, with emphasis on the opportunities for therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbwIAXRgx44LVg90H21EOLACvtfcHk0ljq1FKTzlWdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI&md5=b507c55f0e81cb70cede51f69b3d5870</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0244%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DThe%2520EphA2%2520receptor%2520and%2520ephrinA1%2520ligand%2520in%2520solid%2520tumors%253A%2520function%2520and%2520therapeutic%2520targeting%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2008%26volume%3D6%26issue%3D12%26spage%3D1795%26epage%3D1806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Landen, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sood, A. K.</span><span> </span><span class="NLM_article-title">EphA2 as a target for ovarian cancer therapy</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1179</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1517%2F14728222.9.6.1179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=16300469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gks7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=1179-1187&issue=6&author=C.+N.+Landenauthor=M.+S.+Kinchauthor=A.+K.+Sood&title=EphA2+as+a+target+for+ovarian+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 as a target for ovarian cancer therapy</span></div><div class="casAuthors">Landen, Charles N.; Kinch, Michael S.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1179-1187</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  EphA2 is a receptor tyrosine kinase that is overexpressed by many human cancers, and is often assocd. with poor prognostic features.  It is involved in many processes crucial to malignant progression, such as migration, invasion, metastasis, proliferation, survival and angiogenesis.  Inducing EphA2 downregulation by any one of several mechanisms (antibody-mediated inhibition of signaling, antibody-mediated downregulation of total EphA2 expression and siRNA-mediated inhibition of expression) has been shown to decrease tumor growth, prolong survival and inhibit angiogenesis in multiple preclin. models of ovarian, breast and pancreatic cancer.  Targeting EphA2 is esp. attractive in ovarian cancer, in which overexpression is present in > 75% of cases.  This disease is highly responsive to chemotherapy, and EphA2 inhibition is esp. effective in combination with taxanes.  This demonstrated efficacy, along with the low expression of EphA2 by normal adult tissues and lack of demonstrable toxicities in preclin. models, suggest that long-term treatment with EphA2-targeting agents is an attractive approach for ovarian cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEwtrrmSHwPrVg90H21EOLACvtfcHk0ljq1FKTzlWdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gks7nE&md5=05f1de1bc374e54064756c408d603a5d</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1517%2F14728222.9.6.1179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.9.6.1179%26sid%3Dliteratum%253Aachs%26aulast%3DLanden%26aufirst%3DC.%2BN.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DEphA2%2520as%2520a%2520target%2520for%2520ovarian%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2005%26volume%3D9%26issue%3D6%26spage%3D1179%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tandon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemula, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, S. K.</span><span> </span><span class="NLM_article-title">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1517%2F14728222.2011.538682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21142802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=31-51&issue=1&author=M.+Tandonauthor=S.+V.+Vemulaauthor=S.+K.+Mittal&title=Emerging+strategies+for+EphA2+receptor+targeting+for+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span></div><div class="casAuthors">Tandon, Manish; Vemula, Sai Vikram; Mittal, Suresh K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-51</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: High mortality rates with cancers warrant further development of earlier diagnostics and better treatment strategies.  Membrane-bound erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 (EphA2) is overexpressed in breast, prostate, urinary bladder, skin, lung, ovary and brain cancers.  Areas covered in this review: EphA2 overexpression in cancers, its signaling mechanisms and strategies to target its deregulation.  What the reader will gain: High EphA2 expression in cancer cells is correlated with a poor prognosis assocd. with recurrence due to enhanced metastasis.  Interaction of the EphA2 receptor with its ligand (e.g., ephrinA1) triggers events that are deregulated and implicated in carcinogenesis.  EphrinA1-independent oncogenic activity and ephrinA1-dependent tumor suppressor roles for EphA2 are described.  Mol. interactions of EphA2 with signaling proteins are assocd. with the modulation of cytoskeleton dynamics, cell adhesion, proliferation, differentiation and metastasis.  The deregulated signaling by EphA2 and its involvement in oncogenesis provide multiple avenues for the rational design of intervention approaches.  Take home message: EphA2 has been tested as a drug target using multiple approaches such as agonist antibodies, RNA interference, immunotherapy, virus vector-mediated gene transfer, small-mol. inhibitors and nanoparticles.  With over a decade of research, encouraging results with targeting of EphA2 expression in various pre-clin. cancer models necessitate further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUoM-7uf_sLVg90H21EOLACvtfcHk0lj8krxhZz9nuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP&md5=2b082cbbe88132ae4e6b21c56e7defc1</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.538682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.538682%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DVemula%26aufirst%3DS.%2BV.%26aulast%3DMittal%26aufirst%3DS.%2BK.%26atitle%3DEmerging%2520strategies%2520for%2520EphA2%2520receptor%2520targeting%2520for%2520cancer%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26issue%3D1%26spage%3D31%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Biao-Xue, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi-Guang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuan-Ying, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong-Juan, M.</span><span> </span><span class="NLM_article-title">Epha2-dependent molecular targeting therapy for malignant tumors</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F156800911798073050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21933105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1082-1097&issue=9&author=R.+Biao-Xueauthor=C.+Xi-Guangauthor=Y.+Shuan-Yingauthor=L.+Weiauthor=M.+Zong-Juan&title=Epha2-dependent+molecular+targeting+therapy+for+malignant+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2-dependent molecular targeting therapy for malignant tumors</span></div><div class="casAuthors">Biao-xue Rong; Xi-guang Cai; Shuan-ying Yang; Wei Li; Zong-juan Ming</div><div class="citationInfo"><span class="NLM_cas:title">Current cancer drug targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1082-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clarification of the molecular mechanisms of oncogenesis and drug resistance is a prerequisite for the development of new treatment strategies like molecularly targeted therapies.  Recent studies demonstrate that EphA2 is overexpressed in human cancers and that EphA2 increases tumor invasion and survival.  Thus, an EphA2 receptor antagonist, such as a specific tyrosine kinase inhibitor (in the form of an antibody, small molecule, peptide, or siRNA) or an antibody-drug conjugate that targets the EphA2 receptor could be the basis for a novel targeted antineoplastic therapy.  This review summarizes the role of EphA2 in tumorigenesis and the development of EphA2 receptor antagonists as candidate anti-cancer agents.  We suggests that continued research into the function of EphA2 signaling in the pathobiology of neoplasia could lead to more rationally designed therapeutics targeting EphA2 in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMsB4DmqQ9_pp6t8nS6Nc3fW6udTcc2eaPtdyidcYPl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D&md5=04ec16254a29e8ee8e910def8cafef70</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F156800911798073050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911798073050%26sid%3Dliteratum%253Aachs%26aulast%3DBiao-Xue%26aufirst%3DR.%26aulast%3DXi-Guang%26aufirst%3DC.%26aulast%3DShuan-Ying%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DZong-Juan%26aufirst%3DM.%26atitle%3DEpha2-dependent%2520molecular%2520targeting%2520therapy%2520for%2520malignant%2520tumors%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26issue%3D9%26spage%3D1082%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wykosky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibo, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debinski, W.</span><span> </span><span class="NLM_article-title">A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12, Part 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">3208</span><span class="NLM_x">–</span> <span class="NLM_lpage">3218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1158%2F1535-7163.MCT-07-0200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=18089715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3208-3218&issue=12%2C+Part+1&author=J.+Wykoskyauthor=D.+M.+Giboauthor=W.+Debinski&title=A+novel%2C+potent%2C+and+specific+ephrinA1-based+cytotoxin+against+EphA2+receptor+expressing+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells</span></div><div class="casAuthors">Wykosky, Jill; Gibo, Denise M.; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3208-3218</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We have previously shown that the EphA2 receptor tyrosine kinase is overexpressed in glioblastoma multiforme (GBM) and represents a novel, attractive therapeutic target for the treatment of brain tumors.  Here, we have developed an EphA2-targeted agent, ephrinA1-PE38QQR, a novel cytotoxin composed of ephrinA1, a ligand for EphA2, and PE38QQR, a mutated form of Pseudomonas aeruginosa exotoxin A.  EphrinA1-PE38QQR showed potent and dose-dependent killing of GBM cells overexpressing the EphA2 receptor in cell viability and clonogenic survival assays, with an av. IC50 of ∼10-11 mol/L.  The conjugate was also highly effective in killing breast and prostate cancer cells overexpressing EphA2.  The cytotoxic effect of ephrinA1-PE38QQR was specific, as it was neutralized by an excess of EphA2 ligands.  Moreover, normal human endothelial cells and breast cancer cells that do not overexpress EphA2, as well as GBM cells that have down-regulated EphA2, were not susceptible to the cytotoxin.  EphrinA1-PE38QQR-mediated cytotoxicity induced caspase-dependent apoptosis, which was, however, not responsible for cell death in response to the conjugate.  In addn., the conjugate elicited no changes in the activity of survival pathways such as phosphoinositide 3-kinase, measured by AKT phosphorylation.  This is the first attempt to create a cytotoxic therapy using any of the ephrin ligands of either class (A or B) conjugated to a bacterial toxin.  EphrinA1-PE38QQR is very potent and specific, produces cell death that is caspase independent, and forms the basis for the further development of clin. applicable EphA2-targeted cytotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD5phNVN_qMrVg90H21EOLACvtfcHk0lj8krxhZz9nuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3J&md5=144487963c1108024fba0d2fcdd56303</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0200%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DGibo%26aufirst%3DD.%2BM.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DA%2520novel%252C%2520potent%252C%2520and%2520specific%2520ephrinA1-based%2520cytotoxin%2520against%2520EphA2%2520receptor%2520expressing%2520tumor%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D12%252C%2520Part%25201%26spage%3D3208%26epage%3D3218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sun, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R. X.</span><span> </span><span class="NLM_article-title">Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1016%2Fj.canlet.2011.07.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21924825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlars7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2011&pages=168-177&issue=2&author=X.+L.+Sunauthor=Z.+M.+Xuauthor=Y.+Q.+Keauthor=C.+C.+Huauthor=S.+Y.+Wangauthor=G.+Q.+Lingauthor=Z.+J.+Yanauthor=Y.+J.+Liuauthor=Z.+H.+Songauthor=X.+D.+Jiangauthor=R.+X.+Xu&title=Molecular+targeting+of+malignant+glioma+cells+with+an+EphA2-specific+immunotoxin+delivered+by+human+bone+marrow-derived+mesenchymal+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells</span></div><div class="casAuthors">Sun, Xin-lin; Xu, Zhi-min; Ke, Yi-quan; Hu, Chang-chen; Wang, Shi-yong; Ling, Geng-qiang; Yan, Zhong-jie; Liu, Yi-jing; Song, Zhen-hua; Jiang, Xiao-dan; Xu, Ru-xiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-177</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Immunotoxins have shown great promise as an alternative treatment for brain malignancies such as gliomas, but their failure to penetrate into the tumor mass remains a major problem.  Mesenchymal stem cells exhibit tropism to tumor tissue and may serve as a cellular vehicle for the delivery and local prodn. of antitumor agents.  In this study, we used human bone marrow-derived mesenchymal stem cells (hMSCs) as a vehicle for the targeted delivery of EphrinA1-PE38, a very specific immunotoxin against the EphA2 receptor that is overexpressed in gliomas. hMSCs were transduced with adenovirus to express secretable EphrinA1-PE38.  Our in vitro assays confirmed the expression, release and selective killing effect of the immunotoxin produced by hMSCs.  Furthermore, the intratumoral injection of engineered hMSCs was effective at inhibiting tumor growth in a malignant glioma tumor model.  These results indicate that gene therapy utilizing EphrinA1-PE38-secreting hMSCs may provide a novel approach for the local treatment of malignant gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRp0ps7iawqLVg90H21EOLACvtfcHk0lglloeNnEA4sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlars7nP&md5=28f4f08d44dab72754fb4b124ec48929</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%2BL.%26aulast%3DXu%26aufirst%3DZ.%2BM.%26aulast%3DKe%26aufirst%3DY.%2BQ.%26aulast%3DHu%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DLing%26aufirst%3DG.%2BQ.%26aulast%3DYan%26aufirst%3DZ.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26aulast%3DSong%26aufirst%3DZ.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BD.%26aulast%3DXu%26aufirst%3DR.%2BX.%26atitle%3DMolecular%2520targeting%2520of%2520malignant%2520glioma%2520cells%2520with%2520an%2520EphA2-specific%2520immunotoxin%2520delivered%2520by%2520human%2520bone%2520marrow-derived%2520mesenchymal%2520stem%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D312%26issue%3D2%26spage%3D168%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Jackson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gooya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinneer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazenbaker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swamynathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiener, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, D. A.</span><span> </span><span class="NLM_article-title">A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">9367</span><span class="NLM_x">–</span> <span class="NLM_lpage">9374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9367-9374&issue=22&author=D.+Jacksonauthor=J.+Gooyaauthor=S.+Maoauthor=K.+Kinneerauthor=L.+Xuauthor=M.+Camaraauthor=C.+Fazenbakerauthor=R.+Flemingauthor=S.+Swamynathanauthor=D.+Meyerauthor=P.+D.+Senterauthor=C.+Gaoauthor=H.+Wuauthor=M.+Kinchauthor=S.+Coatsauthor=P.+A.+Kienerauthor=D.+A.+Tice&title=A+human+antibody-drug+conjugate+targeting+EphA2+inhibits+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCamara%26aufirst%3DM.%26aulast%3DFazenbaker%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DR.%26aulast%3DSwamynathan%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DCoats%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DA%2520human%2520antibody-drug%2520conjugate%2520targeting%2520EphA2%2520inhibits%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9367%26epage%3D9374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Scarberry, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. J.</span><span> </span><span class="NLM_article-title">Magnetic nanoparticle–peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">10258</span><span class="NLM_x">–</span> <span class="NLM_lpage">10262</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja801969b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=10258-10262&issue=31&author=K.+E.+Scarberryauthor=E.+B.+Dickersonauthor=J.+F.+McDonaldauthor=Z.+J.+Zhang&title=Magnetic+nanoparticle%E2%80%93peptide+conjugates+for+in+vitro+and+in+vivo+targeting+and+extraction+of+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fja801969b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja801969b%26sid%3Dliteratum%253Aachs%26aulast%3DScarberry%26aufirst%3DK.%2BE.%26aulast%3DDickerson%26aufirst%3DE.%2BB.%26aulast%3DMcDonald%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DZ.%2BJ.%26atitle%3DMagnetic%2520nanoparticle%25E2%2580%2593peptide%2520conjugates%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520targeting%2520and%2520extraction%2520of%2520cancer%2520cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26issue%3D31%26spage%3D10258%26epage%3D10262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Mitra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggineni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koolpe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquale, E. B.</span><span> </span><span class="NLM_article-title">Structure–activity relationship analysis of peptides targeting the EphA2 receptor</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">6687</span><span class="NLM_x">–</span> <span class="NLM_lpage">6695</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi1006223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6687-6695&issue=31&author=S.+Mitraauthor=S.+Duggineniauthor=M.+Koolpeauthor=X.+Zhuauthor=Z.+Huangauthor=E.+B.+Pasquale&title=Structure%E2%80%93activity+relationship+analysis+of+peptides+targeting+the+EphA2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fbi1006223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1006223%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520analysis%2520of%2520peptides%2520targeting%2520the%2520EphA2%2520receptor%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26issue%3D31%26spage%3D6687%26epage%3D6695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Macrae, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Viciana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haqq, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span> </span><span class="NLM_article-title">A conditional feedback loop regulates Ras activity through EphA2</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=111-118&issue=2&author=M.+Macraeauthor=R.+M.+Neveauthor=P.+Rodriguez-Vicianaauthor=C.+Haqqauthor=J.+Yehauthor=C.+Chenauthor=J.+W.+Grayauthor=F.+McCormick&title=A+conditional+feedback+loop+regulates+Ras+activity+through+EphA2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacrae%26aufirst%3DM.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DRodriguez-Viciana%26aufirst%3DP.%26aulast%3DHaqq%26aufirst%3DC.%26aulast%3DYeh%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DA%2520conditional%2520feedback%2520loop%2520regulates%2520Ras%2520activity%2520through%2520EphA2%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26issue%3D2%26spage%3D111%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Click chemistry: diverse chemical function from a few good reactions</span> <span class="citation_source-journal">Angew. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2004</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=2004-2021&issue=11&author=H.+C.+Kolbauthor=M.+G.+Finnauthor=K.+B.+Sharpless&title=Click+chemistry%3A+diverse+chemical+function+from+a+few+good+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DClick%2520chemistry%253A%2520diverse%2520chemical%2520function%2520from%2520a%2520few%2520good%2520reactions%26jtitle%3DAngew.%2520Chem.%26date%3D2001%26volume%3D40%26issue%3D11%26spage%3D2004%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Deshayes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurizot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clochard, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthelot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esnouf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lairez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moenner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleris, G.</span><span> </span><span class="NLM_article-title">“Click” conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1631</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=1631-1642&issue=7&author=S.+Deshayesauthor=V.+Maurizotauthor=M.+C.+Clochardauthor=C.+Baudinauthor=T.+Berthelotauthor=S.+Esnoufauthor=D.+Lairezauthor=M.+Moennerauthor=G.+Deleris&title=%E2%80%9CClick%E2%80%9D+conjugation+of+peptide+on+the+surface+of+polymeric+nanoparticles+for+targeting+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeshayes%26aufirst%3DS.%26aulast%3DMaurizot%26aufirst%3DV.%26aulast%3DClochard%26aufirst%3DM.%2BC.%26aulast%3DBaudin%26aufirst%3DC.%26aulast%3DBerthelot%26aufirst%3DT.%26aulast%3DEsnouf%26aufirst%3DS.%26aulast%3DLairez%26aufirst%3DD.%26aulast%3DMoenner%26aufirst%3DM.%26aulast%3DDeleris%26aufirst%3DG.%26atitle%3D%25E2%2580%259CClick%25E2%2580%259D%2520conjugation%2520of%2520peptide%2520on%2520the%2520surface%2520of%2520polymeric%2520nanoparticles%2520for%2520targeting%2520tumor%2520angiogenesis%26jtitle%3DPharm.%2520Res.%26date%3D2011%26volume%3D28%26issue%3D7%26spage%3D1631%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dijkgraaf, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijnders, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soede, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dechesne, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Esse, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corstens, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijkers, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liskamp, R. M.</span><span> </span><span class="NLM_article-title">Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1039%2Fb615940k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=17340009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2gt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=935-944&issue=6&author=I.+Dijkgraafauthor=A.+Y.+Rijndersauthor=A.+Soedeauthor=A.+C.+Dechesneauthor=G.+W.+van+Esseauthor=A.+J.+Brouwerauthor=F.+H.+Corstensauthor=O.+C.+Boermanauthor=D.+T.+Rijkersauthor=R.+M.+Liskamp&title=Synthesis+of+DOTA-conjugated+multivalent+cyclic-RGD+peptide+dendrimers+via+1%2C3-dipolar+cycloaddition+and+their+biological+evaluation%3A+implications+for+tumor+targeting+and+tumor+imaging+purposes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes</span></div><div class="casAuthors">Dijkgraaf, Ingrid; Rijnders, Anneloes Y.; Soede, Annemieke; Dechesne, Annemarie C.; Van Esse, G. Wilma; Brouwer, Arwin J.; Corstens, Frans H. M.; Boerman, Otto C.; Rijkers, Dirk T. S.; Liskamp, Rob M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">935-944</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The design and synthesis of a series of αVβ3 integrin-directed monomeric, dimeric and tetrameric cyclo[Arg-Gly-Asp-d-Phe-Lys] dendrimers using "click chem." is described.  It was found that the unprotected N-.vepsiln.-azido deriv. of cyclo[Arg-Gly-Asp-d-Phe-Lys] underwent a highly chemoselective conjugation to amino acid-based dendrimers bearing terminal alkynes using a microwave-assisted Cu(i)-catalyzed 1,3-dipolar cycloaddn.  The αVβ3 binding characteristics of the dendrimers were detd. in vitro and their in vivo αVβ3 targeting properties were assessed in nude mice with s.c. growing human SK-RC-52 tumors.  The multivalent RGD-dendrimers were found to have enhanced affinity toward the αVβ3 integrin receptor as compared to the monomeric deriv. as detd. in an in vitro binding assay.  In case of the DOTA-conjugated 111In-labeled RGD-dendrimers, it was found that the radiolabeled multimeric dendrimers showed specifically enhanced uptake in αVβ3 integrin expressing tumors in vivo.  These studies showed that the tetrameric RGD-dendrimer had better tumor targeting properties than its dimeric and monomeric congeners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm0eoRXxFJ3bVg90H21EOLACvtfcHk0ljXL_aZFJl6GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2gt7Y%253D&md5=d9014e4e74cad4d28ad0b2c018c4cddc</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1039%2Fb615940k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb615940k%26sid%3Dliteratum%253Aachs%26aulast%3DDijkgraaf%26aufirst%3DI.%26aulast%3DRijnders%26aufirst%3DA.%2BY.%26aulast%3DSoede%26aufirst%3DA.%26aulast%3DDechesne%26aufirst%3DA.%2BC.%26aulast%3Dvan%2BEsse%26aufirst%3DG.%2BW.%26aulast%3DBrouwer%26aufirst%3DA.%2BJ.%26aulast%3DCorstens%26aufirst%3DF.%2BH.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DRijkers%26aufirst%3DD.%2BT.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%26atitle%3DSynthesis%2520of%2520DOTA-conjugated%2520multivalent%2520cyclic-RGD%2520peptide%2520dendrimers%2520via%25201%252C3-dipolar%2520cycloaddition%2520and%2520their%2520biological%2520evaluation%253A%2520implications%2520for%2520tumor%2520targeting%2520and%2520tumor%2520imaging%2520purposes%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2007%26volume%3D5%26issue%3D6%26spage%3D935%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">von Maltzahn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotamraju, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayakumar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sailor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span> </span><span class="NLM_article-title">In vivo tumor cell targeting with “click” nanoparticles</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1570</span><span class="NLM_x">–</span> <span class="NLM_lpage">1578</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc800077y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1ertLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1570-1578&issue=8&author=G.+von+Maltzahnauthor=Y.+Renauthor=J.+H.+Parkauthor=D.+H.+Minauthor=V.+R.+Kotamrajuauthor=J.+Jayakumarauthor=V.+Fogalauthor=M.+J.+Sailorauthor=E.+Ruoslahtiauthor=S.+N.+Bhatia&title=In+vivo+tumor+cell+targeting+with+%E2%80%9Cclick%E2%80%9D+nanoparticles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16dR"><div class="casContent"><span class="casTitleNuber">16d</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Tumor Cell Targeting with "Click" Nanoparticles</span></div><div class="casAuthors">von Maltzahn, Geoffrey; Ren, Yin; Park, Ji-Ho; Min, Dal-Hee; Kotamraju, Venkata Ramana; Jayakumar, Jayanthi; Fogal, Valentina; Sailor, Michael J.; Ruoslahti, Erkki; Bhatia, Sangeeta N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1570-1578</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vivo fate of nanomaterials strongly dets. their biomedical efficacy.  Accordingly, much effort has been invested into the development of library screening methods to select targeting ligands for a diversity of sites in vivo.  Still, broad application of chem. and biol. screens to the in vivo targeting of nanomaterials requires ligand attachment chemistries that are generalizable, efficient, covalent, orthogonal to diverse biochem. libraries, applicable under aq. conditions, and stable in in vivo environments.  To date, the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddn. or "click" reaction has shown considerable promise as a method for developing targeted nanomaterials in vitro.  Here, we investigate the utility of "click" chem. for the in vivo targeting of inorg. nanoparticles to tumors.  We find that "click" chem. allows cyclic LyP-1 targeting peptides to be specifically linked to azido-nanoparticles and to direct their binding to p32-expressing tumor cells in vitro.  Moreover, "click" nanoparticles are able to stably circulate for hours in vivo following i.v. administration (>5 h circulation time), extravasate into tumors, and penetrate the tumor interstitium to specifically bind p32-expressing cells in tumors.  In the future, in vivo use of "click" nanomaterials should expedite the progression from ligand discovery to in vivo evaluation and diversify approaches toward multifunctional nanoparticle development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr5zBN6IBSVrVg90H21EOLACvtfcHk0ljXL_aZFJl6GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1ertLs%253D&md5=f60752f3eb8d7a084866ace57101cb54</span></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=10.1021%2Fbc800077y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800077y%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMaltzahn%26aufirst%3DG.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DMin%26aufirst%3DD.%2BH.%26aulast%3DKotamraju%26aufirst%3DV.%2BR.%26aulast%3DJayakumar%26aufirst%3DJ.%26aulast%3DFogal%26aufirst%3DV.%26aulast%3DSailor%26aufirst%3DM.%2BJ.%26aulast%3DRuoslahti%26aufirst%3DE.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26atitle%3DIn%2520vivo%2520tumor%2520cell%2520targeting%2520with%2520%25E2%2580%259Cclick%25E2%2580%259D%2520nanoparticles%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26issue%3D8%26spage%3D1570%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Blackburn, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, L. A.</span><span> </span><span class="NLM_article-title">Peptide-functionalized nanogels for targeted siRNA delivery</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">960</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc800547c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvF2gsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=960-968&issue=5&author=W.+H.+Blackburnauthor=E.+B.+Dickersonauthor=M.+H.+Smithauthor=J.+F.+McDonaldauthor=L.+A.+Lyon&title=Peptide-functionalized+nanogels+for+targeted+siRNA+delivery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Functionalized Nanogels for Targeted siRNA Delivery</span></div><div class="casAuthors">Blackburn, William H.; Dickerson, Erin B.; Smith, Michael H.; McDonald, John F.; Lyon, L. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">960-968</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major bottleneck in the development of siRNA therapies is their delivery to the desired cell type or tissue, followed by effective passage across the cell membrane with subsequent silencing of the targeted mRNA.  To address this problem, we describe the synthesis of core/shell hydrogel nanoparticles (nanogels) with surface-localized peptides that specifically target ovarian carcinoma cell lines possessing high expression levels of the Eph2A receptor.  These nanogels are also demonstrated to be highly effective in the noncovalent encapsulation of siRNA and enable cell-specific delivery of the oligonucleotides in serum-contg. medium.  Cell toxicity and viability assays reveal that the nanogel construct is nontoxic under the conditions studied, as no toxicity or decrease in cell proliferation is obsd. following delivery.  Importantly, a preliminary investigation of gene silencing illustrates that nanogel-mediated delivery of siRNA targeted to the EGF receptor results in knockdown of that receptor.  Excellent protection of siRNA during endosomal uptake and endosomal escape of the nanogels is suggested by these results since siRNA activity in the cytosol is required for gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUkjVgfIwTP7Vg90H21EOLACvtfcHk0ljXL_aZFJl6GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvF2gsr4%253D&md5=58ec9c1a4b32ce314ceed5520adbcb03</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc800547c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800547c%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DW.%2BH.%26aulast%3DDickerson%26aufirst%3DE.%2BB.%26aulast%3DSmith%26aufirst%3DM.%2BH.%26aulast%3DMcDonald%26aufirst%3DJ.%2BF.%26aulast%3DLyon%26aufirst%3DL.%2BA.%26atitle%3DPeptide-functionalized%2520nanogels%2520for%2520targeted%2520siRNA%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26issue%3D5%26spage%3D960%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Cai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimnejad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2024</span><span class="NLM_x">–</span> <span class="NLM_lpage">2036</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1007%2Fs00259-007-0503-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=17673999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=2024-2036&issue=12&author=W.+Caiauthor=A.+Ebrahimnejadauthor=K.+Chenauthor=Q.+Caoauthor=Z.+B.+Liauthor=D.+A.+Ticeauthor=X.+Chen&title=Quantitative+radioimmunoPET+imaging+of+EphA2+in+tumor-bearing+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice</span></div><div class="casAuthors">Cai, Weibo; Ebrahimnejad, Alireza; Chen, Kai; Cao, Qizhen; Li, Zi-Bo; Tice, David A.; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2024-2036</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: EphA2 receptor tyrosine kinase is significantly overexpressed in a wide variety of cancer types.  High EphA2 expression has been correlated with increased metastatic potential and poor patient survival.  Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated.  Methods: We labeled 1C1, a humanized monoclonal antibody against both human and murine EphA2, with 64Cu through the chelating agent 1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid (DOTA) and carried out positron emission tomog. (PET) imaging of eight tumor models with different EphA2 expression levels.  Western blotting of tumor tissue lysate was performed to correlate the EphA2 expression level with 64Cu-DOTA-1C1 uptake in the tumors.  Immunofluorescence staining and biodistribution studies were also carried out to validate the in vivo results.  Results: The radiolabeling yield was 88.9 ± 9.5% (n = 7) and the specific activity of 64Cu-DOTA-1C1 was 1.32 ± 0.14 GBq/mg of 1C1 mAb.  The antibody retained antigen-binding affinity/specificity after DOTA conjugation as measured by FACS anal.  The uptake of 64Cu-DOTA-1C1 in CT-26 tumors was as high as 25.1 ± 2.5 %ID/g (n = 3) at 18 h post injection.  64Cu-DOTA-IgG, an isotype-matched control, exhibited minimal non-specific uptake in all eight tumor models.  In vivo EphA2 specificity of 64Cu-DOTA-1C1 was confirmed by successful blocking of CT-26 tumor uptake by unlabeled 1C1.  Most importantly, the tumor uptake value obtained from PET imaging had excellent linear correlation with the relative tumor tissue EphA2 expression level measured by Western blot, where r 2 equals 0.90 and 0.92 at 18 h and 42 h post injection, resp.  Conclusion: The tumor uptake of 64Cu-DOTA-1C1 measured by microPET imaging reflects tumor EphA2 expression level in vivo.  This is, to our knowledge, the first report of quant. radioimmunoPET imaging of EphA2 in living subjects.  Future clin. investigation of 64Cu-DOTA-1C1 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzMZbuvqQ4m7Vg90H21EOLACvtfcHk0li6R6sh3YVIbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO&md5=6353b6d0f2d30a2fb7e5126f34862c39</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00259-007-0503-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-007-0503-5%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DW.%26aulast%3DEbrahimnejad%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DZ.%2BB.%26aulast%3DTice%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DQuantitative%2520radioimmunoPET%2520imaging%2520of%2520EphA2%2520in%2520tumor-bearing%2520mice%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2007%26volume%3D34%26issue%3D12%26spage%3D2024%26epage%3D2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Fox, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabone, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandpal, R. P.</span><span> </span><span class="NLM_article-title">Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1263</span><span class="NLM_x">–</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2006&pages=1263-1272&issue=4&author=B.+P.+Foxauthor=C.+J.+Taboneauthor=R.+P.+Kandpal&title=Potential+clinical+relevance+of+Eph+receptors+and+ephrin+ligands+expressed+in+prostate+carcinoma+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DB.%2BP.%26aulast%3DTabone%26aufirst%3DC.%2BJ.%26aulast%3DKandpal%26aufirst%3DR.%2BP.%26atitle%3DPotential%2520clinical%2520relevance%2520of%2520Eph%2520receptors%2520and%2520ephrin%2520ligands%2520expressed%2520in%2520prostate%2520carcinoma%2520cell%2520lines%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D342%26issue%3D4%26spage%3D1263%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Vihanto, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh-Do, U.</span><span> </span><span class="NLM_article-title">Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1691</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1689-1691&issue=12&author=M.+M.+Vihantoauthor=J.+Plockauthor=D.+Erniauthor=B.+M.+Freyauthor=F.+J.+Freyauthor=U.+Huynh-Do&title=Hypoxia+up-regulates+expression+of+Eph+receptors+and+ephrins+in+mouse+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVihanto%26aufirst%3DM.%2BM.%26aulast%3DPlock%26aufirst%3DJ.%26aulast%3DErni%26aufirst%3DD.%26aulast%3DFrey%26aufirst%3DB.%2BM.%26aulast%3DFrey%26aufirst%3DF.%2BJ.%26aulast%3DHuynh-Do%26aufirst%3DU.%26atitle%3DHypoxia%2520up-regulates%2520expression%2520of%2520Eph%2520receptors%2520and%2520ephrins%2520in%2520mouse%2520skin%26jtitle%3DFASEB%2520J.%26date%3D2005%26volume%3D19%26issue%3D12%26spage%3D1689%26epage%3D1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, B.</span><span> </span><span class="NLM_article-title">Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">4395</span><span class="NLM_x">–</span> <span class="NLM_lpage">4413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.3390%2Fijms12074395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21845085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFGlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=4395-4413&issue=7&author=Y.+Liuauthor=B.+Zhangauthor=B.+Yan&title=Enabling+anticancer+therapeutics+by+nanoparticle+carriers%3A+the+delivery+of+paclitaxel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel</span></div><div class="casAuthors">Liu, Yongjin; Zhang, Bin; Yan, Bing</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4395-4413</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Anticancer drugs, such as paclitaxel (PTX), are indispensable for the treatment of a variety of malignancies.  However, the application of most drugs is greatly limited by the low water soly., poor permeability, or high efflux from cells.  Nanoparticles have been widely investigated to enable drug delivery due to their low toxicity, sustained drug release, mol. targeting, and addnl. therapeutic and imaging functions.  This review takes paclitaxel as an example and compares different nanoparticle-based delivery systems for their effectiveness in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFxdyKFI2nULVg90H21EOLACvtfcHk0li6R6sh3YVIbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFGlt7s%253D&md5=471b2e6ce69a56e8d409b3ab0db7b75b</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.3390%2Fijms12074395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms12074395%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DEnabling%2520anticancer%2520therapeutics%2520by%2520nanoparticle%2520carriers%253A%2520the%2520delivery%2520of%2520paclitaxel%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2011%26volume%3D12%26issue%3D7%26spage%3D4395%26epage%3D4413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dash, A. K.</span><span> </span><span class="NLM_article-title">Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges</span> <span class="citation_source-journal">Crit. Rev. Ther. Drug Carrier Syst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1615%2FCritRevTherDrugCarrierSyst.v26.i4.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20001890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=333-372&issue=4&author=S.+Singhauthor=A.+K.+Dash&title=Paclitaxel+in+cancer+treatment%3A+perspectives+and+prospects+of+its+delivery+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges</span></div><div class="casAuthors">Singh, Somnath; Dash, Alekha K.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Therapeutic Drug Carrier Systems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-372</span>CODEN:
                <span class="NLM_cas:coden">CRTSEO</span>;
        ISSN:<span class="NLM_cas:issn">0743-4863</span>.
    
            (<span class="NLM_cas:orgname">Begell House, Inc.</span>)
        </div><div class="casAbstract">A review.  Paclitaxel (PTX) is a potent anticancer agent whose clin. usefulness is marred by a delivery problem that is caused by its unfavorable pharmacokinetic and phys. properties.  Paclitaxel is currently formulated in a mixt. of Cremophor EL and ethanol, which is dild. 5-20 times with normal saline or 5% dextrose prior to administration via slow infusion to avoid pptn. in plasma.  Many adverse reactions to the PTX formulation have been reported because of the presence of Cremophor EL, including hypersensitivity reactions, nephrotoxicity, and neurotoxicity.  Cremophor EL also causes vasodilation, labored breathing, lethargy, hypotension, and leaching of plasticizers, such as diethylhexylpthalate, from the polyvinylchloride infusion bags/sets.  Significant research efforts have been conducted to develop an alternative formulation approach to increase the aq. soly. of PTX without using Cremophor, thereby decreasing its toxicity.  This article reviews the various investigated formulation approaches including pastes; liposomes; conjugates with antibodies, peptides, and fatty acids; nanospheres and microspheres; cyclodextrin complexes; emulsions; mucoadhesive gel; prodrugs; and nanoparticulate systems.  The pros and cons of each approach are also discussed.  Finally, this review concludes with a discussion of nanoparticulate delivery, which is the most promising PTX delivery system of the future because it incorporates the benefits of other approaches such as conjugation, complexation, and prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhxjPejwlodLVg90H21EOLACvtfcHk0lgdNfmQd7yVBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyqurw%253D&md5=58a406e461a760d7275a69382d645b40</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1615%2FCritRevTherDrugCarrierSyst.v26.i4.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevTherDrugCarrierSyst.v26.i4.10%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DDash%26aufirst%3DA.%2BK.%26atitle%3DPaclitaxel%2520in%2520cancer%2520treatment%253A%2520perspectives%2520and%2520prospects%2520of%2520its%2520delivery%2520challenges%26jtitle%3DCrit.%2520Rev.%2520Ther.%2520Drug%2520Carrier%2520Syst.%26date%3D2009%26volume%3D26%26issue%3D4%26spage%3D333%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Coffman, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carles-Kinch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donacki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munyon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kifle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langermann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiener, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M. S.</span><span> </span><span class="NLM_article-title">Differential EphA2 epitope display on normal versus malignant cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">7907</span><span class="NLM_x">–</span> <span class="NLM_lpage">7912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7907-7912&issue=22&author=K.+T.+Coffmanauthor=M.+Huauthor=K.+Carles-Kinchauthor=D.+Ticeauthor=N.+Donackiauthor=K.+Munyonauthor=G.+Kifleauthor=R.+Woodsauthor=S.+Langermannauthor=P.+A.+Kienerauthor=M.+S.+Kinch&title=Differential+EphA2+epitope+display+on+normal+versus+malignant+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoffman%26aufirst%3DK.%2BT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DCarles-Kinch%26aufirst%3DK.%26aulast%3DTice%26aufirst%3DD.%26aulast%3DDonacki%26aufirst%3DN.%26aulast%3DMunyon%26aufirst%3DK.%26aulast%3DKifle%26aufirst%3DG.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DLangermann%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520EphA2%2520epitope%2520display%2520on%2520normal%2520versus%2520malignant%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26issue%3D22%26spage%3D7907%26epage%3D7912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wakayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, N.</span><span> </span><span class="NLM_article-title">EphrinA1-EphA2 signal induces compaction and polarization of Madin–Darby canine kidney cells by inactivating ezrin through negative regulation of RhoA</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">44243</span><span class="NLM_x">–</span> <span class="NLM_lpage">44253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=44243-44253&author=Y.+Wakayamaauthor=K.+Miuraauthor=H.+Sabeauthor=N.+Mochizuki&title=EphrinA1-EphA2+signal+induces+compaction+and+polarization+of+Madin%E2%80%93Darby+canine+kidney+cells+by+inactivating+ezrin+through+negative+regulation+of+RhoA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakayama%26aufirst%3DY.%26aulast%3DMiura%26aufirst%3DK.%26aulast%3DSabe%26aufirst%3DH.%26aulast%3DMochizuki%26aufirst%3DN.%26atitle%3DEphrinA1-EphA2%2520signal%2520induces%2520compaction%2520and%2520polarization%2520of%2520Madin%25E2%2580%2593Darby%2520canine%2520kidney%2520cells%2520by%2520inactivating%2520ezrin%2520through%2520negative%2520regulation%2520of%2520RhoA%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D44243%26epage%3D44253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Miura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabe, H.</span><span> </span><span class="NLM_article-title">EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell–cell contacts</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1949</span><span class="NLM_x">–</span> <span class="NLM_lpage">1959</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1091%2Fmbc.E08-06-0549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=19193766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotVyqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=1949-1959&issue=7&author=K.+Miuraauthor=J.+M.+Namauthor=C.+Kojimaauthor=N.+Mochizukiauthor=H.+Sabe&title=EphA2+engages+Git1+to+suppress+Arf6+activity+modulating+epithelial+cell%E2%80%93cell+contacts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts</span></div><div class="casAuthors">Miura, Koichi; Nam, Jin-Min; Kojima, Chie; Mochizuki, Naoki; Sabe, Hisataka</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">ADP-ribosylation factor (Arf) 6 activity is crucially involved in the regulation of E-cadherin-based cell-cell adhesions.  Erythropoietin-producing hepatocellular carcinoma (Eph)-family receptors recognize ligands, namely, ephrins, anchored to the membrane of apposing cells, and they mediate cell-cell contact-dependent events.  Here, we found that Arf6 activity is down-regulated in Madin-Darby canine kidney cells, which is dependent on cell d. and calcium ion concn., and we provide evidence of a novel signaling pathway by which ligand-activated EphA2 suppresses Arf6 activity.  This EphA2-mediated suppression of Arf6 activity was linked to the induction of cell compaction and polarization, but it was independent of the down-regulation of extracellular signal-regulated kinase 1/2 kinase activity.  We show that G protein-coupled receptor kinase-interacting protein (Git) 1 and noncatalytic region of tyrosine kinase (Nck) 1 are involved in this pathway, in which ligand-activated EphA2, via its phosphorylated Tyr594, binds to the Src homol. 2 domain of Nck1, and then via its Src homol. 3 domain binds to the synaptic localizing domain of Git1 to suppress Arf6 activity.  We propose a pos. feedback loop in which E-cadherin-based cell-cell contacts enhance EphA-ephrinA signaling, which in turn down-regulates Arf6 activity to enhance E-cadherin-based cell-cell contacts as well as the apical-basal polarization of epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk5GzPpMJBXbVg90H21EOLACvtfcHk0lj0nrrNsZbN6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotVyqs7k%253D&md5=e86478187f9e9566f08aa61cc86b4ec0</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E08-06-0549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E08-06-0549%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%2BM.%26aulast%3DKojima%26aufirst%3DC.%26aulast%3DMochizuki%26aufirst%3DN.%26aulast%3DSabe%26aufirst%3DH.%26atitle%3DEphA2%2520engages%2520Git1%2520to%2520suppress%2520Arf6%2520activity%2520modulating%2520epithelial%2520cell%25E2%2580%2593cell%2520contacts%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2009%26volume%3D20%26issue%3D7%26spage%3D1949%26epage%3D1959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Flanagan, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldheim, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderhaeghen, P.</span><span> </span><span class="NLM_article-title">Alkaline phosphatase fusions of ligands or receptors as in situ probes for staining of cells, tissues, and embryos</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2000&pages=19-35&author=J.+G.+Flanaganauthor=H.+J.+Chengauthor=D.+A.+Feldheimauthor=M.+Hattoriauthor=Q.+Luauthor=P.+Vanderhaeghen&title=Alkaline+phosphatase+fusions+of+ligands+or+receptors+as+in+situ+probes+for+staining+of+cells%2C+tissues%2C+and+embryos"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DJ.%2BG.%26aulast%3DCheng%26aufirst%3DH.%2BJ.%26aulast%3DFeldheim%26aufirst%3DD.%2BA.%26aulast%3DHattori%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DVanderhaeghen%26aufirst%3DP.%26atitle%3DAlkaline%2520phosphatase%2520fusions%2520of%2520ligands%2520or%2520receptors%2520as%2520in%2520situ%2520probes%2520for%2520staining%2520of%2520cells%252C%2520tissues%252C%2520and%2520embryos%26jtitle%3DMethods%2520Enzymol.%26date%3D2000%26volume%3D327%26spage%3D19%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Carlsson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piller, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M.</span><span> </span><span class="NLM_article-title">Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x"> (</span><span class="NLM_issue">35</span><span class="NLM_x">) </span> <span class="NLM_fpage">18911</span><span class="NLM_x">–</span> <span class="NLM_lpage">18919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1988&pages=18911-18919&issue=35&author=S.+R.+Carlssonauthor=J.+Rothauthor=F.+Pillerauthor=M.+Fukuda&title=Isolation+and+characterization+of+human+lysosomal+membrane+glycoproteins%2C+h-lamp-1+and+h-lamp-2.+Major+sialoglycoproteins+carrying+polylactosaminoglycan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DS.%2BR.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DPiller%26aufirst%3DF.%26aulast%3DFukuda%26aufirst%3DM.%26atitle%3DIsolation%2520and%2520characterization%2520of%2520human%2520lysosomal%2520membrane%2520glycoproteins%252C%2520h-lamp-1%2520and%2520h-lamp-2.%2520Major%2520sialoglycoproteins%2520carrying%2520polylactosaminoglycan%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1988%26volume%3D263%26issue%3D35%26spage%3D18911%26epage%3D18919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Placzek, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy</span> <span class="citation_source-journal">Cell Death Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fcddis.2010.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21364647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A280%3ADC%252BC3M3jtVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=e40&author=W.+J.+Placzekauthor=J.+Weiauthor=S.+Kitadaauthor=D.+Zhaiauthor=J.+C.+Reedauthor=M.+Pellecchia&title=A+survey+of+the+anti-apoptotic+Bcl-2+subfamily+expression+in+cancer+types+provides+a+platform+to+predict+the+efficacy+of+Bcl-2+antagonists+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy</span></div><div class="casAuthors">Placzek W J; Wei J; Kitada S; Zhai D; Reed J C; Pellecchia M</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We investigated the mRNA expression levels of all six antiapoptotic Bcl-2 subfamily members in 68 human cancer cell lines using qPCR techniques and measured the ability of known Bcl-2 inhibitors to induce cell death in 36 of the studied tumor cell lines.  Our study reveals that Mcl-1 represents the anti-apoptotic Bcl-2 subfamily member with the highest mRNA levels in the lung, prostate, breast, ovarian, renal, and glioma cancer cell lines.  In leukemia/lymphoma and melanoma cancer cell lines, Bcl-2 and Bfl-1 had the highest levels of mRNA, respectively.  The observed correlation between the cell killing properties of known Bcl-2 inhibitors and the relative mRNA expression levels of anti-apoptotic Bcl-2 proteins provide critical insights into apoptosis-based anticancer strategies that target Bcl-2 proteins.  Our data may explain current challenges of selective Bcl-2 inhibitors in the clinic, given that severe expression of Bcl-2 seems to be limited to leukemia cell lines.  Furthermore, our data suggest that in most cancer types a strategy targeted to Mcl-1 inhibition, or combination of Bfl-1 and Mcl-1 inhibition for melanoma, may prove to be more successful than therapies targeting only Bcl-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSagH_WEvvgWbFU0A1HOshhfW6udTcc2ebwhDCAQavdirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3jtVKrtg%253D%253D&md5=d6759b1c82e7c72f4819a20c26720a00</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2010.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2010.18%26sid%3Dliteratum%253Aachs%26aulast%3DPlaczek%26aufirst%3DW.%2BJ.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DA%2520survey%2520of%2520the%2520anti-apoptotic%2520Bcl-2%2520subfamily%2520expression%2520in%2520cancer%2520types%2520provides%2520a%2520platform%2520to%2520predict%2520the%2520efficacy%2520of%2520Bcl-2%2520antagonists%2520in%2520cancer%2520therapy%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2010%26volume%3D1%26spage%3De40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b','cit3c','cit3d'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e','cit5f','cit5g','cit5h','cit5i','cit5j','cit5k','cit5l'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c','cit16d'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b','cit22c'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 64 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chunxiao Li, Zhenyu Chen, Dan Zheng, Jingyang Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Jiandu Lei</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug–Polymer Pattern Conjugate Nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Bio Materials</span><span> <strong>2021,</strong> <em>4 </em>
                                    (2)
                                     , 1499-1507. <a href="https://doi.org/10.1021/acsabm.0c01388" title="DOI URL">https://doi.org/10.1021/acsabm.0c01388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsabm.0c01388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsabm.0c01388%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Bio%2520Materials%26atitle%3DTargeted%252BDelivery%252Bof%252BDual%252BAnticancer%252BDrugs%252BBased%252Bon%252BSelf-Assembled%252BiRGD-Modified%252BSoluble%252BDrug%2525E2%252580%252593Polymer%252BPattern%252BConjugate%252BNanoparticles%26aulast%3DLi%26aufirst%3DChunxiao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D25102020%26date%3D21012021%26date%3D02022021%26volume%3D4%26issue%3D2%26spage%3D1499%26epage%3D1507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gemma E. Mudd, Amy Brown, Liuhong Chen, Katerine van Rietschoten, Sophie Watcham, Daniel P. Teufel, Silvia Pavan, Rachid Lani, Philip Huxley, <span class="NLM_string-name hlFld-ContribAuthor">Gavin S. Bennett</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4107-4116. <a href="https://doi.org/10.1021/acs.jmedchem.9b02129" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02129%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252BOptimization%252Bof%252BEphA2-Selective%252BBicycles%252Bfor%252Bthe%252BDelivery%252Bof%252BCytotoxic%252BPayloads%26aulast%3DMudd%26aufirst%3DGemma%2BE.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20122019%26date%3D02042020%26date%3D23032020%26volume%3D63%26issue%3D8%26spage%3D4107%26epage%3D4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Gambini, Ahmed F. Salem, Parima Udompholkul, Xiao-Feng Tan, Carlo Baggio, Neh Shah, Alexander Aronson, Jikui Song, <span class="NLM_string-name hlFld-ContribAuthor">Maurizio Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (9)
                                     , 2633-2644. <a href="https://doi.org/10.1021/acschembio.8b00556" title="DOI URL">https://doi.org/10.1021/acschembio.8b00556</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.8b00556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.8b00556%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DStructure-Based%252BDesign%252Bof%252BNovel%252BEphA2%252BAgonistic%252BAgents%252Bwith%252BNanomolar%252BAffinity%252Bin%252BVitro%252Band%252Bin%252BCell%26aulast%3DGambini%26aufirst%3DLuca%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14062018%26date%3D15082018%26date%3D29082018%26date%3D15082018%26volume%3D13%26issue%3D9%26spage%3D2633%26epage%3D2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ahmed
F. Salem, Si Wang, Sandrine Billet, Jie-Fu Chen, Parima Udompholkul, Luca Gambini, Carlo Baggio, Hsian-Rong Tseng, Edwin M. Posadas, Neil A. Bhowmick, <span class="NLM_string-name hlFld-ContribAuthor">Maurizio Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (5)
                                     , 2052-2061. <a href="https://doi.org/10.1021/acs.jmedchem.7b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DReduction%252Bof%252BCirculating%252BCancer%252BCells%252Band%252BMetastases%252Bin%252BBreast-Cancer%252BModels%252Bby%252Ba%252BPotent%252BEphA2-Agonistic%252BPeptide%2525E2%252580%252593Drug%252BConjugate%26aulast%3DSalem%26aufirst%3DAhmed%2BF.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D15122017%26date%3D27022018%26date%3D22022018%26volume%3D61%26issue%3D5%26spage%3D2052%26epage%3D2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuele  Cazzamalli</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Fontaine  Widmayer</span>, and <span class="hlFld-ContribAuthor ">Dario  Neri</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemically Defined Antibody– and Small Molecule–Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (5)
                                     , 1617-1621. <a href="https://doi.org/10.1021/jacs.7b13361" title="DOI URL">https://doi.org/10.1021/jacs.7b13361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b13361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b13361%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DChemically%252BDefined%252BAntibody%2525E2%252580%252593%252Band%252BSmall%252BMolecule%2525E2%252580%252593Drug%252BConjugates%252Bfor%252Bin%252BVivo%252BTumor%252BTargeting%252BApplications%25253A%252BA%252BComparative%252BAnalysis%26aulast%3DCazzamalli%26aufirst%3DSamuele%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D18122017%26date%3D27012018%26date%3D07022018%26date%3D17012018%26volume%3D140%26issue%3D5%26spage%3D1617%26epage%3D1621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seren  Hamsici</span>, <span class="hlFld-ContribAuthor ">Melis  Sardan Ekiz</span>, <span class="hlFld-ContribAuthor ">Goksu  Cinar Ciftci</span>, <span class="hlFld-ContribAuthor ">Ayse B.  Tekinay</span>, and <span class="hlFld-ContribAuthor ">Mustafa O.  Guler</span>  . </span><span class="cited-content_cbyCitation_article-title">Gemcitabine Integrated Nano-Prodrug Carrier System. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (5)
                                     , 1491-1498. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00155" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00155%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DGemcitabine%252BIntegrated%252BNano-Prodrug%252BCarrier%252BSystem%26aulast%3DHamsici%26aufirst%3DSeren%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22032017%26date%3D23042017%26date%3D03052017%26date%3D17052017%26date%3D25042017%26volume%3D28%26issue%3D5%26spage%3D1491%26epage%3D1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ketan  Patel</span>, <span class="hlFld-ContribAuthor ">Ravi  Doddapaneni</span>, <span class="hlFld-ContribAuthor ">Vasanthakumar  Sekar</span>, <span class="hlFld-ContribAuthor ">Nusrat  Chowdhury</span>, and <span class="hlFld-ContribAuthor ">Mandip  Singh</span>  . </span><span class="cited-content_cbyCitation_article-title">Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (6)
                                     , 2049-2058. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00187" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00187%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DCombination%252BApproach%252Bof%252BYSA%252BPeptide%252BAnchored%252BDocetaxel%252BStealth%252BLiposomes%252Bwith%252BOral%252BAntifibrotic%252BAgent%252Bfor%252Bthe%252BTreatment%252Bof%252BLung%252BCancer%26aulast%3DPatel%26aufirst%3DKetan%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03032016%26date%3D12042016%26date%3D01042016%26date%3D26042016%26date%3D06062016%26date%3D12042016%26volume%3D13%26issue%3D6%26spage%3D2049%26epage%3D2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Man  Ying</span>, <span class="hlFld-ContribAuthor ">Qing  Shen</span>, <span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Yan</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Wei</span>, <span class="hlFld-ContribAuthor ">Changyou  Zhan</span>, <span class="hlFld-ContribAuthor ">Jie  Gao</span>, <span class="hlFld-ContribAuthor ">Cao  Xie</span>, <span class="hlFld-ContribAuthor ">Bingxin  Yao</span>, and <span class="hlFld-ContribAuthor ">Weiyue  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">Stabilized Heptapeptide A7R for Enhanced Multifunctional Liposome-Based Tumor-Targeted Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2016,</strong> <em>8 </em>
                                    (21)
                                     , 13232-13241. <a href="https://doi.org/10.1021/acsami.6b01300" title="DOI URL">https://doi.org/10.1021/acsami.6b01300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.6b01300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.6b01300%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DStabilized%252BHeptapeptide%252BA7R%252Bfor%252BEnhanced%252BMultifunctional%252BLiposome-Based%252BTumor-Targeted%252BDrug%252BDelivery%26aulast%3DYing%26aufirst%3DMan%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D31012016%26date%3D12052016%26date%3D19052016%26date%3D01062016%26volume%3D8%26issue%3D21%26spage%3D13232%26epage%3D13241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alaaldin M.  Alkilany</span>, <span class="hlFld-ContribAuthor ">Stefano P.  Boulos</span>, <span class="hlFld-ContribAuthor ">Samuel E.  Lohse</span>, <span class="hlFld-ContribAuthor ">Lucas B.  Thompson</span>, and <span class="hlFld-ContribAuthor ">Catherine J.  Murphy</span>  . </span><span class="cited-content_cbyCitation_article-title">Homing Peptide-Conjugated Gold Nanorods: The Effect of Amino Acid Sequence Display on Nanorod Uptake and Cellular Proliferation. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2014,</strong> <em>25 </em>
                                    (6)
                                     , 1162-1171. <a href="https://doi.org/10.1021/bc500174b" title="DOI URL">https://doi.org/10.1021/bc500174b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bc500174b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbc500174b%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DHoming%252BPeptide-Conjugated%252BGold%252BNanorods%25253A%252BThe%252BEffect%252Bof%252BAmino%252BAcid%252BSequence%252BDisplay%252Bon%252BNanorod%252BUptake%252Band%252BCellular%252BProliferation%26aulast%3DAlkilany%26aufirst%3DAlaaldin%2BM.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D19042014%26date%3D15052014%26date%3D03062014%26date%3D18062014%26date%3D20052014%26volume%3D25%26issue%3D6%26spage%3D1162%26epage%3D1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matteo  Incerti</span>, <span class="hlFld-ContribAuthor ">Massimiliano  Tognolini</span>, <span class="hlFld-ContribAuthor ">Simonetta  Russo</span>, <span class="hlFld-ContribAuthor ">Daniele  Pala</span>, <span class="hlFld-ContribAuthor ">Carmine  Giorgio</span>, <span class="hlFld-ContribAuthor ">Iftiin  Hassan-Mohamed</span>, <span class="hlFld-ContribAuthor ">Roberta  Noberini</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, <span class="hlFld-ContribAuthor ">Paola  Vicini</span>, <span class="hlFld-ContribAuthor ">Silvia  Piersanti</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Barocelli</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, and <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>  . </span><span class="cited-content_cbyCitation_article-title">Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (7)
                                     , 2936-2947. <a href="https://doi.org/10.1021/jm301890k" title="DOI URL">https://doi.org/10.1021/jm301890k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301890k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301890k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAmino%252BAcid%252BConjugates%252Bof%252BLithocholic%252BAcid%252BAs%252BAntagonists%252Bof%252Bthe%252BEphA2%252BReceptor%26aulast%3DIncerti%26aufirst%3DMatteo%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D21122012%26date%3D22032013%26date%3D11042013%26date%3D14032013%26volume%3D56%26issue%3D7%26spage%3D2936%26epage%3D2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srinivas  Duggineni</span>, <span class="hlFld-ContribAuthor ">Sayantan  Mitra</span>, <span class="hlFld-ContribAuthor ">Ilaria  Lamberto</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Han</span>, <span class="hlFld-ContribAuthor ">Yan  Xu</span>, <span class="hlFld-ContribAuthor ">Jing  An</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, and <span class="hlFld-ContribAuthor ">Ziwei  Huang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (3)
                                     , 344-348. <a href="https://doi.org/10.1021/ml3004523" title="DOI URL">https://doi.org/10.1021/ml3004523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml3004523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml3004523%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BPotent%252BBivalent%252BPeptide%252BAgonists%252BTargeting%252Bthe%252BEphA2%252BReceptor%26aulast%3DDuggineni%26aufirst%3DSrinivas%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D17122012%26date%3D05022013%26date%3D08022013%26date%3D14032013%26date%3D05022013%26volume%3D4%26issue%3D3%26spage%3D344%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongtao  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing  Dong</span>, <span class="hlFld-ContribAuthor ">Karine  Lafleur</span>, <span class="hlFld-ContribAuthor ">Cristina  Nevado</span>, and <span class="hlFld-ContribAuthor ">Amedeo  Caflisch</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular Dynamics. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>3 </em>
                                    (10)
                                     , 834-838. <a href="https://doi.org/10.1021/ml3001984" title="DOI URL">https://doi.org/10.1021/ml3001984</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml3001984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml3001984%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BChemotype%252Bof%252BTyrosine%252BKinase%252BInhibitors%252Bby%252BFragment-Based%252BDocking%252Band%252BMolecular%252BDynamics%26aulast%3DZhao%26aufirst%3DHongtao%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D16072012%26date%3D23082012%26date%3D29082012%26date%3D11102012%26date%3D23082012%26volume%3D3%26issue%3D10%26spage%3D834%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun Kumar  Jannu</span>, <span class="hlFld-ContribAuthor ">Eswara Rao  Puppala</span>, <span class="hlFld-ContribAuthor ">Basveshwar  Gawali</span>, <span class="hlFld-ContribAuthor ">N.P.  Syamprasad</span>, <span class="hlFld-ContribAuthor ">Amit  Alexander</span>, <span class="hlFld-ContribAuthor ">Srujan  Marepally</span>, <span class="hlFld-ContribAuthor ">Naveen  Chella</span>, <span class="hlFld-ContribAuthor ">Jagadeesh Kumar  Gangasani</span>, <span class="hlFld-ContribAuthor ">V.G.M.  Naidu</span>. </span><span class="cited-content_cbyCitation_article-title">Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2021,</strong> <em>605 </em>, 120819. <a href="https://doi.org/10.1016/j.ijpharm.2021.120819" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2021.120819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2021.120819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2021.120819%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DLithocholic%252Bacid-tryptophan%252Bconjugate%252B%252528UniPR126%252529%252Bbased%252Bmixed%252Bmicelle%252Bas%252Ba%252Bnano%252Bcarrier%252Bfor%252Bspecific%252Bdelivery%252Bof%252Bniclosamide%252Bto%252Bprostate%252Bcancer%252Bvia%252BEphA2%252Breceptor%26aulast%3DJannu%26aufirst%3DArun%2BKumar%26date%3D2021%26volume%3D605%26spage%3D120819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junxia  Wang</span>, <span class="hlFld-ContribAuthor ">Jingjing  Guo</span>, <span class="hlFld-ContribAuthor ">Kaifeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Weidong  Ruan</span>, <span class="hlFld-ContribAuthor ">Liang  Li</span>, <span class="hlFld-ContribAuthor ">Jiajun  Ling</span>, <span class="hlFld-ContribAuthor ">Ruixiao  Peng</span>, <span class="hlFld-ContribAuthor ">Huimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Chaoyong  Yang</span>, <span class="hlFld-ContribAuthor ">Zhi  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Auto-Panning: a highly integrated and automated biopanning platform for peptide screening. </span><span class="cited-content_cbyCitation_journal-name">Lab on a Chip</span><span> <strong>2021,</strong> <em>21 </em>
                                    (14)
                                     , 2702-2710. <a href="https://doi.org/10.1039/D1LC00129A" title="DOI URL">https://doi.org/10.1039/D1LC00129A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1LC00129A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1LC00129A%26sid%3Dliteratum%253Aachs%26jtitle%3DLab%2520on%2520a%2520Chip%26atitle%3DAuto-Panning%25253A%252Ba%252Bhighly%252Bintegrated%252Band%252Bautomated%252Bbiopanning%252Bplatform%252Bfor%252Bpeptide%252Bscreening%26aulast%3DWang%26aufirst%3DJunxia%26date%3D2021%26date%3D2021%26volume%3D21%26issue%3D14%26spage%3D2702%26epage%3D2710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parima  Udompholkul</span>, <span class="hlFld-ContribAuthor ">Carlo  Baggio</span>, <span class="hlFld-ContribAuthor ">Luca  Gambini</span>, <span class="hlFld-ContribAuthor ">Yu  Sun</span>, <span class="hlFld-ContribAuthor ">Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Robert M.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (12)
                                     , 3687. <a href="https://doi.org/10.3390/molecules26123687" title="DOI URL">https://doi.org/10.3390/molecules26123687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26123687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26123687%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DEffective%252BTumor%252BTargeting%252Bby%252BEphA2-Agonist-Biotin-Streptavidin%252BConjugates%26aulast%3DUdompholkul%26aufirst%3DParima%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D12%26spage%3D3687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ta  Xiao</span>, <span class="hlFld-ContribAuthor ">Yuhang  Xiao</span>, <span class="hlFld-ContribAuthor ">Wenxiang  Wang</span>, <span class="hlFld-ContribAuthor ">Yan Yan  Tang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Xiao</span>, <span class="hlFld-ContribAuthor ">Min  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EphA2 in cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00944-9" title="DOI URL">https://doi.org/10.1186/s13045-020-00944-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00944-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00944-9%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DTargeting%252BEphA2%252Bin%252Bcancer%26aulast%3DXiao%26aufirst%3DTa%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roghayyeh  Baghban</span>, <span class="hlFld-ContribAuthor ">Leila  Roshangar</span>, <span class="hlFld-ContribAuthor ">Rana  Jahanban-Esfahlan</span>, <span class="hlFld-ContribAuthor ">Khaled  Seidi</span>, <span class="hlFld-ContribAuthor ">Abbas  Ebrahimi-Kalan</span>, <span class="hlFld-ContribAuthor ">Mehdi  Jaymand</span>, <span class="hlFld-ContribAuthor ">Saeed  Kolahian</span>, <span class="hlFld-ContribAuthor ">Tahereh  Javaheri</span>, <span class="hlFld-ContribAuthor ">Peyman  Zare</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor microenvironment complexity and therapeutic implications at a glance. </span><span class="cited-content_cbyCitation_journal-name">Cell Communication and Signaling</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12964-020-0530-4" title="DOI URL">https://doi.org/10.1186/s12964-020-0530-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12964-020-0530-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12964-020-0530-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Communication%2520and%2520Signaling%26atitle%3DTumor%252Bmicroenvironment%252Bcomplexity%252Band%252Btherapeutic%252Bimplications%252Bat%252Ba%252Bglance%26aulast%3DBaghban%26aufirst%3DRoghayyeh%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Max  London</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gallo</span>. </span><span class="cited-content_cbyCitation_article-title">The EphA2 and cancer connection: potential for immune-based interventions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2020,</strong> <em>47 </em>
                                    (10)
                                     , 8037-8048. <a href="https://doi.org/10.1007/s11033-020-05767-y" title="DOI URL">https://doi.org/10.1007/s11033-020-05767-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-020-05767-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-020-05767-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DThe%252BEphA2%252Band%252Bcancer%252Bconnection%25253A%252Bpotential%252Bfor%252Bimmune-based%252Binterventions%26aulast%3DLondon%26aufirst%3DMax%26date%3D2020%26date%3D2020%26volume%3D47%26issue%3D10%26spage%3D8037%26epage%3D8048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed F.  Salem</span>, <span class="hlFld-ContribAuthor ">Luca  Gambini</span>, <span class="hlFld-ContribAuthor ">Sandrine  Billet</span>, <span class="hlFld-ContribAuthor ">Yu  Sun</span>, <span class="hlFld-ContribAuthor ">Hiromichi  Oshiro</span>, <span class="hlFld-ContribAuthor ">Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Robert M.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Neil A.  Bhowmick</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2854. <a href="https://doi.org/10.3390/cancers12102854" title="DOI URL">https://doi.org/10.3390/cancers12102854</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102854%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DProstate%252BCancer%252BMetastases%252BAre%252BStrongly%252BInhibited%252Bby%252BAgonistic%252BEpha2%252BLigands%252Bin%252Ban%252BOrthotopic%252BMouse%252BModel%26aulast%3DSalem%26aufirst%3DAhmed%2BF.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Malgorzata  Gajdzis</span>, <span class="hlFld-ContribAuthor ">Stamatios  Theocharis</span>, <span class="hlFld-ContribAuthor ">Pawel  Gajdzis</span>, <span class="hlFld-ContribAuthor ">Nathalie  Cassoux</span>, <span class="hlFld-ContribAuthor ">Sophie  Gardrat</span>, <span class="hlFld-ContribAuthor ">Piotr  Donizy</span>, <span class="hlFld-ContribAuthor ">Jerzy  Klijanienko</span>, <span class="hlFld-ContribAuthor ">Radoslaw  Kaczmarek</span>. </span><span class="cited-content_cbyCitation_article-title">Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival. </span><span class="cited-content_cbyCitation_journal-name">Life</span><span> <strong>2020,</strong> <em>10 </em>
                                    (10)
                                     , 225. <a href="https://doi.org/10.3390/life10100225" title="DOI URL">https://doi.org/10.3390/life10100225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/life10100225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Flife10100225%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%26atitle%3DEphrin%252BReceptors%252B%252528Eph%252529%25253A%252BEphA1%25252C%252BEphA5%25252C%252Band%252BEphA7%252BExpression%252Bin%252BUveal%252BMelanoma%2525E2%252580%252594Associations%252Bwith%252BClinical%252BParameters%252Band%252BPatient%252BSurvival%26aulast%3DGajdzis%26aufirst%3DMalgorzata%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D10%26spage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gavin  Bennett</span>, <span class="hlFld-ContribAuthor ">Amy  Brown</span>, <span class="hlFld-ContribAuthor ">Gemma  Mudd</span>, <span class="hlFld-ContribAuthor ">Philip  Huxley</span>, <span class="hlFld-ContribAuthor ">Katerine  Van Rietschoten</span>, <span class="hlFld-ContribAuthor ">Silvia  Pavan</span>, <span class="hlFld-ContribAuthor ">Liuhong  Chen</span>, <span class="hlFld-ContribAuthor ">Sophie  Watcham</span>, <span class="hlFld-ContribAuthor ">Johanna  Lahdenranta</span>, <span class="hlFld-ContribAuthor ">Nicholas  Keen</span>. </span><span class="cited-content_cbyCitation_article-title">MMAE Delivery Using the
              Bicycle
              Toxin Conjugate BT5528. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (7)
                                     , 1385-1394. <a href="https://doi.org/10.1158/1535-7163.MCT-19-1092" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-1092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-1092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-1092%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DMMAE%252BDelivery%252BUsing%252Bthe%252BBicycle%252BToxin%252BConjugate%252BBT5528%26aulast%3DBennett%26aufirst%3DGavin%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D7%26spage%3D1385%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Hughes</span>, <span class="hlFld-ContribAuthor ">Jitka A.I.  Virag</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (6)
                                     , 112. <a href="https://doi.org/10.3390/ph13060112" title="DOI URL">https://doi.org/10.3390/ph13060112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13060112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13060112%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DHarnessing%252Bthe%252BPower%252Bof%252BEph%25252Fephrin%252BBiosemiotics%252Bfor%252BTheranostic%252BApplications%26aulast%3DHughes%26aufirst%3DRobert%2BM.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmine  Giorgio</span>, <span class="hlFld-ContribAuthor ">Ilaria  Zanotti</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Massimiliano  Tognolini</span>. </span><span class="cited-content_cbyCitation_article-title">Ephrin or not? Six tough questions on Eph targeting. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2020,</strong> <em>24 </em>
                                    (5)
                                     , 403-415. <a href="https://doi.org/10.1080/14728222.2020.1745187" title="DOI URL">https://doi.org/10.1080/14728222.2020.1745187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728222.2020.1745187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728222.2020.1745187%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DEphrin%252Bor%252Bnot%25253F%252BSix%252Btough%252Bquestions%252Bon%252BEph%252Btargeting%26aulast%3DGiorgio%26aufirst%3DCarmine%26date%3D2020%26date%3D2020%26volume%3D24%26issue%3D5%26spage%3D403%26epage%3D415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed F.  Salem</span>, <span class="hlFld-ContribAuthor ">Luca  Gambini</span>, <span class="hlFld-ContribAuthor ">Parima  Udompholkul</span>, <span class="hlFld-ContribAuthor ">Carlo  Baggio</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (5)
                                     , 90. <a href="https://doi.org/10.3390/ph13050090" title="DOI URL">https://doi.org/10.3390/ph13050090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13050090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13050090%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DTherapeutic%252BTargeting%252Bof%252BPancreatic%252BCancer%252Bvia%252BEphA2%252BDimeric%252BAgonistic%252BAgents%26aulast%3DSalem%26aufirst%3DAhmed%2BF.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D5%26spage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoying  Zhou</span>, <span class="hlFld-ContribAuthor ">Lu  Guo</span>, <span class="hlFld-ContribAuthor ">Dandan  Shi</span>, <span class="hlFld-ContribAuthor ">Sujuan  Duan</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Biocompatible Chitosan Nanobubbles for Ultrasound-Mediated Targeted Delivery of Doxorubicin. </span><span class="cited-content_cbyCitation_journal-name">Nanoscale Research Letters</span><span> <strong>2019,</strong> <em>14 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s11671-019-2853-x" title="DOI URL">https://doi.org/10.1186/s11671-019-2853-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s11671-019-2853-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs11671-019-2853-x%26sid%3Dliteratum%253Aachs%26jtitle%3DNanoscale%2520Research%2520Letters%26atitle%3DBiocompatible%252BChitosan%252BNanobubbles%252Bfor%252BUltrasound-Mediated%252BTargeted%252BDelivery%252Bof%252BDoxorubicin%26aulast%3DZhou%26aufirst%3DXiaoying%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yige  Fu</span>, <span class="hlFld-ContribAuthor ">Drishti  Rathod</span>, <span class="hlFld-ContribAuthor ">Ehab  Abo-Ali</span>, <span class="hlFld-ContribAuthor ">Vikas  Dukhande</span>, <span class="hlFld-ContribAuthor ">Ketan  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (10)
                                     , 504. <a href="https://doi.org/10.3390/pharmaceutics11100504" title="DOI URL">https://doi.org/10.3390/pharmaceutics11100504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics11100504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics11100504%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DEphA2-Receptor%252BTargeted%252BPEGylated%252BNanoliposomes%252Bfor%252Bthe%252BTreatment%252Bof%252BBRAFV600E%252BMutated%252BParent-%252Band%252BVemurafenib-Resistant%252BMelanoma%26aulast%3DFu%26aufirst%3DYige%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D10%26spage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rongjun  He</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">John P.  Mayer</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (10)
                                     , 1855. <a href="https://doi.org/10.3390/molecules24101855" title="DOI URL">https://doi.org/10.3390/molecules24101855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24101855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24101855%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPeptide%252BConjugates%252Bwith%252BSmall%252BMolecules%252BDesigned%252Bto%252BEnhance%252BEfficacy%252Band%252BSafety%26aulast%3DHe%26aufirst%3DRongjun%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D10%26spage%3D1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maricel  Gomez-Soler</span>, <span class="hlFld-ContribAuthor ">Marina  Petersen Gehring</span>, <span class="hlFld-ContribAuthor ">Bernhard C.  Lechtenberg</span>, <span class="hlFld-ContribAuthor ">Elmer  Zapata-Mercado</span>, <span class="hlFld-ContribAuthor ">Kalina  Hristova</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>. </span><span class="cited-content_cbyCitation_article-title">Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2019,</strong> <em>294 </em>
                                    (22)
                                     , 8791-8805. <a href="https://doi.org/10.1074/jbc.RA119.008213" title="DOI URL">https://doi.org/10.1074/jbc.RA119.008213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.008213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.008213%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DEngineering%252Bnanomolar%252Bpeptide%252Bligands%252Bthat%252Bdifferentially%252Bmodulate%252BEphA2%252Breceptor%252Bsignaling%26aulast%3DGomez-Soler%26aufirst%3DMaricel%26date%3D2019%26volume%3D294%26issue%3D22%26spage%3D8791%26epage%3D8805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mukesh  Bansal</span>, <span class="hlFld-ContribAuthor ">Jing  He</span>, <span class="hlFld-ContribAuthor ">Michael  Peyton</span>, <span class="hlFld-ContribAuthor ">Manjunath  Kustagi</span>, <span class="hlFld-ContribAuthor ">Archana  Iyer</span>, <span class="hlFld-ContribAuthor ">Michael  Comb</span>, <span class="hlFld-ContribAuthor ">Michael  White</span>, <span class="hlFld-ContribAuthor ">John D.  Minna</span>, <span class="hlFld-ContribAuthor ">Andrea  Califano</span>, . </span><span class="cited-content_cbyCitation_article-title">Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2019,</strong> <em>14 </em>
                                    (1)
                                     , e0208646. <a href="https://doi.org/10.1371/journal.pone.0208646" title="DOI URL">https://doi.org/10.1371/journal.pone.0208646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0208646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0208646%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DElucidating%252Bsynergistic%252Bdependencies%252Bin%252Blung%252Badenocarcinoma%252Bby%252Bproteome-wide%252Bsignaling-network%252Banalysis%26aulast%3DBansal%26aufirst%3DMukesh%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D1%26spage%3De0208646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ningning  Song</span>, <span class="hlFld-ContribAuthor ">Lingzhou  Zhao</span>, <span class="hlFld-ContribAuthor ">Meilin  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinhua  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in LyP-1-based strategies for targeted imaging and therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery</span><span> <strong>2019,</strong> <em>26 </em>
                                    (1)
                                     , 363-375. <a href="https://doi.org/10.1080/10717544.2019.1587047" title="DOI URL">https://doi.org/10.1080/10717544.2019.1587047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10717544.2019.1587047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10717544.2019.1587047%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%26atitle%3DRecent%252Bprogress%252Bin%252BLyP-1-based%252Bstrategies%252Bfor%252Btargeted%252Bimaging%252Band%252Btherapy%26aulast%3DSong%26aufirst%3DNingning%26date%3D2019%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3D363%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deo R.  Singh</span>, <span class="hlFld-ContribAuthor ">Pranjali  Kanvinde</span>, <span class="hlFld-ContribAuthor ">Christopher  King</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, <span class="hlFld-ContribAuthor ">Kalina  Hristova</span>. </span><span class="cited-content_cbyCitation_article-title">The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2018,</strong> <em>1 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-018-0017-7" title="DOI URL">https://doi.org/10.1038/s42003-018-0017-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-018-0017-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-018-0017-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DThe%252BEphA2%252Breceptor%252Bis%252Bactivated%252Bthrough%252Binduction%252Bof%252Bdistinct%25252C%252Bligand-dependent%252Boligomeric%252Bstructures%26aulast%3DSingh%26aufirst%3DDeo%2BR.%26date%3D2018%26date%3D2018%26volume%3D1%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christin  Möser</span>, <span class="hlFld-ContribAuthor ">Jessica  Lorenz</span>, <span class="hlFld-ContribAuthor ">Martin  Sajfutdinow</span>, <span class="hlFld-ContribAuthor ">David  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Pinpointed Stimulation of EphA2 Receptors via DNA-Templated Oligovalence. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (11)
                                     , 3482. <a href="https://doi.org/10.3390/ijms19113482" title="DOI URL">https://doi.org/10.3390/ijms19113482</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19113482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19113482%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPinpointed%252BStimulation%252Bof%252BEphA2%252BReceptors%252Bvia%252BDNA-Templated%252BOligovalence%26aulast%3DM%25C3%25B6ser%26aufirst%3DChristin%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D11%26spage%3D3482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Theodora  Chatzisideri</span>, <span class="hlFld-ContribAuthor ">George  Leonidis</span>, <span class="hlFld-ContribAuthor ">Vasiliki  Sarli</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer-targeted delivery systems based on peptides. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (18)
                                     , 2201-2226. <a href="https://doi.org/10.4155/fmc-2018-0174" title="DOI URL">https://doi.org/10.4155/fmc-2018-0174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0174%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DCancer-targeted%252Bdelivery%252Bsystems%252Bbased%252Bon%252Bpeptides%26aulast%3DChatzisideri%26aufirst%3DTheodora%26date%3D2018%26volume%3D10%26issue%3D18%26spage%3D2201%26epage%3D2226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanxia  Gong</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Wu</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Jia  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhi  Yao</span>, <span class="hlFld-ContribAuthor ">Qingyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xi  Liu</span>, <span class="hlFld-ContribAuthor ">Xu  Jian</span>. </span><span class="cited-content_cbyCitation_article-title">Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Oncology Letters</span><span> <strong>2017,</strong> <em>14 </em>
                                    (4)
                                     , 4158-4166. <a href="https://doi.org/10.3892/ol.2017.6724" title="DOI URL">https://doi.org/10.3892/ol.2017.6724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ol.2017.6724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fol.2017.6724%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Letters%26atitle%3DSpecific%252Bexpression%252Bof%252Bproton-coupled%252Boligopeptide%252Btransporter%252B1%252Bin%252Bprimary%252Bhepatocarcinoma-a%252Bnovel%252Bstrategy%252Bfor%252Btumor-targeted%252Btherapy%26aulast%3DGong%26aufirst%3DYanxia%26date%3D2017%26date%3D2017%26volume%3D14%26issue%3D4%26spage%3D4158%26epage%3D4166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zi-Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-Xue  Sun</span>, <span class="hlFld-ContribAuthor ">Xue  Wang</span>, <span class="hlFld-ContribAuthor ">Ya-Han  Zhang</span>, <span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Jin-Liang  Qi</span>, <span class="hlFld-ContribAuthor ">Yan-Jun  Pang</span>, <span class="hlFld-ContribAuthor ">Gui-Hua  Lu</span>, <span class="hlFld-ContribAuthor ">Xiao-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Fu-Gen  Yu</span>, <span class="hlFld-ContribAuthor ">Yong-Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin-dioxazole combination as tubulin targeting anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (2)
                                     , 236-243. <a href="https://doi.org/10.1111/cbdd.12942" title="DOI URL">https://doi.org/10.1111/cbdd.12942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12942%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%25252C%252Band%252B3D-QSAR%252Banalysis%252Bof%252Bpodophyllotoxin-dioxazole%252Bcombination%252Bas%252Btubulin%252Btargeting%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DZi-Zhen%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D2%26spage%3D236%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew G  Cheetham</span>, <span class="hlFld-ContribAuthor ">Yi-an  Lin</span>, <span class="hlFld-ContribAuthor ">Ran  Lin</span>, <span class="hlFld-ContribAuthor ">Honggang  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design and synthesis of self-assembling camptothecin drug amphiphiles. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2017,</strong> <em>38 </em>
                                    (6)
                                     , 874-884. <a href="https://doi.org/10.1038/aps.2016.151" title="DOI URL">https://doi.org/10.1038/aps.2016.151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2016.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2016.151%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DMolecular%252Bdesign%252Band%252Bsynthesis%252Bof%252Bself-assembling%252Bcamptothecin%252Bdrug%252Bamphiphiles%26aulast%3DCheetham%26aufirst%3DAndrew%2BG%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D6%26spage%3D874%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Man  Ying</span>, <span class="hlFld-ContribAuthor ">Qing  Shen</span>, <span class="hlFld-ContribAuthor ">Changyou  Zhan</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Wei</span>, <span class="hlFld-ContribAuthor ">Jie  Gao</span>, <span class="hlFld-ContribAuthor ">Cao  Xie</span>, <span class="hlFld-ContribAuthor ">Bingxin  Yao</span>, <span class="hlFld-ContribAuthor ">Weiyue  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A stabilized peptide ligand for multifunctional glioma targeted drug delivery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2016,</strong> <em>243 </em>, 86-98. <a href="https://doi.org/10.1016/j.jconrel.2016.09.035" title="DOI URL">https://doi.org/10.1016/j.jconrel.2016.09.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2016.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2016.09.035%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DA%252Bstabilized%252Bpeptide%252Bligand%252Bfor%252Bmultifunctional%252Bglioma%252Btargeted%252Bdrug%252Bdelivery%26aulast%3DYing%26aufirst%3DMan%26date%3D2016%26volume%3D243%26spage%3D86%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Fengfeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiyong  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Fan</span>, <span class="hlFld-ContribAuthor ">Guoqiu  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Secondary nuclear targeting of mesoporous silica nano-particles for cancer-specific drug delivery based on charge inversion. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (43)
                                     , 70100-70112. <a href="https://doi.org/10.18632/oncotarget.12149" title="DOI URL">https://doi.org/10.18632/oncotarget.12149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.12149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.12149%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DSecondary%252Bnuclear%252Btargeting%252Bof%252Bmesoporous%252Bsilica%252Bnano-particles%252Bfor%252Bcancer-specific%252Bdrug%252Bdelivery%252Bbased%252Bon%252Bcharge%252Binversion%26aulast%3DZhao%26aufirst%3DJianwen%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D43%26spage%3D70100%26epage%3D70112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia J.  Yao</span>, <span class="hlFld-ContribAuthor ">Sara  D'Angelo</span>, <span class="hlFld-ContribAuthor ">Kimberly S.  Butler</span>, <span class="hlFld-ContribAuthor ">Christophe  Theron</span>, <span class="hlFld-ContribAuthor ">Tracey L.  Smith</span>, <span class="hlFld-ContribAuthor ">Serena  Marchiò</span>, <span class="hlFld-ContribAuthor ">Juri G.  Gelovani</span>, <span class="hlFld-ContribAuthor ">Richard L.  Sidman</span>, <span class="hlFld-ContribAuthor ">Andrey S.  Dobroff</span>, <span class="hlFld-ContribAuthor ">C. Jeffrey  Brinker</span>, <span class="hlFld-ContribAuthor ">Andrew R.M.  Bradbury</span>, <span class="hlFld-ContribAuthor ">Wadih  Arap</span>, <span class="hlFld-ContribAuthor ">Renata  Pasqualini</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-targeted theranostic nanomedicines against cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2016,</strong> <em>240 </em>, 267-286. <a href="https://doi.org/10.1016/j.jconrel.2016.01.002" title="DOI URL">https://doi.org/10.1016/j.jconrel.2016.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2016.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2016.01.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DLigand-targeted%252Btheranostic%252Bnanomedicines%252Bagainst%252Bcancer%26aulast%3DYao%26aufirst%3DVirginia%2BJ.%26date%3D2016%26volume%3D240%26spage%3D267%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deo R.  Singh</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, <span class="hlFld-ContribAuthor ">Kalina  Hristova</span>. </span><span class="cited-content_cbyCitation_article-title">A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2016,</strong> <em>1860 </em>
                                    (9)
                                     , 1922-1928. <a href="https://doi.org/10.1016/j.bbagen.2016.06.004" title="DOI URL">https://doi.org/10.1016/j.bbagen.2016.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2016.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2016.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DA%252Bsmall%252Bpeptide%252Bpromotes%252BEphA2%252Bkinase-dependent%252Bsignaling%252Bby%252Bstabilizing%252BEphA2%252Bdimers%26aulast%3DSingh%26aufirst%3DDeo%2BR.%26date%3D2016%26volume%3D1860%26issue%3D9%26spage%3D1922%26epage%3D1928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji-Young  Kim</span>, <span class="hlFld-ContribAuthor ">Ji-Hae  Han</span>, <span class="hlFld-ContribAuthor ">Geon  Park</span>, <span class="hlFld-ContribAuthor ">Young-Woo  Seo</span>, <span class="hlFld-ContribAuthor ">Cheol-Won  Yun</span>, <span class="hlFld-ContribAuthor ">Byung-Chul  Lee</span>, <span class="hlFld-ContribAuthor ">Jeehyeon  Bae</span>, <span class="hlFld-ContribAuthor ">Ae Ran  Moon</span>, <span class="hlFld-ContribAuthor ">Tae-Hyoung  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (22)
                                     , 32449-32461. <a href="https://doi.org/10.18632/oncotarget.8719" title="DOI URL">https://doi.org/10.18632/oncotarget.8719</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.8719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.8719%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DNecrosis-inducing%252Bpeptide%252Bhas%252Bthe%252Bbeneficial%252Beffect%252Bon%252Bkilling%252Btumor%252Bcells%252Bthrough%252Bneuropilin%252B%252528NRP-1%252529%252Btargeting%26aulast%3DKim%26aufirst%3DJi-Young%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D22%26spage%3D32449%26epage%3D32461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bridget A.  Quinn</span>, <span class="hlFld-ContribAuthor ">Si  Wang</span>, <span class="hlFld-ContribAuthor ">Elisa  Barile</span>, <span class="hlFld-ContribAuthor ">Swadesh K.  Das</span>, <span class="hlFld-ContribAuthor ">Luni  Emdad</span>, <span class="hlFld-ContribAuthor ">Devanand  Sarkar</span>, <span class="hlFld-ContribAuthor ">Surya K.  De</span>, <span class="hlFld-ContribAuthor ">Susan Kharagh  Morvaridi</span>, <span class="hlFld-ContribAuthor ">John L.  Stebbins</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Pandol</span>, <span class="hlFld-ContribAuthor ">Paul B.  Fisher</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (13)
                                     , 17103-17110. <a href="https://doi.org/10.18632/oncotarget.7931" title="DOI URL">https://doi.org/10.18632/oncotarget.7931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.7931%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTherapy%252Bof%252Bpancreatic%252Bcancer%252Bvia%252Ban%252BEphA2%252Breceptor-targeted%252Bdelivery%252Bof%252Bgemcitabine%26aulast%3DQuinn%26aufirst%3DBridget%2BA.%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D13%26spage%3D17103%26epage%3D17110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyang  Xie</span>, <span class="hlFld-ContribAuthor ">Yanfang  Yang</span>, <span class="hlFld-ContribAuthor ">Wen  Lin</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Xudong  Fu</span>, <span class="hlFld-ContribAuthor ">Jianping  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery. </span><span class="cited-content_cbyCitation_journal-name">Colloids and Surfaces B: Biointerfaces</span><span> <strong>2015,</strong> <em>136 </em>, 641-650. <a href="https://doi.org/10.1016/j.colsurfb.2015.10.004" title="DOI URL">https://doi.org/10.1016/j.colsurfb.2015.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colsurfb.2015.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colsurfb.2015.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DColloids%2520and%2520Surfaces%2520B%253A%2520Biointerfaces%26atitle%3DCell-penetrating%252Bpeptide-siRNA%252Bconjugate%252Bloaded%252BYSA-modified%252Bnanobubbles%252Bfor%252Bultrasound%252Btriggered%252BsiRNA%252Bdelivery%26aulast%3DXie%26aufirst%3DXiangyang%26date%3D2015%26volume%3D136%26spage%3D641%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Massimiliano  Tognolini</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Matteo  Incerti</span>, <span class="hlFld-ContribAuthor ">Daniele  Pala</span>, <span class="hlFld-ContribAuthor ">Donatella  Callegari</span>, <span class="hlFld-ContribAuthor ">Simona  Bertoni</span>, <span class="hlFld-ContribAuthor ">Carmine  Giorgio</span>, <span class="hlFld-ContribAuthor ">Iftiin  Hassan-Mohamed</span>, <span class="hlFld-ContribAuthor ">Ilaria  Zanotti</span>, <span class="hlFld-ContribAuthor ">Antonella  Bugatti</span>, <span class="hlFld-ContribAuthor ">Marco  Rusnati</span>, <span class="hlFld-ContribAuthor ">Claudio  Festuccia</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Barocelli</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>. </span><span class="cited-content_cbyCitation_article-title">Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph–ephrin system. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>103 </em>, 312-324. <a href="https://doi.org/10.1016/j.ejmech.2015.08.048" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.048%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525945-Cholenoyl-amino%252Bacids%252Bas%252Bselective%252Band%252Borally%252Bavailable%252Bantagonists%252Bof%252Bthe%252BEph%2525E2%252580%252593ephrin%252Bsystem%26aulast%3DCastelli%26aufirst%3DRiccardo%26date%3D2015%26volume%3D103%26spage%3D312%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Ullman</span>, <span class="hlFld-ContribAuthor ">Pascale  Mathonet</span>, <span class="hlFld-ContribAuthor ">Arkadiusz  Oleksy</span>, <span class="hlFld-ContribAuthor ">Agata  Diamandakis</span>, <span class="hlFld-ContribAuthor ">Licia  Tomei</span>, <span class="hlFld-ContribAuthor ">Anna  Demartis</span>, <span class="hlFld-ContribAuthor ">Chiara  Nardi</span>, <span class="hlFld-ContribAuthor ">Sonia  Sambucini</span>, <span class="hlFld-ContribAuthor ">Antonino  Missineo</span>, <span class="hlFld-ContribAuthor ">Karen  Alt</span>, <span class="hlFld-ContribAuthor ">Christoph E.  Hagemeyer</span>, <span class="hlFld-ContribAuthor ">Matt  Harris</span>, <span class="hlFld-ContribAuthor ">Amos  Hedt</span>, <span class="hlFld-ContribAuthor ">Roland  Weis</span>, <span class="hlFld-ContribAuthor ">Kurt R.  Gehlsen</span>, . </span><span class="cited-content_cbyCitation_article-title">High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (8)
                                     , e0135278. <a href="https://doi.org/10.1371/journal.pone.0135278" title="DOI URL">https://doi.org/10.1371/journal.pone.0135278</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0135278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0135278%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DHigh%252BAffinity%252BBinders%252Bto%252BEphA2%252BIsolated%252Bfrom%252BAbdurin%252BScaffold%252BLibraries%25253B%252BCharacterization%25252C%252BBinding%252Band%252BTumor%252BTargeting%26aulast%3DUllman%26aufirst%3DChristopher%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D8%26spage%3De0135278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bainan  Wu</span>, <span class="hlFld-ContribAuthor ">Si  Wang</span>, <span class="hlFld-ContribAuthor ">Surya K.  De</span>, <span class="hlFld-ContribAuthor ">Elisa  Barile</span>, <span class="hlFld-ContribAuthor ">Bridget A.  Quinn</span>, <span class="hlFld-ContribAuthor ">Irina  Zharkikh</span>, <span class="hlFld-ContribAuthor ">Angela  Purves</span>, <span class="hlFld-ContribAuthor ">John L.  Stebbins</span>, <span class="hlFld-ContribAuthor ">Robert G.  Oshima</span>, <span class="hlFld-ContribAuthor ">Paul B.  Fisher</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biology</span><span> <strong>2015,</strong> <em>22 </em>
                                    (7)
                                     , 876-887. <a href="https://doi.org/10.1016/j.chembiol.2015.06.011" title="DOI URL">https://doi.org/10.1016/j.chembiol.2015.06.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2015.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2015.06.011%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biology%26atitle%3DDesign%252Band%252BCharacterization%252Bof%252BNovel%252BEphA2%252BAgonists%252Bfor%252BTargeted%252BDelivery%252Bof%252BChemotherapy%252Bto%252BCancer%252BCells%26aulast%3DWu%26aufirst%3DBainan%26date%3D2015%26volume%3D22%26issue%3D7%26spage%3D876%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caixia  Ma</span>, <span class="hlFld-ContribAuthor ">Chunyan  Li</span>, <span class="hlFld-ContribAuthor ">Dongliang  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Gao</span>, <span class="hlFld-ContribAuthor ">Juanjuan  Han</span>, <span class="hlFld-ContribAuthor ">Nan  Xu</span>, <span class="hlFld-ContribAuthor ">Qiong  Wu</span>, <span class="hlFld-ContribAuthor ">Guochao  Nie</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Fenghuei  Lin</span>, <span class="hlFld-ContribAuthor ">Yingchun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Probes</span><span> <strong>2015,</strong> <em>29 </em>
                                    (3)
                                     , 182-189. <a href="https://doi.org/10.1016/j.mcp.2015.04.001" title="DOI URL">https://doi.org/10.1016/j.mcp.2015.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mcp.2015.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mcp.2015.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Probes%26atitle%3DScreening%252Bof%252Ba%252Bspecific%252Bpeptide%252Bbinding%252Bto%252Besophageal%252Bsquamous%252Bcarcinoma%252Bcells%252Bfrom%252Bphage%252Bdisplayed%252Bpeptide%252Blibrary%26aulast%3DMa%26aufirst%3DCaixia%26date%3D2015%26volume%3D29%26issue%3D3%26spage%3D182%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Puttick</span>, <span class="hlFld-ContribAuthor ">Brett W.  Stringer</span>, <span class="hlFld-ContribAuthor ">Bryan W.  Day</span>, <span class="hlFld-ContribAuthor ">Zara C.  Bruce</span>, <span class="hlFld-ContribAuthor ">Kathleen S.  Ensbey</span>, <span class="hlFld-ContribAuthor ">Karine  Mardon</span>, <span class="hlFld-ContribAuthor ">Gary J.  Cowin</span>, <span class="hlFld-ContribAuthor ">Kristofer J.  Thurecht</span>, <span class="hlFld-ContribAuthor ">Andrew K.  Whittaker</span>, <span class="hlFld-ContribAuthor ">Michael  Fay</span>, <span class="hlFld-ContribAuthor ">Andrew W.  Boyd</span>, <span class="hlFld-ContribAuthor ">Stephen  Rose</span>. </span><span class="cited-content_cbyCitation_article-title">EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging</span><span> <strong>2015,</strong> <em>14 </em>
                                    (6)
                                     , 7290.2015.00008. <a href="https://doi.org/10.2310/7290.2015.00008" title="DOI URL">https://doi.org/10.2310/7290.2015.00008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2310/7290.2015.00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2310%2F7290.2015.00008%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%26atitle%3DEphA2%252Bas%252Ba%252BDiagnostic%252BImaging%252BTarget%252Bin%252BGlioblastoma%25253A%252BA%252BPositron%252BEmission%252BTomography%25252FMagnetic%252BResonance%252BImaging%252BStudy%26aulast%3DPuttick%26aufirst%3DSimon%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D6%26spage%3D7290.2015.00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khadija  Rhoda</span>, <span class="hlFld-ContribAuthor ">Yahya E  Choonara</span>, <span class="hlFld-ContribAuthor ">Pradeep  Kumar</span>, <span class="hlFld-ContribAuthor ">Divya  Bijukumar</span>, <span class="hlFld-ContribAuthor ">Lisa C  du Toit</span>, <span class="hlFld-ContribAuthor ">Viness  Pillay</span>. </span><span class="cited-content_cbyCitation_article-title">Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Delivery</span><span> <strong>2015,</strong> <em>12 </em>
                                    (4)
                                     , 613-634. <a href="https://doi.org/10.1517/17425247.2015.970162" title="DOI URL">https://doi.org/10.1517/17425247.2015.970162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17425247.2015.970162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17425247.2015.970162%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Delivery%26atitle%3DPotential%252Bnanotechnologies%252Band%252Bmolecular%252Btargets%252Bin%252Bthe%252Bquest%252Bfor%252Befficient%252Bchemotherapy%252Bin%252Bovarian%252Bcancer%26aulast%3DRhoda%26aufirst%3DKhadija%26date%3D2015%26date%3D2014%26volume%3D12%26issue%3D4%26spage%3D613%26epage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">YUNYUN  WANG</span>, <span class="hlFld-ContribAuthor ">YONG  LIU</span>, <span class="hlFld-ContribAuthor ">GUO  LI</span>, <span class="hlFld-ContribAuthor ">ZHONGWU  SU</span>, <span class="hlFld-ContribAuthor ">SHULING  REN</span>, <span class="hlFld-ContribAuthor ">PINGQING  TAN</span>, <span class="hlFld-ContribAuthor ">XIN  ZHANG</span>, <span class="hlFld-ContribAuthor ">YUANZHENG  QIU</span>, <span class="hlFld-ContribAuthor ">YONGQUAN  TIAN</span>. </span><span class="cited-content_cbyCitation_article-title">Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway. </span><span class="cited-content_cbyCitation_journal-name">Molecular Medicine Reports</span><span> <strong>2015,</strong> <em>11 </em>
                                    (2)
                                     , 924-930. <a href="https://doi.org/10.3892/mmr.2014.2799" title="DOI URL">https://doi.org/10.3892/mmr.2014.2799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/mmr.2014.2799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fmmr.2014.2799%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Medicine%2520Reports%26atitle%3DEphrin%252Btype-A%252Breceptor%252B2%252Bregulates%252Bsensitivity%252Bto%252Bpaclitaxel%252Bin%252Bnasopharyngeal%252Bcarcinoma%252Bvia%252Bthe%252Bphosphoinositide%252B3-kinase%25252FAkt%252Bsignalling%252Bpathway%26aulast%3DWANG%26aufirst%3DYUNYUN%26date%3D2015%26date%3D2014%26volume%3D11%26issue%3D2%26spage%3D924%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonio  Barquilla</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>. </span><span class="cited-content_cbyCitation_article-title">Eph Receptors and Ephrins: Therapeutic Opportunities. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Pharmacology and Toxicology</span><span> <strong>2015,</strong> <em>55 </em>
                                    (1)
                                     , 465-487. <a href="https://doi.org/10.1146/annurev-pharmtox-011112-140226" title="DOI URL">https://doi.org/10.1146/annurev-pharmtox-011112-140226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-pharmtox-011112-140226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-pharmtox-011112-140226%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Pharmacology%2520and%2520Toxicology%26atitle%3DEph%252BReceptors%252Band%252BEphrins%25253A%252BTherapeutic%252BOpportunities%26aulast%3DBarquilla%26aufirst%3DAntonio%26date%3D2015%26volume%3D55%26issue%3D1%26spage%3D465%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bridget A.  Quinn</span>, <span class="hlFld-ContribAuthor ">Nathaniel A.  Lee</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Kegelman</span>, <span class="hlFld-ContribAuthor ">Praveen  Bhoopathi</span>, <span class="hlFld-ContribAuthor ">Luni  Emdad</span>, <span class="hlFld-ContribAuthor ">Swadesh K.  Das</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>, <span class="hlFld-ContribAuthor ">Devanand  Sarkar</span>, <span class="hlFld-ContribAuthor ">Paul B.  Fisher</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for an Effective Treatment for an Intractable Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 283-306. <a href="https://doi.org/10.1016/bs.acr.2015.04.009" title="DOI URL">https://doi.org/10.1016/bs.acr.2015.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.acr.2015.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.acr.2015.04.009%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BQuest%252Bfor%252Ban%252BEffective%252BTreatment%252Bfor%252Ban%252BIntractable%252BCancer%26aulast%3DQuinn%26aufirst%3DBridget%2BA.%26date%3D2015%26spage%3D283%26epage%3D306%26pub%3DElsevier%26date%3D2015%26volume%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apurva R.  Patel</span>, <span class="hlFld-ContribAuthor ">Mahavir  Chougule</span>, <span class="hlFld-ContribAuthor ">Mandip  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">EphA2 Targeting Pegylated Nanocarrier Drug Delivery System for Treatment of Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2014,</strong> <em>31 </em>
                                    (10)
                                     , 2796-2809. <a href="https://doi.org/10.1007/s11095-014-1377-4" title="DOI URL">https://doi.org/10.1007/s11095-014-1377-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-014-1377-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-014-1377-4%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DEphA2%252BTargeting%252BPegylated%252BNanocarrier%252BDrug%252BDelivery%252BSystem%252Bfor%252BTreatment%252Bof%252BLung%252BCancer%26aulast%3DPatel%26aufirst%3DApurva%2BR.%26date%3D2014%26date%3D2014%26volume%3D31%26issue%3D10%26spage%3D2796%26epage%3D2809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc  Pretze</span>, <span class="hlFld-ContribAuthor ">Birgit  Mosch</span>, <span class="hlFld-ContribAuthor ">Ralf  Bergmann</span>, <span class="hlFld-ContribAuthor ">Jörg  Steinbach</span>, <span class="hlFld-ContribAuthor ">Jens  Pietzsch</span>, <span class="hlFld-ContribAuthor ">Constantin  Mamat</span>. </span><span class="cited-content_cbyCitation_article-title">Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Labelled Compounds and Radiopharmaceuticals</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 660-665. <a href="https://doi.org/10.1002/jlcr.3237" title="DOI URL">https://doi.org/10.1002/jlcr.3237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jlcr.3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjlcr.3237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Labelled%2520Compounds%2520and%2520Radiopharmaceuticals%26atitle%3DRadiofluorination%252Band%252Bfirst%252Bradiopharmacological%252Bcharacterization%252Bof%252Ba%252BSWLAY%252Bpeptide-based%252Bligand%252Btargeting%252BEphA2%26aulast%3DPretze%26aufirst%3DMarc%26date%3D2014%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D660%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Barile</span>, <span class="hlFld-ContribAuthor ">Si  Wang</span>, <span class="hlFld-ContribAuthor ">Swadesh K.  Das</span>, <span class="hlFld-ContribAuthor ">Roberta  Noberini</span>, <span class="hlFld-ContribAuthor ">Russell  Dahl</span>, <span class="hlFld-ContribAuthor ">John L.  Stebbins</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, <span class="hlFld-ContribAuthor ">Paul B.  Fisher</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>9 </em>
                                    (7)
                                     , 1403-1412. <a href="https://doi.org/10.1002/cmdc.201400067" title="DOI URL">https://doi.org/10.1002/cmdc.201400067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201400067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201400067%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBioevaluation%252Bof%252Ban%252BEphA2%252BReceptor-Based%252BTargeted%252BDelivery%252BSystem%26aulast%3DBarile%26aufirst%3DElisa%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D7%26spage%3D1403%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Lan</span>, <span class="hlFld-ContribAuthor ">Tao  Wu</span>, <span class="hlFld-ContribAuthor ">Juntao  Lang</span>, <span class="hlFld-ContribAuthor ">Xueyan  Jin</span>, <span class="hlFld-ContribAuthor ">Xun  Sun</span>, <span class="hlFld-ContribAuthor ">Qiong  Wen</span>, <span class="hlFld-ContribAuthor ">Rui  An</span>. </span><span class="cited-content_cbyCitation_article-title">99mTc-labeled SWL specific peptide for targeting EphA2 receptor. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2014,</strong> <em>41 </em>
                                    (6)
                                     , 450-456. <a href="https://doi.org/10.1016/j.nucmedbio.2014.03.020" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2014.03.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2014.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2014.03.020%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3D99mTc-labeled%252BSWL%252Bspecific%252Bpeptide%252Bfor%252Btargeting%252BEphA2%252Breceptor%26aulast%3DLiu%26aufirst%3DYu%26date%3D2014%26volume%3D41%26issue%3D6%26spage%3D450%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimiliano  Tognolini</span>, <span class="hlFld-ContribAuthor ">Matteo  Incerti</span>, <span class="hlFld-ContribAuthor ">Daniele  Pala</span>, <span class="hlFld-ContribAuthor ">Simonetta  Russo</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Iftiin  Hassan-Mohamed</span>, <span class="hlFld-ContribAuthor ">Carmine  Giorgio</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>. </span><span class="cited-content_cbyCitation_article-title">Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein-Protein Antagonists. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>9 </em>
                                    (1)
                                     , 67-72. <a href="https://doi.org/10.1002/cmdc.201300305" title="DOI URL">https://doi.org/10.1002/cmdc.201300305</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300305%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTarget%252BHopping%252Bas%252Ba%252BUseful%252BTool%252Bfor%252Bthe%252BIdentification%252Bof%252BNovel%252BEphA2%252BProtein-Protein%252BAntagonists%26aulast%3DTognolini%26aufirst%3DMassimiliano%26date%3D2014%26date%3D2013%26volume%3D9%26issue%3D1%26spage%3D67%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  He</span>, <span class="hlFld-ContribAuthor ">W. Berkeley  Kauffman</span>, <span class="hlFld-ContribAuthor ">Taylor  Fuselier</span>, <span class="hlFld-ContribAuthor ">Somanna K.  Naveen</span>, <span class="hlFld-ContribAuthor ">Thomas G.  Voss</span>, <span class="hlFld-ContribAuthor ">Kalina  Hristova</span>, <span class="hlFld-ContribAuthor ">William C.  Wimley</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Cytosolic Delivery of Polar Cargo to Cells by Spontaneous Membrane-translocating Peptides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2013,</strong> <em>288 </em>
                                    (41)
                                     , 29974-29986. <a href="https://doi.org/10.1074/jbc.M113.488312" title="DOI URL">https://doi.org/10.1074/jbc.M113.488312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.M113.488312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.M113.488312%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DDirect%252BCytosolic%252BDelivery%252Bof%252BPolar%252BCargo%252Bto%252BCells%252Bby%252BSpontaneous%252BMembrane-translocating%252BPeptides%26aulast%3DHe%26aufirst%3DJing%26date%3D2013%26volume%3D288%26issue%3D41%26spage%3D29974%26epage%3D29986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc  Pretze</span>, <span class="hlFld-ContribAuthor ">Manuela  Kuchar</span>, <span class="hlFld-ContribAuthor ">Ralf  Bergmann</span>, <span class="hlFld-ContribAuthor ">Jörg  Steinbach</span>, <span class="hlFld-ContribAuthor ">Jens  Pietzsch</span>, <span class="hlFld-ContribAuthor ">Constantin  Mamat</span>. </span><span class="cited-content_cbyCitation_article-title">An Efficient Bioorthogonal Strategy Using CuAAC Click Chemistry for Radiofluorinations of SNEW Peptides and the Role of Copper Depletion. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2013,</strong> <em>8 </em>
                                    (6)
                                     , 935-945. <a href="https://doi.org/10.1002/cmdc.201300053" title="DOI URL">https://doi.org/10.1002/cmdc.201300053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300053%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DAn%252BEfficient%252BBioorthogonal%252BStrategy%252BUsing%252BCuAAC%252BClick%252BChemistry%252Bfor%252BRadiofluorinations%252Bof%252BSNEW%252BPeptides%252Band%252Bthe%252BRole%252Bof%252BCopper%252BDepletion%26aulast%3DPretze%26aufirst%3DMarc%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D6%26spage%3D935%26epage%3D945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Y.  Nishimura</span>, <span class="hlFld-ContribAuthor ">W.  Mimura</span>, <span class="hlFld-ContribAuthor ">I. F.  Mohamed Suffian</span>, <span class="hlFld-ContribAuthor ">T.  Amino</span>, <span class="hlFld-ContribAuthor ">J.  Ishii</span>, <span class="hlFld-ContribAuthor ">C.  Ogino</span>, <span class="hlFld-ContribAuthor ">A.  Kondo</span>. </span><span class="cited-content_cbyCitation_article-title">Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biochemistry</span><span> <strong>2013,</strong> <em>153 </em>
                                    (3)
                                     , 251-256. <a href="https://doi.org/10.1093/jb/mvs140" title="DOI URL">https://doi.org/10.1093/jb/mvs140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jb/mvs140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjb%2Fmvs140%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biochemistry%26atitle%3DGranting%252Bspecificity%252Bfor%252Bbreast%252Bcancer%252Bcells%252Busing%252Ba%252Bhepatitis%252BB%252Bcore%252Bparticle%252Bwith%252Ba%252BHER2-targeted%252Baffibody%252Bmolecule%26aulast%3DNishimura%26aufirst%3DY.%26date%3D2013%26date%3D2012%26volume%3D153%26issue%3D3%26spage%3D251%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikolaus  Krall</span>, <span class="hlFld-ContribAuthor ">Jörg  Scheuermann</span>, <span class="hlFld-ContribAuthor ">Dario  Neri</span>. </span><span class="cited-content_cbyCitation_article-title">Entwicklung zielgerichteter niedermolekularer zytotoxischer Wirkstoffverbindungen mit DNA-codierten chemischen Bibliotheken. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2013,</strong> <em>125 </em>
                                    (5)
                                     , 1424-1443. <a href="https://doi.org/10.1002/ange.201204631" title="DOI URL">https://doi.org/10.1002/ange.201204631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201204631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201204631%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEntwicklung%252Bzielgerichteter%252Bniedermolekularer%252Bzytotoxischer%252BWirkstoffverbindungen%252Bmit%252BDNA-codierten%252Bchemischen%252BBibliotheken%26aulast%3DKrall%26aufirst%3DNikolaus%26date%3D2013%26date%3D2013%26volume%3D125%26issue%3D5%26spage%3D1424%26epage%3D1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikolaus  Krall</span>, <span class="hlFld-ContribAuthor ">Jörg  Scheuermann</span>, <span class="hlFld-ContribAuthor ">Dario  Neri</span>. </span><span class="cited-content_cbyCitation_article-title">Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2013,</strong> <em>52 </em>
                                    (5)
                                     , 1384-1402. <a href="https://doi.org/10.1002/anie.201204631" title="DOI URL">https://doi.org/10.1002/anie.201204631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201204631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201204631%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DSmall%252BTargeted%252BCytotoxics%25253A%252BCurrent%252BState%252Band%252BPromises%252Bfrom%252BDNA-Encoded%252BChemical%252BLibraries%26aulast%3DKrall%26aufirst%3DNikolaus%26date%3D2013%26date%3D2013%26volume%3D52%26issue%3D5%26spage%3D1384%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si  Wang</span>, <span class="hlFld-ContribAuthor ">Roberta  Noberini</span>, <span class="hlFld-ContribAuthor ">John L.  Stebbins</span>, <span class="hlFld-ContribAuthor ">Swadesh  Das</span>, <span class="hlFld-ContribAuthor ">Ziming  Zhang</span>, <span class="hlFld-ContribAuthor ">Bainan  Wu</span>, <span class="hlFld-ContribAuthor ">Sayantan  Mitra</span>, <span class="hlFld-ContribAuthor ">Sandrine  Billet</span>, <span class="hlFld-ContribAuthor ">Ana  Fernandez</span>, <span class="hlFld-ContribAuthor ">Neil A.  Bhowmick</span>, <span class="hlFld-ContribAuthor ">Shinichi  Kitada</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, <span class="hlFld-ContribAuthor ">Paul B.  Fisher</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2013,</strong> <em>19 </em>
                                    (1)
                                     , 128-137. <a href="https://doi.org/10.1158/1078-0432.CCR-12-2654" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-12-2654</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-12-2654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-12-2654%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DTargeted%252BDelivery%252Bof%252BPaclitaxel%252Bto%252BEphA2-Expressing%252BCancer%252BCells%26aulast%3DWang%26aufirst%3DSi%26date%3D2013%26date%3D2012%26volume%3D19%26issue%3D1%26spage%3D128%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Constantin  Mamat</span>, <span class="hlFld-ContribAuthor ">Birgit  Mosch</span>, <span class="hlFld-ContribAuthor ">Christin  Neuber</span>, <span class="hlFld-ContribAuthor ">Martin  Köckerling</span>, <span class="hlFld-ContribAuthor ">Ralf  Bergmann</span>, <span class="hlFld-ContribAuthor ">Jens  Pietzsch</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2012,</strong> <em>7 </em>
                                    (11)
                                     , 1991-2003. <a href="https://doi.org/10.1002/cmdc.201200264" title="DOI URL">https://doi.org/10.1002/cmdc.201200264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201200264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201200264%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DFluorine-18%252BRadiolabeling%252Band%252BRadiopharmacological%252BCharacterization%252Bof%252Ba%252BBenzodioxolylpyrimidine-based%252BRadiotracer%252BTargeting%252Bthe%252BReceptor%252BTyrosine%252BKinase%252BEphB4%26aulast%3DMamat%26aufirst%3DConstantin%26date%3D2012%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3D1991%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_trg1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0004.gif" alt="" id="trg1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=f_trg1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. EphA2 and EphA4 expression in 68 human cancer cell lines and 17 normal tissue RNA samples. (A) EphA2 and EphA4 receptor expression in normal and cancer cell lines. Bar graph shows the fold expression of both EphA2 and EphA4 receptors in MDA-MD-231, PC-3, and LNCaP cancer cell lines compared to cultured human dermal fibroblast (HDF) and to a total human prostate RNA sample (prostate). (B) Correlation between EphA2 mRNA expression and EphA2 protein levels in 30 selected human cancer cell lines. (C) Box and Whisker plots of the 10th to 90th percentile of EphA2 expression for the RNA samples grouped according to their tissue of origin. Dotted lines depict cutoffs for 7-fold and 14-fold expression levels observed in the reference HDF cell line, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. YSA peptide targets cells expressing EphA2. (A) The YSA peptide targets quantum dots to EphA2 on the cell surface. COS cells transfected with either the extracellular and transmembrane portions of EphA2 fused to enhanced green fluorescent protein (EphA2-EGFP) or membrane targeted EGFP-F were incubated with YSA bound to red fluorescent quantum dots (YSA–Qdots). YSA–Qdots only bind to cells transfected with EphA2-EGFP. EGFP fluorescence is green. Nuclei are stained in blue with DAPI. (B) YSA targets quantum dots to endogenous EphA2 on the cell surface. HUVE cells were incubated at 4 °C with YSA conjugated Qdots (YSA–Qdots), an unrelated 12-mer control peptide that does not bind to EphA2 also conjugated to Qdots (Ctrl-Qdots), or unconjugated Qdots (Qdots). Only quantum dots conjugated to the YSA peptide bind to the HUVE cells. (C) YSA targets Qdots to lysosomes. MDA-MB-231 cells, which express high levels of endogenous EphA2, were incubated at 4 °C with YSA–Qdots followed by incubation at 37 °C for 0, 15, and 60 min. YSA–Qdots are seen on the cell surface at 0 min but become concentrated in structures near the nucleus at 15 and 60 min (arrow). Double labeling with the lysosomal marker Lamp1 (green) shows colocalization of the quantum dots in lysosomes at 60 min (arrows).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. YSA–PTX retains high potency for inhibition of EphA2-ephrin-A5 binding and high EphA2 binding affinity. (A) General chemical structures of YSA and DYP peptide–drug conjugates. (B) YSA, YSA–PTX, and control DYP–PTX were incubated at the indicated concentrations together with a constant concentration of ephrin-A5 AP in ELISA wells precoated with EphA2 Fc. The ratio of ephrin-A5 AP bound in the presence and in the absence of peptide is shown. (C) Biotinylated YSA–PTX and control DYP–PTX were incubated at the indicated concentrations in EphA2 Fc-coated ELISA wells and were then detected with streptavidin–HRP. The graphs show averages ± SE from quadruplicate measurements in representative experiments, while the <i>K</i><sub>D</sub> and IC<sub>50</sub> values are calculated from three to five experiments. (D) ATP-Lite analysis of viability of PC-3 cells 72 h after the addition of DYP, DYP–PTX, YSA, YSA–PTX, or PTX at 10 nM (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. YSA–PTX is internalized in cancer and endothelial cells expressing EphA2. (A) YSA–PTX coupled to fluorescent quantum dots, but not DYP–PTX, is internalized with EphA2 into lysosomes of prostate cancer cells expressing EphA2. PC3 prostate cancer cells, which express high levels of EphA2, or LNCaP prostate cancer cells, which do not detectably express EphA2 protein, were treated for 20 min with 100 μM YSA–PTX or control DYP–PTX, followed by a 20 min of incubation with streptavidin-conjugated quantum dots (Qdots). After removal of the solution containing the peptides and the quantum dots, the cells were incubated for 2 h at 37 °C to allow EphA2 internalization induced by YSA–PTX binding. The cells were stained for EphA2 (left) or the lysosomal marker Lamp1 (right). Qdots were also imaged, and nuclei were labeled with DAPI in blue. Representative fluorescence micrographs are shown. Scale bar = 25 μM. (B) Ephrin-A1 Fc and YSA–PTX, but not DYP–PTX, cause EphA2 internalization into lysosomes. PC3 cells were treated for 2 h with 0.2 μg/mL ephrin-A1 Fc, 100 μM YSA–PTX, or 100 μM control DYP–PTX. The cells were stained for Lamp1 (red) and EphA2 (green). Nuclei were labeled with DAPI (blue). Representative confocal micrographs are shown. Scale bar = 25 μm. (C) Ephrin-A1 Fc and YSA–PTX, but not DYP–PTX, cause EphA2 internalization into cells. PC3 prostate cancer and HUVE endothelial cells were treated for 1 h with 0.2 μg/mL ephrin-A1 Fc, 100 μM YSA–PTX, or 100 μM control DYP–PTX. Proteins present on the cell surface were then labeled with biotin. EphA2 immunoprecipitates were probed with antiphosphotyrosine antibody (PTyr), streptavidin–HRP (biotin), and EphA2 antibody. The amount of GAPDH in the cell lysates used for the immune precipitations is also shown as a control for equal amounts of protein in the lysates used for immunoprecipitation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/medium/jm-2011-01743s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Expression of EphA2 and cellular and in vivo activity of drug conjugates. (A) Groups of five to seven SCID beige mice bearing pre-established subcutaneous PC3 tumors were treated with twice weekly with intravenous doses of vehicle (CT), paclitaxel (5 mg/kg), YSA–paclitaxel (equimolar doses of the paclitaxel dose), starting at day 0. Tumor sizes were measured, and averages ± SEM are shown. <i>p</i> < 0.05 for the comparison of YSA–paclitaxel with control, by repeated-measures two-way ANOVA using all the measurements as well as by one-way ANOVA and Dunnett’s post hoc test using the measurements at day 18. (B) Biodistribution analysis. PC3 tumors (<i>n</i> = 3, average volume of 200 mm<sup>3</sup>) were excised 30 min after equimolar amounts of YSA–PTX or PTX (25 mg/kg) were injected intravenously. LC–MS analysis was performed to quantify PTX levels from tumor extracts. The histogram shows averages ± SEM. <i>p < </i>0.05 for the comparison of PTX levels, by <i>t</i> test analysis. Plasma levels of PTX were not significantly different (YSA–PTX = 998 ± 742 ng/mL; PTX = 771 ± 585 ng/mL).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201743s/production/images/large/jm-2011-01743s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201743s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Gangloff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesner, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiesewetter, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pio, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czernin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, D. H.</span><span> </span><span class="NLM_article-title">Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1866</span><span class="NLM_x">–</span> <span class="NLM_lpage">1871</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=1866-1871&issue=11&author=A.+Gangloffauthor=W.+A.+Hsuehauthor=A.+L.+Kesnerauthor=D.+O.+Kiesewetterauthor=B.+S.+Pioauthor=M.+D.+Pegramauthor=M.+Berytauthor=A.+Townsendauthor=J.+Czerninauthor=M.+E.+Phelpsauthor=D.+H.+Silverman&title=Estimation+of+paclitaxel+biodistribution+and+uptake+in+human-derived+xenografts+in+vivo+with+%2818%29F-fluoropaclitaxel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangloff%26aufirst%3DA.%26aulast%3DHsueh%26aufirst%3DW.%2BA.%26aulast%3DKesner%26aufirst%3DA.%2BL.%26aulast%3DKiesewetter%26aufirst%3DD.%2BO.%26aulast%3DPio%26aufirst%3DB.%2BS.%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DBeryt%26aufirst%3DM.%26aulast%3DTownsend%26aufirst%3DA.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DPhelps%26aufirst%3DM.%2BE.%26aulast%3DSilverman%26aufirst%3DD.%2BH.%26atitle%3DEstimation%2520of%2520paclitaxel%2520biodistribution%2520and%2520uptake%2520in%2520human-derived%2520xenografts%2520in%2520vivo%2520with%2520%252818%2529F-fluoropaclitaxel%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2005%26volume%3D46%26issue%3D11%26spage%3D1866%26epage%3D1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sugahara, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teesalu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karmali, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotamraju, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agemy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwald, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x"> (</span><span class="NLM_issue">5981</span><span class="NLM_x">) </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1126%2Fscience.1183057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20378772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2010&pages=1031-1035&issue=5981&author=K.+N.+Sugaharaauthor=T.+Teesaluauthor=P.+P.+Karmaliauthor=V.+R.+Kotamrajuauthor=L.+Agemyauthor=D.+R.+Greenwaldauthor=E.+Ruoslahti&title=Coadministration+of+a+tumor-penetrating+peptide+enhances+the+efficacy+of+cancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs</span></div><div class="casAuthors">Sugahara, Kazuki N.; Teesalu, Tambet; Karmali, Priya Prakash; Kotamraju, Venkata Ramana; Agemy, Lilach; Greenwald, Daniel R.; Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">5981</span>),
    <span class="NLM_cas:pages">1031-1035</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy.  We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue.  Importantly, this effect did not require the drugs to be chem. conjugated to the peptide.  Systemic injection with iRGD improved the therapeutic index of drugs of various compns., including a small mol. (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab).  Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnpbZBSXSmfrVg90H21EOLACvtfcHk0lhb7Bhws9Mz7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D&md5=c8103ff227adc4061b92a62157b7a36f</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1183057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1183057%26sid%3Dliteratum%253Aachs%26aulast%3DSugahara%26aufirst%3DK.%2BN.%26aulast%3DTeesalu%26aufirst%3DT.%26aulast%3DKarmali%26aufirst%3DP.%2BP.%26aulast%3DKotamraju%26aufirst%3DV.%2BR.%26aulast%3DAgemy%26aufirst%3DL.%26aulast%3DGreenwald%26aufirst%3DD.%2BR.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DCoadministration%2520of%2520a%2520tumor-penetrating%2520peptide%2520enhances%2520the%2520efficacy%2520of%2520cancer%2520drugs%26jtitle%3DScience%26date%3D2010%26volume%3D328%26issue%3D5981%26spage%3D1031%26epage%3D1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&issue=9&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0liDMNrDE3bG_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26issue%3D9%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jaracz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuznetsova, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Recent advances in tumor-targeting anticancer drug conjugates</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5043</span><span class="NLM_x">–</span> <span class="NLM_lpage">5054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5043-5054&issue=17&author=S.+Jaraczauthor=J.+Chenauthor=L.+V.+Kuznetsovaauthor=I.+Ojima&title=Recent+advances+in+tumor-targeting+anticancer+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJaracz%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKuznetsova%26aufirst%3DL.%2BV.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DRecent%2520advances%2520in%2520tumor-targeting%2520anticancer%2520drug%2520conjugates%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26issue%3D17%26spage%3D5043%26epage%3D5054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">New methods of drug delivery</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">249</span><span class="NLM_x"> (</span><span class="NLM_issue">4976</span><span class="NLM_x">) </span> <span class="NLM_fpage">1527</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=1990&pages=1527-1533&issue=4976&author=R.+Langer&title=New+methods+of+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DNew%2520methods%2520of%2520drug%2520delivery%26jtitle%3DScience%26date%3D1990%26volume%3D249%26issue%3D4976%26spage%3D1527%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schrama, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisfeld, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span> </span><span class="NLM_article-title">Antibody targeted drugs as cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=147-159&issue=2&author=D.+Schramaauthor=R.+A.+Reisfeldauthor=J.+C.+Becker&title=Antibody+targeted+drugs+as+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchrama%26aufirst%3DD.%26aulast%3DReisfeld%26aufirst%3DR.%2BA.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26atitle%3DAntibody%2520targeted%2520drugs%2520as%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D2%26spage%3D147%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">van Vlerken, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiji, M. M.</span><span> </span><span class="NLM_article-title">Multi-functional polymeric nanoparticles for tumour-targeted drug delivery</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=205-216&issue=2&author=L.+E.+van+Vlerkenauthor=M.+M.+Amiji&title=Multi-functional+polymeric+nanoparticles+for+tumour-targeted+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVlerken%26aufirst%3DL.%2BE.%26aulast%3DAmiji%26aufirst%3DM.%2BM.%26atitle%3DMulti-functional%2520polymeric%2520nanoparticles%2520for%2520tumour-targeted%2520drug%2520delivery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2006%26volume%3D3%26issue%3D2%26spage%3D205%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leader, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baca, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golan, D. E.</span><span> </span><span class="NLM_article-title">Protein therapeutics: a summary and pharmacological classification</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fnrd2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=18097458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=21-39&issue=1&author=B.+Leaderauthor=Q.+J.+Bacaauthor=D.+E.+Golan&title=Protein+therapeutics%3A+a+summary+and+pharmacological+classification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Protein therapeutics: a summary and pharmacological classification</span></div><div class="casAuthors">Leader, Benjamin; Baca, Quentin J.; Golan, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-39</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in no. and frequency of use since the introduction of the first recombinant protein therapeutic - human insulin - 25 years ago.  Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy.  This article overviews some of the key characteristics of protein therapeutics, summarizes the more than 130 protein therapeutics used currently and suggests a new classification of these proteins according to their pharmacol. action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDJwirgv5WN7Vg90H21EOLACvtfcHk0ljuoPuQLrVhWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ygtQ%253D%253D&md5=761a9860e38c98295385641dda94b31f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2399%26sid%3Dliteratum%253Aachs%26aulast%3DLeader%26aufirst%3DB.%26aulast%3DBaca%26aufirst%3DQ.%2BJ.%26aulast%3DGolan%26aufirst%3DD.%2BE.%26atitle%3DProtein%2520therapeutics%253A%2520a%2520summary%2520and%2520pharmacological%2520classification%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26issue%3D1%26spage%3D21%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Marx, J. L.</span><span> </span><span class="NLM_article-title">Monoclonal antibodies in cancer</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">216</span><span class="NLM_x"> (</span><span class="NLM_issue">4543</span><span class="NLM_x">) </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=1982&pages=283-285&issue=4543&author=J.+L.+Marx&title=Monoclonal+antibodies+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarx%26aufirst%3DJ.%2BL.%26atitle%3DMonoclonal%2520antibodies%2520in%2520cancer%26jtitle%3DScience%26date%3D1982%26volume%3D216%26issue%3D4543%26spage%3D283%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aina, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutcliffe, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. S.</span><span> </span><span class="NLM_article-title">From combinatorial chemistry to cancer-targeting peptides</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp700073y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=631-651&issue=5&author=O.+H.+Ainaauthor=R.+Liuauthor=J.+L.+Sutcliffeauthor=J.+Marikauthor=C.+X.+Panauthor=K.+S.+Lam&title=From+combinatorial+chemistry+to+cancer-targeting+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">From Combinatorial Chemistry to Cancer-Targeting Peptides</span></div><div class="casAuthors">Aina, Olulanu H.; Liu, Ruiwu; Sutcliffe, Julie L.; Marik, Jan; Pan, Chong-Xian; Lam, Kit S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">631-651</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S.  Food and Drug Administration and are widely used in the treatment of some cancers.  These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy.  The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kDa) and its relatively nonspecific binding to the reticuloendothelial system.  This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site.  Peptides, peptidomimetic, or small mols. are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy.  Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets.  Phage-display peptide library and one-bead one-compd. (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells.  The phage-display peptide library method, because of its biol. nature, can only display L-amino acid peptides.  In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain L-amino acids, D-amino acids, unnatural amino acids, or other org. moieties.  We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity.  Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot7yoDgcS21LVg90H21EOLACvtfcHk0ljuoPuQLrVhWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKgtbfI&md5=3e65fab3d9f5b9d2cf20773d65482b87</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fmp700073y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp700073y%26sid%3Dliteratum%253Aachs%26aulast%3DAina%26aufirst%3DO.%2BH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BL.%26aulast%3DMarik%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DC.%2BX.%26aulast%3DLam%26aufirst%3DK.%2BS.%26atitle%3DFrom%2520combinatorial%2520chemistry%2520to%2520cancer-targeting%2520peptides%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2007%26volume%3D4%26issue%3D5%26spage%3D631%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koolpe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dail, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquale, E. B.</span><span> </span><span class="NLM_article-title">An ephrin mimetic peptide that selectively targets the EphA2 receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">46974</span><span class="NLM_x">–</span> <span class="NLM_lpage">46979</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46974-46979&issue=49&author=M.+Koolpeauthor=M.+Dailauthor=E.+B.+Pasquale&title=An+ephrin+mimetic+peptide+that+selectively+targets+the+EphA2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DDail%26aufirst%3DM.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DAn%2520ephrin%2520mimetic%2520peptide%2520that%2520selectively%2520targets%2520the%2520EphA2%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D49%26spage%3D46974%26epage%3D46979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hatakeyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akama, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobkov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohyama, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M. N.</span><span> </span><span class="NLM_article-title">Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">19587</span><span class="NLM_x">–</span> <span class="NLM_lpage">19592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=19587-19592&issue=49&author=S.+Hatakeyamaauthor=K.+Sugiharaauthor=T.+K.+Shibataauthor=J.+Nakayamaauthor=T.+O.+Akamaauthor=N.+Tamuraauthor=S.+M.+Wongauthor=A.+A.+Bobkovauthor=Y.+Takanoauthor=C.+Ohyamaauthor=M.+Fukudaauthor=M.+N.+Fukuda&title=Targeted+drug+delivery+to+tumor+vasculature+by+a+carbohydrate+mimetic+peptide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DT.%2BK.%26aulast%3DNakayama%26aufirst%3DJ.%26aulast%3DAkama%26aufirst%3DT.%2BO.%26aulast%3DTamura%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DS.%2BM.%26aulast%3DBobkov%26aufirst%3DA.%2BA.%26aulast%3DTakano%26aufirst%3DY.%26aulast%3DOhyama%26aufirst%3DC.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DM.%2BN.%26atitle%3DTargeted%2520drug%2520delivery%2520to%2520tumor%2520vasculature%2520by%2520a%2520carbohydrate%2520mimetic%2520peptide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26issue%3D49%26spage%3D19587%26epage%3D19592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cutrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dibra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fmt.2011.38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21386825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVGgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1468-1477&issue=8&author=J.+Cutreraauthor=D.+Dibraauthor=X.+Xiaauthor=A.+Hasanauthor=S.+Reedauthor=S.+Li&title=Discovery+of+a+linear+peptide+for+improving+tumor+targeting+of+gene+products+and+treatment+of+distal+tumors+by+IL-12+gene+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and Treatment of Distal Tumors by IL-12 Gene Therapy</span></div><div class="casAuthors">Cutrera, Jeffry; Dibra, Denada; Xia, Xueqing; Hasan, Azeem; Reed, Scott; Li, Shulin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1468-1477</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Like many effective therapeutics, interleukin-12 (IL-12) therapy often causes side effects.  Tumor targeted delivery may improve the efficacy and decrease the toxicity of systemic IL-12 treatments.  In this study, a novel targeting approach was investigated.  A secreted alk. phosphatase (SEAP) reporter gene-based screening process was used to identify a mini-peptide which can be produced in vivo to target gene products to tumors.  The coding region for the best peptide was inserted into an IL-12 gene to det. the antitumor efficacy.  Affinity chromatog., mass spectrometry anal., and binding studies were used to identify a receptor for this peptide.  The authors discovered that the linear peptide VNTANST increased the tumor accumulation of the reporter gene products in five independent tumor models including one human xenogeneic model.  The product from VNTANST-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment, and in three tumor models, VNTANST-IL-12 gene therapy inhibited distal tumor growth.  In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced.  The receptor for VNTANST was identified as vimentin.  These results show the promise of using VNTANST to improve IL-12 treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5-GLHuvlz1LVg90H21EOLACvtfcHk0liFhMptA1a8Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVGgtLo%253D&md5=f5ffc6569bcc18cd7708490e23c4607a</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1038%2Fmt.2011.38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2011.38%26sid%3Dliteratum%253Aachs%26aulast%3DCutrera%26aufirst%3DJ.%26aulast%3DDibra%26aufirst%3DD.%26aulast%3DXia%26aufirst%3DX.%26aulast%3DHasan%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520linear%2520peptide%2520for%2520improving%2520tumor%2520targeting%2520of%2520gene%2520products%2520and%2520treatment%2520of%2520distal%2520tumors%2520by%2520IL-12%2520gene%2520therapy%26jtitle%3DMol.%2520Ther.%26date%3D2011%26volume%3D19%26issue%3D8%26spage%3D1468%26epage%3D1477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Corti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curnis, F.</span><span> </span><span class="NLM_article-title">Tumor vasculature targeting through NGR peptide-based drug delivery systems</span> <span class="citation_source-journal">Curr. Pharm. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1128</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F138920111796117373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21470145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1128-1134&issue=8&author=A.+Cortiauthor=F.+Curnis&title=Tumor+vasculature+targeting+through+NGR+peptide-based+drug+delivery+systems"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor vasculature targeting through NGR peptide-based drug delivery systems</span></div><div class="casAuthors">Corti, Angelo; Curnis, Flavio</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1128-1134</span>CODEN:
                <span class="NLM_cas:coden">CPBUBP</span>;
        ISSN:<span class="NLM_cas:issn">1389-2010</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Various peptide sequences were discovered by selecting peptide-phage display libraries in vitro against specific receptors or in vivo in tumor-bearing animals.  One class of these peptides is characterized by the presence of Asn-Gly-Asp (NGR), a structural motif that can recognize the endothelium and other cells of neoangiogenic vessels.  Because of this property these peptides were used by several investigators to deliver a variety of drugs, cytokines, nanoparticles, viruses and imaging agents to tumor blood vessels.  Here the authors review the reports on these conjugates and discuss the structural, functional and stability properties of NGR embedded into different mol. scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCmXOz-qEG5bVg90H21EOLACvtfcHk0liFhMptA1a8Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqsrjE&md5=a854755bfdbc74ec368792e279aa681e</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.2174%2F138920111796117373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920111796117373%26sid%3Dliteratum%253Aachs%26aulast%3DCorti%26aufirst%3DA.%26aulast%3DCurnis%26aufirst%3DF.%26atitle%3DTumor%2520vasculature%2520targeting%2520through%2520NGR%2520peptide-based%2520drug%2520delivery%2520systems%26jtitle%3DCurr.%2520Pharm.%2520Biotechnol.%26date%3D2011%26volume%3D12%26issue%3D8%26spage%3D1128%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wu, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, D. K.</span><span> </span><span class="NLM_article-title">Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy</span> <span class="citation_source-journal">J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">723798</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1155%2F2010%2F723798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20454584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A280%3ADC%252BC3czit12ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=723798&author=H.+C.+Wuauthor=D.+K.+Chang&title=Peptide-mediated+liposomal+drug+delivery+system+targeting+tumor+blood+vessels+in+anticancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5fR"><div class="casContent"><span class="casTitleNuber">5f</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy</span></div><div class="casAuthors">Wu Han-Chung; Chang De-Kuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2010</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">723798</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Solid tumors are known to recruit new blood vessels to support their growth.  Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer.  Current efforts are focusing on developing therapeutic agents capable of specifically targeting cancer cells and tumor-associated microenvironments including tumor blood vessels.  These therapies hold the promise of high efficacy and low toxicity.  One recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics is to encapsulate anticancer drugs into targeting liposomes that bind to the cell surface receptors expressed on tumor-associated endothelial cells.  These anti-angiogenic drug delivery systems could be used to target both tumor blood vessels as well as the tumor cells, themselves.  This article reviews the mechanisms and advantages of various present and potential methods using peptide-conjugated liposomes to specifically destroy tumor blood vessels in anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOi_tOgfpAYlvAgqb2vdc5fW6udTcc2ebjMOuEmcBYILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czit12ktg%253D%253D&md5=ea59379c165dc202f6cd828b7e06cf1c</span></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.1155%2F2010%2F723798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2010%252F723798%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BC.%26aulast%3DChang%26aufirst%3DD.%2BK.%26atitle%3DPeptide-mediated%2520liposomal%2520drug%2520delivery%2520system%2520targeting%2520tumor%2520blood%2520vessels%2520in%2520anticancer%2520therapy%26jtitle%3DJ.%2520Oncol.%26date%3D2010%26volume%3D2010%26spage%3D723798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Brown, K. C.</span><span> </span><span class="NLM_article-title">Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1040</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F138161210790963788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20030617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFymu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1040-1054&issue=9&author=K.+C.+Brown&title=Peptidic+tumor+targeting+agents%3A+the+road+from+phage+display+peptide+selections+to+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5gR"><div class="casContent"><span class="casTitleNuber">5g</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications</span></div><div class="casAuthors">Brown, Kathlynn C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1054</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer has become the no. one cause of death amongst Americans, killing approx. 1,600 people per day.  Novel methods for early detection and the development of effective treatments are an eminent priority in medicine.  For this reason, isolation of tumor-specific ligands is a growing area of research.  Tumor-specific binding agents can be used to probe the tumor cell surface phenotype and customize treatment accordingly by conjugating the appropriate cell-targeting ligand to an anticancer drug.  This refines the mol. diagnosis of the tumor and creates guided drugs that can target the tumor while sparing healthy tissues.  Addnl., these targeting agents can be used as in vivo imaging agents that allow for earlier detection of tumors and micrometastasis.  Phage display is a powerful technique for the isolation of peptides that bind to a particular target with high affinity and specificity.  The biopanning of intact cancer cells or tumors in animals can be used to isolate peptides that bind to cancer-specific cell surface biomarkers.  Over the past 10 years, unbiased biopanning of phage-displayed peptide libraries has generated a suite of cancer targeting peptidic ligands.  This review discusses the recent advances in the isolation of cancer-targeting peptides by unbiased biopanning methods and highlights the use of the isolated peptides in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAdZc950F8i7Vg90H21EOLACvtfcHk0liFhMptA1a8Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFymu74%253D&md5=2e9f83012dab637a7b50943d576733e4</span></div><a href="/servlet/linkout?suffix=cit5g&amp;dbid=16384&amp;doi=10.2174%2F138161210790963788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210790963788%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DK.%2BC.%26atitle%3DPeptidic%2520tumor%2520targeting%2520agents%253A%2520the%2520road%2520from%2520phage%2520display%2520peptide%2520selections%2520to%2520clinical%2520applications%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26issue%3D9%26spage%3D1040%26epage%3D1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Newton, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutscher, S. L.</span><span> </span><span class="NLM_article-title">In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">504</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1007%2F978-1-60327-569-9_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=19159103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslWhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2009&pages=275-290&author=J.+R.+Newtonauthor=S.+L.+Deutscher&title=In+vivo+bacteriophage+display+for+the+discovery+of+novel+peptide-based+tumor-targeting+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5hR"><div class="casContent"><span class="casTitleNuber">5h</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents</span></div><div class="casAuthors">Newton, Jessica R.; Deutscher, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">Biosensors and Biodetection, Volume 2</span>),
    <span class="NLM_cas:pages">275-290</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A powerful strategy for targeted drug discovery is the use of bacteriophage (phage) display technol. for identification of peptide-based tumor targeting agents.  Peptide pharmaceuticals may possess clin. desirable properties because of their rapid blood clearance, non-immunogenic nature, and ease of synthesis.  Phage display has identified hundreds of different peptide sequences that bind a desired target in vitro.  Regrettably, few of these peptides offer good targeting efficacy in vivo.  One reason for this is the synthesized peptide may not retain its optimal activity outside the microenvironment of the phage.  Another possible explanation is that traditionally, phage selections are performed in vitro outside the complicated milieu of a living animal.  Given these shortcomings, we have developed methods to select phage peptide display libraries in living mice, to identify, a priori, phage (and corresponding synthesized peptides) with ideal tumor-targeting propensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLhfOLuJWIqrVg90H21EOLACvtfcHk0lgr9X2yRWMGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslWhtr8%253D&md5=b863514a9b31546c78a81659cd6bea52</span></div><a href="/servlet/linkout?suffix=cit5h&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-569-9_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60327-569-9_17%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DJ.%2BR.%26aulast%3DDeutscher%26aufirst%3DS.%2BL.%26atitle%3DIn%2520vivo%2520bacteriophage%2520display%2520for%2520the%2520discovery%2520of%2520novel%2520peptide-based%2520tumor-targeting%2520agents%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D504%26spage%3D275%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span> </span><span class="NLM_article-title">TMTP1, a novel tumor-homing peptide specifically targeting metastasis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5494</span><span class="NLM_x">–</span> <span class="NLM_lpage">5502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5i&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1158%2F1078-0432.CCR-08-0233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5i&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=18765541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5i&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5494-5502&issue=17&author=W.+Yangauthor=D.+Luoauthor=S.+Wangauthor=R.+Wangauthor=R.+Chenauthor=Y.+Liuauthor=T.+Zhuauthor=X.+Maauthor=R.+Liuauthor=G.+Xuauthor=L.+Mengauthor=Y.+Luauthor=J.+Zhouauthor=D.+Ma&title=TMTP1%2C+a+novel+tumor-homing+peptide+specifically+targeting+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5iR"><div class="casContent"><span class="casTitleNuber">5i</span><div class="casTitle"><span class="NLM_cas:atitle">TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis</span></div><div class="casAuthors">Yang, Wanhua; Luo, Danfeng; Wang, Shixuan; Wang, Rui; Chen, Rui; Liu, Yan; Zhu, Tao; Ma, Xiangyi; Liu, Ronghua; Xu, Gang; Meng, Li; Lu, Yunping; Zhou, Jianfeng; Ma, Ding</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5494-5502</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor metastasis continues to be the major obstacle to cancer therapy and the leading cause of cancer-related death.  Methods used to detect metastasis, esp. occult metastases, have received a great deal attention.  In this study, a novel selective peptide was assessed for its specific binding to metastasis.  The FliTrx bacterial peptide display system, an alternative to phage peptide display, was used to identify a 5-amino acid peptide termed TMTP1 (NVVRQ), which binds to the highly metastatic prostate cancer cell line PC-3M-1E8.  The synthetic TMTP1 was tested in vitro for its binding specificity and affinity to highly metastatic cancer cells.  The tumor targeting assays were done in vivo by i.v. injection of FITC-conjugated TMTP1 into tumor-bearing mice.  TMTP1 specifically bound to a series of highly metastatic tumor cells, including prostate cancer PC-3M-1E8, breast cancer MDA-MB-435S, lung cancer PG-BE1, and gastric cancer MKN-45sci, in vitro and in vivo but not to the poorly metastatic or nonmetastatic cell line, including prostate cancer PC-3M-2B4, breast cancer MCF-7, lung cancer PG-LH7, or murine fibroblast cell NIH/3T3.  FITC-TMTP1 strongly and specifically targeted the metastasis foci in tumor-bearing mice 24 h after i.v. peptide injection.  Moreover, the occult metastases were specifically detected by FITC-TMTP1.  Our results suggest that TMTP1 is a potential strategy for the development of new diagnostic tracers or alternative anticancer agents for tumor metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OGApMAXOSLVg90H21EOLACvtfcHk0lgr9X2yRWMGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbnN&md5=ee52c659e51a92f971b96b19033e187a</span></div><a href="/servlet/linkout?suffix=cit5i&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0233%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DTMTP1%252C%2520a%2520novel%2520tumor-homing%2520peptide%2520specifically%2520targeting%2520metastasis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D17%26spage%3D5494%26epage%3D5502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Laakkonen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porkka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">A tumor-homing peptide with a targeting specificity related to lymphatic vessels</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">751</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5j&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=12053175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5j&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFehsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=751-755&issue=7&author=P.+Laakkonenauthor=K.+Porkkaauthor=J.+A.+Hoffmanauthor=E.+Ruoslahti&title=A+tumor-homing+peptide+with+a+targeting+specificity+related+to+lymphatic+vessels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5jR"><div class="casContent"><span class="casTitleNuber">5j</span><div class="casTitle"><span class="NLM_cas:atitle">A tumor-homing peptide with a targeting specificity related to lymphatic vessels</span></div><div class="casAuthors">Laakkonen, Pirjo; Porkka, Kimmo; Hoffman, Jason A.; Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">751-755</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Blood vessels of tumors carry specific markers that are usually angiogenesis-related.  We previously used phage-displayed peptide libraries in vivo to identify peptides that home to tumors through the circulation and that specifically bind to the endothelia of tumor blood vessels.  Here we devised a phage screening procedure that would favor tumor-homing to targets that are accessible to circulating phage, but are not blood vessels.  Screening on MDA-MB-435 breast carcinoma xenografts yielded multiple copies of a phage that displays a cyclic 9-amino-acid peptide, LyP-1.  Homing and binding to tumor-derived cell suspensions indicated that LyP-1 also recognizes an osteosarcoma xenograft, and spontaneous prostate and breast cancers in transgenic mice, but not two other tumor xenografts.  Fluorescein-labeled LyP-1 peptide was detected in tumor structures that were pos. for three lymphatic endothelial markers and neg. for three blood vessel markers.  LyP-1 accumulated in the nuclei of the putative lymphatic cells, and in the nuclei of tumor cells.  These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8uLZe86w8sLVg90H21EOLACvtfcHk0lgr9X2yRWMGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFehsb8%253D&md5=4cec9c4b05a860bc45bd9499728c906c</span></div><a href="/servlet/linkout?suffix=cit5j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaakkonen%26aufirst%3DP.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DHoffman%26aufirst%3DJ.%2BA.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DA%2520tumor-homing%2520peptide%2520with%2520a%2520targeting%2520specificity%2520related%2520to%2520lymphatic%2520vessels%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26issue%3D7%26spage%3D751%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">Targeting tumor vasculature with homing peptides from phage display</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5k&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1006%2Fscbi.2000.0334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5k&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=11170865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5k&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVGhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=435-442&issue=6&author=E.+Ruoslahti&title=Targeting+tumor+vasculature+with+homing+peptides+from+phage+display"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5kR"><div class="casContent"><span class="casTitleNuber">5k</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumor vasculature with homing peptides from phage display</span></div><div class="casAuthors">Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-442</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with refs.  Tumor vasculature expresses a no. of mol. markers at much lower levels than those seen in the blood vessels of normal tissues, and in some cases, such markers are undetectable.  The presence of these markers relates to angiogenesis; the same markers are shared by all blood vessels undergoing angiogenesis.  The endothelial cells, pericytes and smooth muscle cells, and the vascular extracellular matrix in angiogenic vessels can each express such markers.  Molecularly, they represent vascular growth factor receptors, cell adhesion proteins and their receptors.  Screening of phage display libraries for peptides that home to tumor vasculature when injected into mice has recently provided a new tool for analyzing the distinguishing features of tumor vasculature.  Tumor-homing peptides isolated in this manner, as well as an antibody against a form of fibronectin expressed in tumor blood vessels, have been found to serve as targeting devices to conc. drugs and other therapeutic materials to tumors in in vivo models.  Such a targeting strategy can therefore potentially improve the efficacy of drugs and reduce their side effects.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6KxHiU1n6y7Vg90H21EOLACvtfcHk0lgr9X2yRWMGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVGhtbY%253D&md5=9b0907617a9fcf8e8a69f6a25364e2f4</span></div><a href="/servlet/linkout?suffix=cit5k&amp;dbid=16384&amp;doi=10.1006%2Fscbi.2000.0334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fscbi.2000.0334%26sid%3Dliteratum%253Aachs%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DTargeting%2520tumor%2520vasculature%2520with%2520homing%2520peptides%2520from%2520phage%2520display%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2000%26volume%3D10%26issue%3D6%26spage%3D435%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Koivunen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arap, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtanen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainisalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikkila, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gahmberg, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorsa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualini, R.</span><span> </span><span class="NLM_article-title">Tumor targeting with a selective gelatinase inhibitor</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">768</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=768-774&issue=8&author=E.+Koivunenauthor=W.+Arapauthor=H.+Valtanenauthor=A.+Rainisaloauthor=O.+P.+Medinaauthor=P.+Heikkilaauthor=C.+Kantorauthor=C.+G.+Gahmbergauthor=T.+Saloauthor=Y.+T.+Konttinenauthor=T.+Sorsaauthor=E.+Ruoslahtiauthor=R.+Pasqualini&title=Tumor+targeting+with+a+selective+gelatinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5l&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoivunen%26aufirst%3DE.%26aulast%3DArap%26aufirst%3DW.%26aulast%3DValtanen%26aufirst%3DH.%26aulast%3DRainisalo%26aufirst%3DA.%26aulast%3DMedina%26aufirst%3DO.%2BP.%26aulast%3DHeikkila%26aufirst%3DP.%26aulast%3DKantor%26aufirst%3DC.%26aulast%3DGahmberg%26aufirst%3DC.%2BG.%26aulast%3DSalo%26aufirst%3DT.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26aulast%3DSorsa%26aufirst%3DT.%26aulast%3DRuoslahti%26aufirst%3DE.%26aulast%3DPasqualini%26aufirst%3DR.%26atitle%3DTumor%2520targeting%2520with%2520a%2520selective%2520gelatinase%2520inhibitor%26jtitle%3DNat.%2520Biotechnol.%26date%3D1999%26volume%3D17%26issue%3D8%26spage%3D768%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gersuk, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vessella, R. L.</span><span> </span><span class="NLM_article-title">High-affinity peptide ligands to prostate-specific antigen identified by polysome selection</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">578</span><span class="NLM_x">–</span> <span class="NLM_lpage">582</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=1997&pages=578-582&issue=2&author=G.+M.+Gersukauthor=M.+J.+Coreyauthor=E.+Coreyauthor=J.+E.+Strayauthor=G.+H.+Kawasakiauthor=R.+L.+Vessella&title=High-affinity+peptide+ligands+to+prostate-specific+antigen+identified+by+polysome+selection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGersuk%26aufirst%3DG.%2BM.%26aulast%3DCorey%26aufirst%3DM.%2BJ.%26aulast%3DCorey%26aufirst%3DE.%26aulast%3DStray%26aufirst%3DJ.%2BE.%26aulast%3DKawasaki%26aufirst%3DG.%2BH.%26aulast%3DVessella%26aufirst%3DR.%2BL.%26atitle%3DHigh-affinity%2520peptide%2520ligands%2520to%2520prostate-specific%2520antigen%2520identified%2520by%2520polysome%2520selection%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1997%26volume%3D232%26issue%3D2%26spage%3D578%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pasquale, E. B.</span><span> </span><span class="NLM_article-title">Eph receptors and ephrins in cancer: bidirectional signalling and beyond</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fnrc2806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20179713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=165-180&issue=3&author=E.+B.+Pasquale&title=Eph+receptors+and+ephrins+in+cancer%3A+bidirectional+signalling+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Eph receptors and ephrins in cancer: bidirectional signaling and beyond</span></div><div class="casAuthors">Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-180</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumor blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression.  Eph gene mutations probably also contribute to cancer pathogenesis.  Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumor growth, invasiveness, angiogenesis and metastasis in vivo.  However, Eph signaling activities in cancer seem to be complex, and are characterized by puzzling dichotomies.  Nevertheless, the Eph receptors are promising new therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryHNhAMFltdbVg90H21EOLACvtfcHk0lj1x2W__0WvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D&md5=bbbb8188202649354faa3c50d204d0c5</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2806%26sid%3Dliteratum%253Aachs%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DEph%2520receptors%2520and%2520ephrins%2520in%2520cancer%253A%2520bidirectional%2520signalling%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D3%26spage%3D165%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Noberini, R.; Lamberto, I.; Pasquale, E. B.</span><span> </span><span class="NLM_article-title">Targeting Eph receptors with peptides and small molecules: progress and challenges</span>.  <span class="citation_source-journal">Semin. Cell Dev. Biol.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1016/j.semcdb.2011.10.023</span> . Published Online: Oct 25,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1016%2Fj.semcdb.2011.10.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Noberini&author=I.+Lamberto&author=E.+B.+Pasquale&title=Targeting+Eph+receptors+with+peptides+and+small+molecules%3A+progress+and+challenges&doi=10.1016%2Fj.semcdb.2011.10.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2011.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2011.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DNoberini%26aufirst%3DR.%26atitle%3DTargeting%2520Eph%2520receptors%2520with%2520peptides%2520and%2520small%2520molecules%253A%2520progress%2520and%2520challenges%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26doi%3D10.1016%2Fj.semcdb.2011.10.023%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ireton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span> </span><span class="NLM_article-title">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&issue=3&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+receptor+tyrosine+kinase+as+a+promising+target+for+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0lj1x2W__0WvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520target%2520for%2520cancer%2520therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wykosky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debinski, W.</span><span> </span><span class="NLM_article-title">The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1795</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1158%2F1541-7786.MCR-08-0244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=19074825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1795-1806&issue=12&author=J.+Wykoskyauthor=W.+Debinski&title=The+EphA2+receptor+and+ephrinA1+ligand+in+solid+tumors%3A+function+and+therapeutic+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting</span></div><div class="casAuthors">Wykosky, Jill; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1795-1806</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and ephrin ligands have been studied extensively for their roles in developmental processes.  In recent years, Eph receptors and ephrins have been found to be integral players in cancer formation and progression.  Among these are EphA2 and ephrinA1, which are involved in the development and maintenance of many different types of solid tumors.  The function of EphA2 and ephrinA1 in tumorigenesis and tumor progression is complex and seems to be dependent on cell type and microenvironment.  These variables affect the expression of the EphA2 and ephrinA1 proteins, the pathways through which they induce signaling, and the functional consequences of that signaling on the behavior of tumor cells and tumor-assocd. cells.  This review will specifically focus on the roles that EphA2 and ephrinA1 play in the different cell types that contribute to the malignancy of solid tumors, with emphasis on the opportunities for therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbwIAXRgx44LVg90H21EOLACvtfcHk0lhkg6fFkEH3pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI&md5=b507c55f0e81cb70cede51f69b3d5870</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0244%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DThe%2520EphA2%2520receptor%2520and%2520ephrinA1%2520ligand%2520in%2520solid%2520tumors%253A%2520function%2520and%2520therapeutic%2520targeting%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2008%26volume%3D6%26issue%3D12%26spage%3D1795%26epage%3D1806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Landen, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sood, A. K.</span><span> </span><span class="NLM_article-title">EphA2 as a target for ovarian cancer therapy</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1179</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1517%2F14728222.9.6.1179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=16300469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gks7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=1179-1187&issue=6&author=C.+N.+Landenauthor=M.+S.+Kinchauthor=A.+K.+Sood&title=EphA2+as+a+target+for+ovarian+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 as a target for ovarian cancer therapy</span></div><div class="casAuthors">Landen, Charles N.; Kinch, Michael S.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1179-1187</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  EphA2 is a receptor tyrosine kinase that is overexpressed by many human cancers, and is often assocd. with poor prognostic features.  It is involved in many processes crucial to malignant progression, such as migration, invasion, metastasis, proliferation, survival and angiogenesis.  Inducing EphA2 downregulation by any one of several mechanisms (antibody-mediated inhibition of signaling, antibody-mediated downregulation of total EphA2 expression and siRNA-mediated inhibition of expression) has been shown to decrease tumor growth, prolong survival and inhibit angiogenesis in multiple preclin. models of ovarian, breast and pancreatic cancer.  Targeting EphA2 is esp. attractive in ovarian cancer, in which overexpression is present in > 75% of cases.  This disease is highly responsive to chemotherapy, and EphA2 inhibition is esp. effective in combination with taxanes.  This demonstrated efficacy, along with the low expression of EphA2 by normal adult tissues and lack of demonstrable toxicities in preclin. models, suggest that long-term treatment with EphA2-targeting agents is an attractive approach for ovarian cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEwtrrmSHwPrVg90H21EOLACvtfcHk0lhkg6fFkEH3pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gks7nE&md5=05f1de1bc374e54064756c408d603a5d</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1517%2F14728222.9.6.1179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.9.6.1179%26sid%3Dliteratum%253Aachs%26aulast%3DLanden%26aufirst%3DC.%2BN.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DEphA2%2520as%2520a%2520target%2520for%2520ovarian%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2005%26volume%3D9%26issue%3D6%26spage%3D1179%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tandon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemula, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, S. K.</span><span> </span><span class="NLM_article-title">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1517%2F14728222.2011.538682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21142802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=31-51&issue=1&author=M.+Tandonauthor=S.+V.+Vemulaauthor=S.+K.+Mittal&title=Emerging+strategies+for+EphA2+receptor+targeting+for+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span></div><div class="casAuthors">Tandon, Manish; Vemula, Sai Vikram; Mittal, Suresh K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-51</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: High mortality rates with cancers warrant further development of earlier diagnostics and better treatment strategies.  Membrane-bound erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 (EphA2) is overexpressed in breast, prostate, urinary bladder, skin, lung, ovary and brain cancers.  Areas covered in this review: EphA2 overexpression in cancers, its signaling mechanisms and strategies to target its deregulation.  What the reader will gain: High EphA2 expression in cancer cells is correlated with a poor prognosis assocd. with recurrence due to enhanced metastasis.  Interaction of the EphA2 receptor with its ligand (e.g., ephrinA1) triggers events that are deregulated and implicated in carcinogenesis.  EphrinA1-independent oncogenic activity and ephrinA1-dependent tumor suppressor roles for EphA2 are described.  Mol. interactions of EphA2 with signaling proteins are assocd. with the modulation of cytoskeleton dynamics, cell adhesion, proliferation, differentiation and metastasis.  The deregulated signaling by EphA2 and its involvement in oncogenesis provide multiple avenues for the rational design of intervention approaches.  Take home message: EphA2 has been tested as a drug target using multiple approaches such as agonist antibodies, RNA interference, immunotherapy, virus vector-mediated gene transfer, small-mol. inhibitors and nanoparticles.  With over a decade of research, encouraging results with targeting of EphA2 expression in various pre-clin. cancer models necessitate further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUoM-7uf_sLVg90H21EOLACvtfcHk0lhkg6fFkEH3pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP&md5=2b082cbbe88132ae4e6b21c56e7defc1</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.538682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.538682%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DVemula%26aufirst%3DS.%2BV.%26aulast%3DMittal%26aufirst%3DS.%2BK.%26atitle%3DEmerging%2520strategies%2520for%2520EphA2%2520receptor%2520targeting%2520for%2520cancer%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26issue%3D1%26spage%3D31%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Biao-Xue, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi-Guang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuan-Ying, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong-Juan, M.</span><span> </span><span class="NLM_article-title">Epha2-dependent molecular targeting therapy for malignant tumors</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.2174%2F156800911798073050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21933105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1082-1097&issue=9&author=R.+Biao-Xueauthor=C.+Xi-Guangauthor=Y.+Shuan-Yingauthor=L.+Weiauthor=M.+Zong-Juan&title=Epha2-dependent+molecular+targeting+therapy+for+malignant+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2-dependent molecular targeting therapy for malignant tumors</span></div><div class="casAuthors">Biao-xue Rong; Xi-guang Cai; Shuan-ying Yang; Wei Li; Zong-juan Ming</div><div class="citationInfo"><span class="NLM_cas:title">Current cancer drug targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1082-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clarification of the molecular mechanisms of oncogenesis and drug resistance is a prerequisite for the development of new treatment strategies like molecularly targeted therapies.  Recent studies demonstrate that EphA2 is overexpressed in human cancers and that EphA2 increases tumor invasion and survival.  Thus, an EphA2 receptor antagonist, such as a specific tyrosine kinase inhibitor (in the form of an antibody, small molecule, peptide, or siRNA) or an antibody-drug conjugate that targets the EphA2 receptor could be the basis for a novel targeted antineoplastic therapy.  This review summarizes the role of EphA2 in tumorigenesis and the development of EphA2 receptor antagonists as candidate anti-cancer agents.  We suggests that continued research into the function of EphA2 signaling in the pathobiology of neoplasia could lead to more rationally designed therapeutics targeting EphA2 in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMsB4DmqQ9_pp6t8nS6Nc3fW6udTcc2eavUrOoRwRTirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D&md5=04ec16254a29e8ee8e910def8cafef70</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F156800911798073050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911798073050%26sid%3Dliteratum%253Aachs%26aulast%3DBiao-Xue%26aufirst%3DR.%26aulast%3DXi-Guang%26aufirst%3DC.%26aulast%3DShuan-Ying%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DZong-Juan%26aufirst%3DM.%26atitle%3DEpha2-dependent%2520molecular%2520targeting%2520therapy%2520for%2520malignant%2520tumors%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26issue%3D9%26spage%3D1082%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wykosky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibo, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debinski, W.</span><span> </span><span class="NLM_article-title">A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12, Part 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">3208</span><span class="NLM_x">–</span> <span class="NLM_lpage">3218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1158%2F1535-7163.MCT-07-0200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=18089715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3208-3218&issue=12%2C+Part+1&author=J.+Wykoskyauthor=D.+M.+Giboauthor=W.+Debinski&title=A+novel%2C+potent%2C+and+specific+ephrinA1-based+cytotoxin+against+EphA2+receptor+expressing+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells</span></div><div class="casAuthors">Wykosky, Jill; Gibo, Denise M.; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3208-3218</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We have previously shown that the EphA2 receptor tyrosine kinase is overexpressed in glioblastoma multiforme (GBM) and represents a novel, attractive therapeutic target for the treatment of brain tumors.  Here, we have developed an EphA2-targeted agent, ephrinA1-PE38QQR, a novel cytotoxin composed of ephrinA1, a ligand for EphA2, and PE38QQR, a mutated form of Pseudomonas aeruginosa exotoxin A.  EphrinA1-PE38QQR showed potent and dose-dependent killing of GBM cells overexpressing the EphA2 receptor in cell viability and clonogenic survival assays, with an av. IC50 of ∼10-11 mol/L.  The conjugate was also highly effective in killing breast and prostate cancer cells overexpressing EphA2.  The cytotoxic effect of ephrinA1-PE38QQR was specific, as it was neutralized by an excess of EphA2 ligands.  Moreover, normal human endothelial cells and breast cancer cells that do not overexpress EphA2, as well as GBM cells that have down-regulated EphA2, were not susceptible to the cytotoxin.  EphrinA1-PE38QQR-mediated cytotoxicity induced caspase-dependent apoptosis, which was, however, not responsible for cell death in response to the conjugate.  In addn., the conjugate elicited no changes in the activity of survival pathways such as phosphoinositide 3-kinase, measured by AKT phosphorylation.  This is the first attempt to create a cytotoxic therapy using any of the ephrin ligands of either class (A or B) conjugated to a bacterial toxin.  EphrinA1-PE38QQR is very potent and specific, produces cell death that is caspase independent, and forms the basis for the further development of clin. applicable EphA2-targeted cytotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD5phNVN_qMrVg90H21EOLACvtfcHk0ljEJfMDa5D6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3J&md5=144487963c1108024fba0d2fcdd56303</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0200%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DGibo%26aufirst%3DD.%2BM.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DA%2520novel%252C%2520potent%252C%2520and%2520specific%2520ephrinA1-based%2520cytotoxin%2520against%2520EphA2%2520receptor%2520expressing%2520tumor%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D12%252C%2520Part%25201%26spage%3D3208%26epage%3D3218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sun, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R. X.</span><span> </span><span class="NLM_article-title">Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1016%2Fj.canlet.2011.07.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21924825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlars7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2011&pages=168-177&issue=2&author=X.+L.+Sunauthor=Z.+M.+Xuauthor=Y.+Q.+Keauthor=C.+C.+Huauthor=S.+Y.+Wangauthor=G.+Q.+Lingauthor=Z.+J.+Yanauthor=Y.+J.+Liuauthor=Z.+H.+Songauthor=X.+D.+Jiangauthor=R.+X.+Xu&title=Molecular+targeting+of+malignant+glioma+cells+with+an+EphA2-specific+immunotoxin+delivered+by+human+bone+marrow-derived+mesenchymal+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells</span></div><div class="casAuthors">Sun, Xin-lin; Xu, Zhi-min; Ke, Yi-quan; Hu, Chang-chen; Wang, Shi-yong; Ling, Geng-qiang; Yan, Zhong-jie; Liu, Yi-jing; Song, Zhen-hua; Jiang, Xiao-dan; Xu, Ru-xiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-177</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Immunotoxins have shown great promise as an alternative treatment for brain malignancies such as gliomas, but their failure to penetrate into the tumor mass remains a major problem.  Mesenchymal stem cells exhibit tropism to tumor tissue and may serve as a cellular vehicle for the delivery and local prodn. of antitumor agents.  In this study, we used human bone marrow-derived mesenchymal stem cells (hMSCs) as a vehicle for the targeted delivery of EphrinA1-PE38, a very specific immunotoxin against the EphA2 receptor that is overexpressed in gliomas. hMSCs were transduced with adenovirus to express secretable EphrinA1-PE38.  Our in vitro assays confirmed the expression, release and selective killing effect of the immunotoxin produced by hMSCs.  Furthermore, the intratumoral injection of engineered hMSCs was effective at inhibiting tumor growth in a malignant glioma tumor model.  These results indicate that gene therapy utilizing EphrinA1-PE38-secreting hMSCs may provide a novel approach for the local treatment of malignant gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRp0ps7iawqLVg90H21EOLACvtfcHk0ljEJfMDa5D6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlars7nP&md5=28f4f08d44dab72754fb4b124ec48929</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%2BL.%26aulast%3DXu%26aufirst%3DZ.%2BM.%26aulast%3DKe%26aufirst%3DY.%2BQ.%26aulast%3DHu%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DLing%26aufirst%3DG.%2BQ.%26aulast%3DYan%26aufirst%3DZ.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26aulast%3DSong%26aufirst%3DZ.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BD.%26aulast%3DXu%26aufirst%3DR.%2BX.%26atitle%3DMolecular%2520targeting%2520of%2520malignant%2520glioma%2520cells%2520with%2520an%2520EphA2-specific%2520immunotoxin%2520delivered%2520by%2520human%2520bone%2520marrow-derived%2520mesenchymal%2520stem%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D312%26issue%3D2%26spage%3D168%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Jackson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gooya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinneer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazenbaker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swamynathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiener, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, D. A.</span><span> </span><span class="NLM_article-title">A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">9367</span><span class="NLM_x">–</span> <span class="NLM_lpage">9374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9367-9374&issue=22&author=D.+Jacksonauthor=J.+Gooyaauthor=S.+Maoauthor=K.+Kinneerauthor=L.+Xuauthor=M.+Camaraauthor=C.+Fazenbakerauthor=R.+Flemingauthor=S.+Swamynathanauthor=D.+Meyerauthor=P.+D.+Senterauthor=C.+Gaoauthor=H.+Wuauthor=M.+Kinchauthor=S.+Coatsauthor=P.+A.+Kienerauthor=D.+A.+Tice&title=A+human+antibody-drug+conjugate+targeting+EphA2+inhibits+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCamara%26aufirst%3DM.%26aulast%3DFazenbaker%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DR.%26aulast%3DSwamynathan%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DCoats%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DA%2520human%2520antibody-drug%2520conjugate%2520targeting%2520EphA2%2520inhibits%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9367%26epage%3D9374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Scarberry, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. J.</span><span> </span><span class="NLM_article-title">Magnetic nanoparticle–peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">10258</span><span class="NLM_x">–</span> <span class="NLM_lpage">10262</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja801969b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=10258-10262&issue=31&author=K.+E.+Scarberryauthor=E.+B.+Dickersonauthor=J.+F.+McDonaldauthor=Z.+J.+Zhang&title=Magnetic+nanoparticle%E2%80%93peptide+conjugates+for+in+vitro+and+in+vivo+targeting+and+extraction+of+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fja801969b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja801969b%26sid%3Dliteratum%253Aachs%26aulast%3DScarberry%26aufirst%3DK.%2BE.%26aulast%3DDickerson%26aufirst%3DE.%2BB.%26aulast%3DMcDonald%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DZ.%2BJ.%26atitle%3DMagnetic%2520nanoparticle%25E2%2580%2593peptide%2520conjugates%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520targeting%2520and%2520extraction%2520of%2520cancer%2520cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26issue%3D31%26spage%3D10258%26epage%3D10262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Mitra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggineni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koolpe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquale, E. B.</span><span> </span><span class="NLM_article-title">Structure–activity relationship analysis of peptides targeting the EphA2 receptor</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">6687</span><span class="NLM_x">–</span> <span class="NLM_lpage">6695</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi1006223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6687-6695&issue=31&author=S.+Mitraauthor=S.+Duggineniauthor=M.+Koolpeauthor=X.+Zhuauthor=Z.+Huangauthor=E.+B.+Pasquale&title=Structure%E2%80%93activity+relationship+analysis+of+peptides+targeting+the+EphA2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fbi1006223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1006223%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520analysis%2520of%2520peptides%2520targeting%2520the%2520EphA2%2520receptor%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26issue%3D31%26spage%3D6687%26epage%3D6695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Macrae, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Viciana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haqq, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span> </span><span class="NLM_article-title">A conditional feedback loop regulates Ras activity through EphA2</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=111-118&issue=2&author=M.+Macraeauthor=R.+M.+Neveauthor=P.+Rodriguez-Vicianaauthor=C.+Haqqauthor=J.+Yehauthor=C.+Chenauthor=J.+W.+Grayauthor=F.+McCormick&title=A+conditional+feedback+loop+regulates+Ras+activity+through+EphA2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacrae%26aufirst%3DM.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DRodriguez-Viciana%26aufirst%3DP.%26aulast%3DHaqq%26aufirst%3DC.%26aulast%3DYeh%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DA%2520conditional%2520feedback%2520loop%2520regulates%2520Ras%2520activity%2520through%2520EphA2%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26issue%3D2%26spage%3D111%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Click chemistry: diverse chemical function from a few good reactions</span> <span class="citation_source-journal">Angew. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2004</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=2004-2021&issue=11&author=H.+C.+Kolbauthor=M.+G.+Finnauthor=K.+B.+Sharpless&title=Click+chemistry%3A+diverse+chemical+function+from+a+few+good+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DClick%2520chemistry%253A%2520diverse%2520chemical%2520function%2520from%2520a%2520few%2520good%2520reactions%26jtitle%3DAngew.%2520Chem.%26date%3D2001%26volume%3D40%26issue%3D11%26spage%3D2004%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Deshayes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurizot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clochard, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthelot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esnouf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lairez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moenner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleris, G.</span><span> </span><span class="NLM_article-title">“Click” conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1631</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=1631-1642&issue=7&author=S.+Deshayesauthor=V.+Maurizotauthor=M.+C.+Clochardauthor=C.+Baudinauthor=T.+Berthelotauthor=S.+Esnoufauthor=D.+Lairezauthor=M.+Moennerauthor=G.+Deleris&title=%E2%80%9CClick%E2%80%9D+conjugation+of+peptide+on+the+surface+of+polymeric+nanoparticles+for+targeting+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeshayes%26aufirst%3DS.%26aulast%3DMaurizot%26aufirst%3DV.%26aulast%3DClochard%26aufirst%3DM.%2BC.%26aulast%3DBaudin%26aufirst%3DC.%26aulast%3DBerthelot%26aufirst%3DT.%26aulast%3DEsnouf%26aufirst%3DS.%26aulast%3DLairez%26aufirst%3DD.%26aulast%3DMoenner%26aufirst%3DM.%26aulast%3DDeleris%26aufirst%3DG.%26atitle%3D%25E2%2580%259CClick%25E2%2580%259D%2520conjugation%2520of%2520peptide%2520on%2520the%2520surface%2520of%2520polymeric%2520nanoparticles%2520for%2520targeting%2520tumor%2520angiogenesis%26jtitle%3DPharm.%2520Res.%26date%3D2011%26volume%3D28%26issue%3D7%26spage%3D1631%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dijkgraaf, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijnders, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soede, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dechesne, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Esse, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corstens, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijkers, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liskamp, R. M.</span><span> </span><span class="NLM_article-title">Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1039%2Fb615940k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=17340009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2gt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=935-944&issue=6&author=I.+Dijkgraafauthor=A.+Y.+Rijndersauthor=A.+Soedeauthor=A.+C.+Dechesneauthor=G.+W.+van+Esseauthor=A.+J.+Brouwerauthor=F.+H.+Corstensauthor=O.+C.+Boermanauthor=D.+T.+Rijkersauthor=R.+M.+Liskamp&title=Synthesis+of+DOTA-conjugated+multivalent+cyclic-RGD+peptide+dendrimers+via+1%2C3-dipolar+cycloaddition+and+their+biological+evaluation%3A+implications+for+tumor+targeting+and+tumor+imaging+purposes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes</span></div><div class="casAuthors">Dijkgraaf, Ingrid; Rijnders, Anneloes Y.; Soede, Annemieke; Dechesne, Annemarie C.; Van Esse, G. Wilma; Brouwer, Arwin J.; Corstens, Frans H. M.; Boerman, Otto C.; Rijkers, Dirk T. S.; Liskamp, Rob M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">935-944</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The design and synthesis of a series of αVβ3 integrin-directed monomeric, dimeric and tetrameric cyclo[Arg-Gly-Asp-d-Phe-Lys] dendrimers using "click chem." is described.  It was found that the unprotected N-.vepsiln.-azido deriv. of cyclo[Arg-Gly-Asp-d-Phe-Lys] underwent a highly chemoselective conjugation to amino acid-based dendrimers bearing terminal alkynes using a microwave-assisted Cu(i)-catalyzed 1,3-dipolar cycloaddn.  The αVβ3 binding characteristics of the dendrimers were detd. in vitro and their in vivo αVβ3 targeting properties were assessed in nude mice with s.c. growing human SK-RC-52 tumors.  The multivalent RGD-dendrimers were found to have enhanced affinity toward the αVβ3 integrin receptor as compared to the monomeric deriv. as detd. in an in vitro binding assay.  In case of the DOTA-conjugated 111In-labeled RGD-dendrimers, it was found that the radiolabeled multimeric dendrimers showed specifically enhanced uptake in αVβ3 integrin expressing tumors in vivo.  These studies showed that the tetrameric RGD-dendrimer had better tumor targeting properties than its dimeric and monomeric congeners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm0eoRXxFJ3bVg90H21EOLACvtfcHk0lj6v3c3yFJ3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2gt7Y%253D&md5=d9014e4e74cad4d28ad0b2c018c4cddc</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1039%2Fb615940k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb615940k%26sid%3Dliteratum%253Aachs%26aulast%3DDijkgraaf%26aufirst%3DI.%26aulast%3DRijnders%26aufirst%3DA.%2BY.%26aulast%3DSoede%26aufirst%3DA.%26aulast%3DDechesne%26aufirst%3DA.%2BC.%26aulast%3Dvan%2BEsse%26aufirst%3DG.%2BW.%26aulast%3DBrouwer%26aufirst%3DA.%2BJ.%26aulast%3DCorstens%26aufirst%3DF.%2BH.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DRijkers%26aufirst%3DD.%2BT.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%26atitle%3DSynthesis%2520of%2520DOTA-conjugated%2520multivalent%2520cyclic-RGD%2520peptide%2520dendrimers%2520via%25201%252C3-dipolar%2520cycloaddition%2520and%2520their%2520biological%2520evaluation%253A%2520implications%2520for%2520tumor%2520targeting%2520and%2520tumor%2520imaging%2520purposes%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2007%26volume%3D5%26issue%3D6%26spage%3D935%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">von Maltzahn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotamraju, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayakumar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sailor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span> </span><span class="NLM_article-title">In vivo tumor cell targeting with “click” nanoparticles</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1570</span><span class="NLM_x">–</span> <span class="NLM_lpage">1578</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc800077y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1ertLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1570-1578&issue=8&author=G.+von+Maltzahnauthor=Y.+Renauthor=J.+H.+Parkauthor=D.+H.+Minauthor=V.+R.+Kotamrajuauthor=J.+Jayakumarauthor=V.+Fogalauthor=M.+J.+Sailorauthor=E.+Ruoslahtiauthor=S.+N.+Bhatia&title=In+vivo+tumor+cell+targeting+with+%E2%80%9Cclick%E2%80%9D+nanoparticles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16dR"><div class="casContent"><span class="casTitleNuber">16d</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Tumor Cell Targeting with "Click" Nanoparticles</span></div><div class="casAuthors">von Maltzahn, Geoffrey; Ren, Yin; Park, Ji-Ho; Min, Dal-Hee; Kotamraju, Venkata Ramana; Jayakumar, Jayanthi; Fogal, Valentina; Sailor, Michael J.; Ruoslahti, Erkki; Bhatia, Sangeeta N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1570-1578</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vivo fate of nanomaterials strongly dets. their biomedical efficacy.  Accordingly, much effort has been invested into the development of library screening methods to select targeting ligands for a diversity of sites in vivo.  Still, broad application of chem. and biol. screens to the in vivo targeting of nanomaterials requires ligand attachment chemistries that are generalizable, efficient, covalent, orthogonal to diverse biochem. libraries, applicable under aq. conditions, and stable in in vivo environments.  To date, the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddn. or "click" reaction has shown considerable promise as a method for developing targeted nanomaterials in vitro.  Here, we investigate the utility of "click" chem. for the in vivo targeting of inorg. nanoparticles to tumors.  We find that "click" chem. allows cyclic LyP-1 targeting peptides to be specifically linked to azido-nanoparticles and to direct their binding to p32-expressing tumor cells in vitro.  Moreover, "click" nanoparticles are able to stably circulate for hours in vivo following i.v. administration (>5 h circulation time), extravasate into tumors, and penetrate the tumor interstitium to specifically bind p32-expressing cells in tumors.  In the future, in vivo use of "click" nanomaterials should expedite the progression from ligand discovery to in vivo evaluation and diversify approaches toward multifunctional nanoparticle development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr5zBN6IBSVrVg90H21EOLACvtfcHk0lj6v3c3yFJ3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1ertLs%253D&md5=f60752f3eb8d7a084866ace57101cb54</span></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=10.1021%2Fbc800077y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800077y%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMaltzahn%26aufirst%3DG.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DMin%26aufirst%3DD.%2BH.%26aulast%3DKotamraju%26aufirst%3DV.%2BR.%26aulast%3DJayakumar%26aufirst%3DJ.%26aulast%3DFogal%26aufirst%3DV.%26aulast%3DSailor%26aufirst%3DM.%2BJ.%26aulast%3DRuoslahti%26aufirst%3DE.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26atitle%3DIn%2520vivo%2520tumor%2520cell%2520targeting%2520with%2520%25E2%2580%259Cclick%25E2%2580%259D%2520nanoparticles%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26issue%3D8%26spage%3D1570%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Blackburn, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, L. A.</span><span> </span><span class="NLM_article-title">Peptide-functionalized nanogels for targeted siRNA delivery</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">960</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc800547c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvF2gsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=960-968&issue=5&author=W.+H.+Blackburnauthor=E.+B.+Dickersonauthor=M.+H.+Smithauthor=J.+F.+McDonaldauthor=L.+A.+Lyon&title=Peptide-functionalized+nanogels+for+targeted+siRNA+delivery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Functionalized Nanogels for Targeted siRNA Delivery</span></div><div class="casAuthors">Blackburn, William H.; Dickerson, Erin B.; Smith, Michael H.; McDonald, John F.; Lyon, L. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">960-968</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major bottleneck in the development of siRNA therapies is their delivery to the desired cell type or tissue, followed by effective passage across the cell membrane with subsequent silencing of the targeted mRNA.  To address this problem, we describe the synthesis of core/shell hydrogel nanoparticles (nanogels) with surface-localized peptides that specifically target ovarian carcinoma cell lines possessing high expression levels of the Eph2A receptor.  These nanogels are also demonstrated to be highly effective in the noncovalent encapsulation of siRNA and enable cell-specific delivery of the oligonucleotides in serum-contg. medium.  Cell toxicity and viability assays reveal that the nanogel construct is nontoxic under the conditions studied, as no toxicity or decrease in cell proliferation is obsd. following delivery.  Importantly, a preliminary investigation of gene silencing illustrates that nanogel-mediated delivery of siRNA targeted to the EGF receptor results in knockdown of that receptor.  Excellent protection of siRNA during endosomal uptake and endosomal escape of the nanogels is suggested by these results since siRNA activity in the cytosol is required for gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUkjVgfIwTP7Vg90H21EOLACvtfcHk0ljrTVV4CwX4Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvF2gsr4%253D&md5=58ec9c1a4b32ce314ceed5520adbcb03</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc800547c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800547c%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DW.%2BH.%26aulast%3DDickerson%26aufirst%3DE.%2BB.%26aulast%3DSmith%26aufirst%3DM.%2BH.%26aulast%3DMcDonald%26aufirst%3DJ.%2BF.%26aulast%3DLyon%26aufirst%3DL.%2BA.%26atitle%3DPeptide-functionalized%2520nanogels%2520for%2520targeted%2520siRNA%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26issue%3D5%26spage%3D960%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Cai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimnejad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2024</span><span class="NLM_x">–</span> <span class="NLM_lpage">2036</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1007%2Fs00259-007-0503-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=17673999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=2024-2036&issue=12&author=W.+Caiauthor=A.+Ebrahimnejadauthor=K.+Chenauthor=Q.+Caoauthor=Z.+B.+Liauthor=D.+A.+Ticeauthor=X.+Chen&title=Quantitative+radioimmunoPET+imaging+of+EphA2+in+tumor-bearing+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice</span></div><div class="casAuthors">Cai, Weibo; Ebrahimnejad, Alireza; Chen, Kai; Cao, Qizhen; Li, Zi-Bo; Tice, David A.; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2024-2036</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: EphA2 receptor tyrosine kinase is significantly overexpressed in a wide variety of cancer types.  High EphA2 expression has been correlated with increased metastatic potential and poor patient survival.  Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated.  Methods: We labeled 1C1, a humanized monoclonal antibody against both human and murine EphA2, with 64Cu through the chelating agent 1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid (DOTA) and carried out positron emission tomog. (PET) imaging of eight tumor models with different EphA2 expression levels.  Western blotting of tumor tissue lysate was performed to correlate the EphA2 expression level with 64Cu-DOTA-1C1 uptake in the tumors.  Immunofluorescence staining and biodistribution studies were also carried out to validate the in vivo results.  Results: The radiolabeling yield was 88.9 ± 9.5% (n = 7) and the specific activity of 64Cu-DOTA-1C1 was 1.32 ± 0.14 GBq/mg of 1C1 mAb.  The antibody retained antigen-binding affinity/specificity after DOTA conjugation as measured by FACS anal.  The uptake of 64Cu-DOTA-1C1 in CT-26 tumors was as high as 25.1 ± 2.5 %ID/g (n = 3) at 18 h post injection.  64Cu-DOTA-IgG, an isotype-matched control, exhibited minimal non-specific uptake in all eight tumor models.  In vivo EphA2 specificity of 64Cu-DOTA-1C1 was confirmed by successful blocking of CT-26 tumor uptake by unlabeled 1C1.  Most importantly, the tumor uptake value obtained from PET imaging had excellent linear correlation with the relative tumor tissue EphA2 expression level measured by Western blot, where r 2 equals 0.90 and 0.92 at 18 h and 42 h post injection, resp.  Conclusion: The tumor uptake of 64Cu-DOTA-1C1 measured by microPET imaging reflects tumor EphA2 expression level in vivo.  This is, to our knowledge, the first report of quant. radioimmunoPET imaging of EphA2 in living subjects.  Future clin. investigation of 64Cu-DOTA-1C1 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzMZbuvqQ4m7Vg90H21EOLACvtfcHk0ljrTVV4CwX4Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO&md5=6353b6d0f2d30a2fb7e5126f34862c39</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00259-007-0503-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-007-0503-5%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DW.%26aulast%3DEbrahimnejad%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DZ.%2BB.%26aulast%3DTice%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DQuantitative%2520radioimmunoPET%2520imaging%2520of%2520EphA2%2520in%2520tumor-bearing%2520mice%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2007%26volume%3D34%26issue%3D12%26spage%3D2024%26epage%3D2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Fox, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabone, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandpal, R. P.</span><span> </span><span class="NLM_article-title">Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1263</span><span class="NLM_x">–</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2006&pages=1263-1272&issue=4&author=B.+P.+Foxauthor=C.+J.+Taboneauthor=R.+P.+Kandpal&title=Potential+clinical+relevance+of+Eph+receptors+and+ephrin+ligands+expressed+in+prostate+carcinoma+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DB.%2BP.%26aulast%3DTabone%26aufirst%3DC.%2BJ.%26aulast%3DKandpal%26aufirst%3DR.%2BP.%26atitle%3DPotential%2520clinical%2520relevance%2520of%2520Eph%2520receptors%2520and%2520ephrin%2520ligands%2520expressed%2520in%2520prostate%2520carcinoma%2520cell%2520lines%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D342%26issue%3D4%26spage%3D1263%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Vihanto, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh-Do, U.</span><span> </span><span class="NLM_article-title">Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1691</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1689-1691&issue=12&author=M.+M.+Vihantoauthor=J.+Plockauthor=D.+Erniauthor=B.+M.+Freyauthor=F.+J.+Freyauthor=U.+Huynh-Do&title=Hypoxia+up-regulates+expression+of+Eph+receptors+and+ephrins+in+mouse+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVihanto%26aufirst%3DM.%2BM.%26aulast%3DPlock%26aufirst%3DJ.%26aulast%3DErni%26aufirst%3DD.%26aulast%3DFrey%26aufirst%3DB.%2BM.%26aulast%3DFrey%26aufirst%3DF.%2BJ.%26aulast%3DHuynh-Do%26aufirst%3DU.%26atitle%3DHypoxia%2520up-regulates%2520expression%2520of%2520Eph%2520receptors%2520and%2520ephrins%2520in%2520mouse%2520skin%26jtitle%3DFASEB%2520J.%26date%3D2005%26volume%3D19%26issue%3D12%26spage%3D1689%26epage%3D1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, B.</span><span> </span><span class="NLM_article-title">Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">4395</span><span class="NLM_x">–</span> <span class="NLM_lpage">4413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.3390%2Fijms12074395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21845085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFGlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=4395-4413&issue=7&author=Y.+Liuauthor=B.+Zhangauthor=B.+Yan&title=Enabling+anticancer+therapeutics+by+nanoparticle+carriers%3A+the+delivery+of+paclitaxel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel</span></div><div class="casAuthors">Liu, Yongjin; Zhang, Bin; Yan, Bing</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4395-4413</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Anticancer drugs, such as paclitaxel (PTX), are indispensable for the treatment of a variety of malignancies.  However, the application of most drugs is greatly limited by the low water soly., poor permeability, or high efflux from cells.  Nanoparticles have been widely investigated to enable drug delivery due to their low toxicity, sustained drug release, mol. targeting, and addnl. therapeutic and imaging functions.  This review takes paclitaxel as an example and compares different nanoparticle-based delivery systems for their effectiveness in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFxdyKFI2nULVg90H21EOLACvtfcHk0lhMGpX1pviqDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFGlt7s%253D&md5=471b2e6ce69a56e8d409b3ab0db7b75b</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.3390%2Fijms12074395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms12074395%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DEnabling%2520anticancer%2520therapeutics%2520by%2520nanoparticle%2520carriers%253A%2520the%2520delivery%2520of%2520paclitaxel%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2011%26volume%3D12%26issue%3D7%26spage%3D4395%26epage%3D4413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dash, A. K.</span><span> </span><span class="NLM_article-title">Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges</span> <span class="citation_source-journal">Crit. Rev. Ther. Drug Carrier Syst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1615%2FCritRevTherDrugCarrierSyst.v26.i4.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=20001890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=333-372&issue=4&author=S.+Singhauthor=A.+K.+Dash&title=Paclitaxel+in+cancer+treatment%3A+perspectives+and+prospects+of+its+delivery+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges</span></div><div class="casAuthors">Singh, Somnath; Dash, Alekha K.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Therapeutic Drug Carrier Systems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-372</span>CODEN:
                <span class="NLM_cas:coden">CRTSEO</span>;
        ISSN:<span class="NLM_cas:issn">0743-4863</span>.
    
            (<span class="NLM_cas:orgname">Begell House, Inc.</span>)
        </div><div class="casAbstract">A review.  Paclitaxel (PTX) is a potent anticancer agent whose clin. usefulness is marred by a delivery problem that is caused by its unfavorable pharmacokinetic and phys. properties.  Paclitaxel is currently formulated in a mixt. of Cremophor EL and ethanol, which is dild. 5-20 times with normal saline or 5% dextrose prior to administration via slow infusion to avoid pptn. in plasma.  Many adverse reactions to the PTX formulation have been reported because of the presence of Cremophor EL, including hypersensitivity reactions, nephrotoxicity, and neurotoxicity.  Cremophor EL also causes vasodilation, labored breathing, lethargy, hypotension, and leaching of plasticizers, such as diethylhexylpthalate, from the polyvinylchloride infusion bags/sets.  Significant research efforts have been conducted to develop an alternative formulation approach to increase the aq. soly. of PTX without using Cremophor, thereby decreasing its toxicity.  This article reviews the various investigated formulation approaches including pastes; liposomes; conjugates with antibodies, peptides, and fatty acids; nanospheres and microspheres; cyclodextrin complexes; emulsions; mucoadhesive gel; prodrugs; and nanoparticulate systems.  The pros and cons of each approach are also discussed.  Finally, this review concludes with a discussion of nanoparticulate delivery, which is the most promising PTX delivery system of the future because it incorporates the benefits of other approaches such as conjugation, complexation, and prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhxjPejwlodLVg90H21EOLACvtfcHk0lhMGpX1pviqDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyqurw%253D&md5=58a406e461a760d7275a69382d645b40</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1615%2FCritRevTherDrugCarrierSyst.v26.i4.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevTherDrugCarrierSyst.v26.i4.10%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DDash%26aufirst%3DA.%2BK.%26atitle%3DPaclitaxel%2520in%2520cancer%2520treatment%253A%2520perspectives%2520and%2520prospects%2520of%2520its%2520delivery%2520challenges%26jtitle%3DCrit.%2520Rev.%2520Ther.%2520Drug%2520Carrier%2520Syst.%26date%3D2009%26volume%3D26%26issue%3D4%26spage%3D333%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Coffman, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carles-Kinch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donacki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munyon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kifle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langermann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiener, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M. S.</span><span> </span><span class="NLM_article-title">Differential EphA2 epitope display on normal versus malignant cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">7907</span><span class="NLM_x">–</span> <span class="NLM_lpage">7912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7907-7912&issue=22&author=K.+T.+Coffmanauthor=M.+Huauthor=K.+Carles-Kinchauthor=D.+Ticeauthor=N.+Donackiauthor=K.+Munyonauthor=G.+Kifleauthor=R.+Woodsauthor=S.+Langermannauthor=P.+A.+Kienerauthor=M.+S.+Kinch&title=Differential+EphA2+epitope+display+on+normal+versus+malignant+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoffman%26aufirst%3DK.%2BT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DCarles-Kinch%26aufirst%3DK.%26aulast%3DTice%26aufirst%3DD.%26aulast%3DDonacki%26aufirst%3DN.%26aulast%3DMunyon%26aufirst%3DK.%26aulast%3DKifle%26aufirst%3DG.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DLangermann%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520EphA2%2520epitope%2520display%2520on%2520normal%2520versus%2520malignant%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26issue%3D22%26spage%3D7907%26epage%3D7912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wakayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, N.</span><span> </span><span class="NLM_article-title">EphrinA1-EphA2 signal induces compaction and polarization of Madin–Darby canine kidney cells by inactivating ezrin through negative regulation of RhoA</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">44243</span><span class="NLM_x">–</span> <span class="NLM_lpage">44253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=44243-44253&author=Y.+Wakayamaauthor=K.+Miuraauthor=H.+Sabeauthor=N.+Mochizuki&title=EphrinA1-EphA2+signal+induces+compaction+and+polarization+of+Madin%E2%80%93Darby+canine+kidney+cells+by+inactivating+ezrin+through+negative+regulation+of+RhoA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakayama%26aufirst%3DY.%26aulast%3DMiura%26aufirst%3DK.%26aulast%3DSabe%26aufirst%3DH.%26aulast%3DMochizuki%26aufirst%3DN.%26atitle%3DEphrinA1-EphA2%2520signal%2520induces%2520compaction%2520and%2520polarization%2520of%2520Madin%25E2%2580%2593Darby%2520canine%2520kidney%2520cells%2520by%2520inactivating%2520ezrin%2520through%2520negative%2520regulation%2520of%2520RhoA%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D44243%26epage%3D44253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Miura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabe, H.</span><span> </span><span class="NLM_article-title">EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell–cell contacts</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1949</span><span class="NLM_x">–</span> <span class="NLM_lpage">1959</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1091%2Fmbc.E08-06-0549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=19193766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotVyqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=1949-1959&issue=7&author=K.+Miuraauthor=J.+M.+Namauthor=C.+Kojimaauthor=N.+Mochizukiauthor=H.+Sabe&title=EphA2+engages+Git1+to+suppress+Arf6+activity+modulating+epithelial+cell%E2%80%93cell+contacts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts</span></div><div class="casAuthors">Miura, Koichi; Nam, Jin-Min; Kojima, Chie; Mochizuki, Naoki; Sabe, Hisataka</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">ADP-ribosylation factor (Arf) 6 activity is crucially involved in the regulation of E-cadherin-based cell-cell adhesions.  Erythropoietin-producing hepatocellular carcinoma (Eph)-family receptors recognize ligands, namely, ephrins, anchored to the membrane of apposing cells, and they mediate cell-cell contact-dependent events.  Here, we found that Arf6 activity is down-regulated in Madin-Darby canine kidney cells, which is dependent on cell d. and calcium ion concn., and we provide evidence of a novel signaling pathway by which ligand-activated EphA2 suppresses Arf6 activity.  This EphA2-mediated suppression of Arf6 activity was linked to the induction of cell compaction and polarization, but it was independent of the down-regulation of extracellular signal-regulated kinase 1/2 kinase activity.  We show that G protein-coupled receptor kinase-interacting protein (Git) 1 and noncatalytic region of tyrosine kinase (Nck) 1 are involved in this pathway, in which ligand-activated EphA2, via its phosphorylated Tyr594, binds to the Src homol. 2 domain of Nck1, and then via its Src homol. 3 domain binds to the synaptic localizing domain of Git1 to suppress Arf6 activity.  We propose a pos. feedback loop in which E-cadherin-based cell-cell contacts enhance EphA-ephrinA signaling, which in turn down-regulates Arf6 activity to enhance E-cadherin-based cell-cell contacts as well as the apical-basal polarization of epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk5GzPpMJBXbVg90H21EOLACvtfcHk0lhMGpX1pviqDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotVyqs7k%253D&md5=e86478187f9e9566f08aa61cc86b4ec0</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E08-06-0549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E08-06-0549%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%2BM.%26aulast%3DKojima%26aufirst%3DC.%26aulast%3DMochizuki%26aufirst%3DN.%26aulast%3DSabe%26aufirst%3DH.%26atitle%3DEphA2%2520engages%2520Git1%2520to%2520suppress%2520Arf6%2520activity%2520modulating%2520epithelial%2520cell%25E2%2580%2593cell%2520contacts%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2009%26volume%3D20%26issue%3D7%26spage%3D1949%26epage%3D1959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Flanagan, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldheim, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderhaeghen, P.</span><span> </span><span class="NLM_article-title">Alkaline phosphatase fusions of ligands or receptors as in situ probes for staining of cells, tissues, and embryos</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2000&pages=19-35&author=J.+G.+Flanaganauthor=H.+J.+Chengauthor=D.+A.+Feldheimauthor=M.+Hattoriauthor=Q.+Luauthor=P.+Vanderhaeghen&title=Alkaline+phosphatase+fusions+of+ligands+or+receptors+as+in+situ+probes+for+staining+of+cells%2C+tissues%2C+and+embryos"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DJ.%2BG.%26aulast%3DCheng%26aufirst%3DH.%2BJ.%26aulast%3DFeldheim%26aufirst%3DD.%2BA.%26aulast%3DHattori%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DVanderhaeghen%26aufirst%3DP.%26atitle%3DAlkaline%2520phosphatase%2520fusions%2520of%2520ligands%2520or%2520receptors%2520as%2520in%2520situ%2520probes%2520for%2520staining%2520of%2520cells%252C%2520tissues%252C%2520and%2520embryos%26jtitle%3DMethods%2520Enzymol.%26date%3D2000%26volume%3D327%26spage%3D19%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Carlsson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piller, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, M.</span><span> </span><span class="NLM_article-title">Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x"> (</span><span class="NLM_issue">35</span><span class="NLM_x">) </span> <span class="NLM_fpage">18911</span><span class="NLM_x">–</span> <span class="NLM_lpage">18919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1988&pages=18911-18919&issue=35&author=S.+R.+Carlssonauthor=J.+Rothauthor=F.+Pillerauthor=M.+Fukuda&title=Isolation+and+characterization+of+human+lysosomal+membrane+glycoproteins%2C+h-lamp-1+and+h-lamp-2.+Major+sialoglycoproteins+carrying+polylactosaminoglycan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DS.%2BR.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DPiller%26aufirst%3DF.%26aulast%3DFukuda%26aufirst%3DM.%26atitle%3DIsolation%2520and%2520characterization%2520of%2520human%2520lysosomal%2520membrane%2520glycoproteins%252C%2520h-lamp-1%2520and%2520h-lamp-2.%2520Major%2520sialoglycoproteins%2520carrying%2520polylactosaminoglycan%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1988%26volume%3D263%26issue%3D35%26spage%3D18911%26epage%3D18919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Placzek, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy</span> <span class="citation_source-journal">Cell Death Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm201743s&amp;key=10.1038%2Fcddis.2010.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm201743s&amp;key=21364647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm201743s&amp;key=1%3ACAS%3A280%3ADC%252BC3M3jtVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=e40&author=W.+J.+Placzekauthor=J.+Weiauthor=S.+Kitadaauthor=D.+Zhaiauthor=J.+C.+Reedauthor=M.+Pellecchia&title=A+survey+of+the+anti-apoptotic+Bcl-2+subfamily+expression+in+cancer+types+provides+a+platform+to+predict+the+efficacy+of+Bcl-2+antagonists+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy</span></div><div class="casAuthors">Placzek W J; Wei J; Kitada S; Zhai D; Reed J C; Pellecchia M</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We investigated the mRNA expression levels of all six antiapoptotic Bcl-2 subfamily members in 68 human cancer cell lines using qPCR techniques and measured the ability of known Bcl-2 inhibitors to induce cell death in 36 of the studied tumor cell lines.  Our study reveals that Mcl-1 represents the anti-apoptotic Bcl-2 subfamily member with the highest mRNA levels in the lung, prostate, breast, ovarian, renal, and glioma cancer cell lines.  In leukemia/lymphoma and melanoma cancer cell lines, Bcl-2 and Bfl-1 had the highest levels of mRNA, respectively.  The observed correlation between the cell killing properties of known Bcl-2 inhibitors and the relative mRNA expression levels of anti-apoptotic Bcl-2 proteins provide critical insights into apoptosis-based anticancer strategies that target Bcl-2 proteins.  Our data may explain current challenges of selective Bcl-2 inhibitors in the clinic, given that severe expression of Bcl-2 seems to be limited to leukemia cell lines.  Furthermore, our data suggest that in most cancer types a strategy targeted to Mcl-1 inhibition, or combination of Bfl-1 and Mcl-1 inhibition for melanoma, may prove to be more successful than therapies targeting only Bcl-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSagH_WEvvgWbFU0A1HOshhfW6udTcc2easID_etjYjmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3jtVKrtg%253D%253D&md5=d6759b1c82e7c72f4819a20c26720a00</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2010.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2010.18%26sid%3Dliteratum%253Aachs%26aulast%3DPlaczek%26aufirst%3DW.%2BJ.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DA%2520survey%2520of%2520the%2520anti-apoptotic%2520Bcl-2%2520subfamily%2520expression%2520in%2520cancer%2520types%2520provides%2520a%2520platform%2520to%2520predict%2520the%2520efficacy%2520of%2520Bcl-2%2520antagonists%2520in%2520cancer%2520therapy%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2010%26volume%3D1%26spage%3De40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i21"><a href="/doi/suppl/10.1021/jm201743s">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32542"></div></div></div></div></div><hr /></hr><p class="last">Detailed experimental procedures and spectral and purity analysis of all compounds; data relative to EphA2 and EphA4 RNA expression from 68 cancer cell lines. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201743s/suppl_file/jm201743s_si_001.pdf">jm201743s_si_001.pdf (691.92 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201743s&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm201743s%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201743s" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a7e5d2a0024bb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
